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Abstract 
Multiple neural network integration, influence of bradykinesia and rigidity, and bias of upper 
limb symptom improvement during deep brain stimulation implementation may attribute to 
the variable responsiveness of Parkinsonian gait therapy. Current steering (CS) addresses 
variability through fractionating current to fine-tune the stimulation field shape. It was 
hypothesized that CS would exhibit greater gait improvements and lower the total electrical 
energy delivered (TEED), which reduces power consumption and battery drainage. Divisions 
of 70/30 and 50/50 and single-contact stimulation modelled CS and conventions, 
respectively. Overall ambulation improved with TEED reduction; further, bilateral CS 
improved step time and length but left CS improved stride velocity and the functional 
ambulation performance score. However, total double support time exhibited no differences. 
Separate sub-cortical networks may regulate amplitude, timing, and velocity versus balance, 
and unilateral benefit may elucidate left hemispheric dominance for motor control. Future 
studies should personalize fractionations to contact localizations for clinical relevancy. 
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Chapter 1  
1  Introduction  
1.1 Epidemiology and etiology of Parkinson’s Disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease of adult 
onset with a prevalence of two per one thousand individuals affected (Bertram & Tanzi, 
2005; Tysnes & Storstein, 2017). The etiology of PD is attributed to a complex 
interaction between genetic, non-environmental, and environmental factors (Kalia & 
Lang, 2015). Synuclein alpha was the first gene associated with inherited forms of early 
onset PD and encodes the alpha ()-synuclein protein, which exists in concentrated 
aggregates within Lewy bodies—a pathological hallmark of PD (Breydo, Wu, & 
Uversky, 2012; Polymeropoulos et al., 1997). In addition, higher risk of PD is associated 
with familial diagnosis of PD or tremor (Noyce et al., 2012). Furthermore, age, sex, and 
ethnicity are prominent non-environmental risk factors (Kalia & Lang; 2015). Age 
serves as the greatest risk factor, as incidence and prevalence increase exponentially with 
age peaking at 80 years of life (Kalia & Lang, 2015; Pringsheim, Jette, Frolkis, & 
Steeves, 2014). Moreover, males have been reported to exhibit a higher risk of 
developing PD with a relative risk factor of 3:2 (DeLau & Breteler, 2006; Kalia & Lang, 
2015; Wooten, Currie, Bovbjerg, Lee, & Patrie, 2004). Greater incidence among males 
may be attributed to potential neuroprotective effects of estrogen or social determinants 
that influence a male dominance in certain occupations such as agricultural roles with 
pesticide use (Inestrosa Cantín, 1998; Wooten et al., 2004). PD appears to be more 
prevalent in Caucasians than those of African or Asian descent; comparisons of PD 
incidence and prevalence in the East (Asia and Middle East) versus the West (Americas, 
Australia, and New Zealand) report that PD is less prevalent in the East (Abbas, Xu, & 
Tan, 2018). In addition, Noyce and colleagues performed a meta-analysis of potential 
environmental factors and concluded that pesticide exposure and previous head injury 
exhibited the strongest association with increased PD risk; on the other hand, tobacco 
smoking and coffee consumption were most associated with lowering PD risk (Noyce et 
al., 2012).  
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1.2 Pathophysiology of Parkinson’s disease 
Two hallmark features of PD pathophysiology are the loss of dopaminergic neurons of 
the substantia nigra pars compacta (SNc) and presence of Lewy pathology, which are 
both confirmed post-mortem (Kalia & Lang, 2015). Dopaminergic neurons progressively 
degenerate in the SNc; accordingly, motor symptoms only manifest after a certain degree 
of dopaminergic cell death (Dickson et al., 2009; Kalia & Lang, 2015; Magrinelli et al., 
2016). When accounting for age, around 30% of neuronal loss in the substantia nigra 
(SN) is postulated to elicit motor symptom onset (Cheng, Ulane, & Burke, 2010; 
Fearnley & Lees, 1991). In addition, dopaminergic striatal denervation initially arises 
asymmetrically, which accounts for the asymmetrical manifestation of motor symptoms 
and a tendency for the initial side of onset to remain more severe (Hornykiewicz, 1966; 
Lizarraga et al., 2017). Notably, the putamen of the dorsal striatum is particularly 
impacted by dopamine deficiencies and degeneration is postulated to occur in other areas 
as well, including: the locus coeruleus, pedunculopontine nucleus (PPN), raphe nucleus, 
amygdala, and hypothalamus (Dickson, 2012; Kish, Shannak, & Hornykiewicz, 1988).  
 In addition, PD is characterized by the presence of Lewy bodies and neurites, 
throughout the central and peripheral nervous system (Kalia & Lang, 2015). Lewy bodies 
and neurites are composed of abnormally folded, insoluble aggregates of the protein -
synuclein (Breydo et al., 2012; Goedert, Spillantini, Del Tredici, & Braak, 2012; Kalia & 
Lang, 2015; Polymeropoulos et al., 1997). The exact mechanism of the association 
between Lewy pathology and neurodegeneration is debated; however, generally it is 
agreed that certain, not all, -synuclein aggregates are neurotoxic (Breydo et al., 2012; 
Kalia, Kalia, McLean, Lozano, & Lang, 2013). Nonetheless, PD is classified as a 
synucleinopathy, which encompasses neurodegenerative diseases associated with atypical 
accumulation of -synuclein in glial cells, nerve fibres, or neurons (McCann, Stevens, 
Cartwright, Halliday, 2014).  
1.3 Clinical characteristics of Parkinson’s disease 
PD is a neurodegenerative movement disorder characterized by the cardinal motor 
symptoms of bradykinesia, rigidity, rest tremor, and postural and gait instability (Gibb & 
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Lees, 1988; Kalia & Lang, 2015). Motor symptoms are categorized based on anatomical 
influence; therefore, appendicular symptoms affect the limbs and axial symptoms 
influence the midline of the body, including the head, neck, and truncal regions. 
Accordingly, appendicular motor symptoms include bradykinesia, rigidity, and tremor 
and axial motor symptoms include speech deficits, gait impairment, and postural 
instabilities. Namely, bradykinesia is the term to describe slowness of on-going 
movement (Magrinelli et al., 2016). Appendicular symptoms tend to manifest earlier; 
thus, are typically present around diagnosis; however, gait and postural deficits present as 
the disease progresses (Kalia & Lang, 2015). Notably, bradykinesia and limb rigidity 
contribute to a hypokinetic gait that typically responds to Levodopa (L-DOPA) 
manifesting before other treatment-resistant axial symptoms such as freezing of gait 
(FOG) (Beradelli, Rothwell, Thompson, & Hallett, 2001; Collomb-Clerc & Welter, 2015; 
Kalia & Lang, 2015). Empirically, the late stages of PD refer to the period encompassing 
over ten years of motor symptom onset and involves the continuous exacerbation of 
motor and non-motor symptoms that often become resistant to previously effective 
therapies (Kalia & Lang, 2015). In addition, non-motor symptoms such as dementia and 
autonomic dysfunction present and more severe axial motor symptoms such as FOG, 
spontaneous falls due to postural instability, dysphagia, and speech deficits manifest 
(Kalia & Lang, 2015). Late stages are marked by a substantial decrease in independence, 
quality of life, and functionality; hence, an increased mortality risk and need for 
institution (Hass et al., 2012).   
Motor symptom asymmetry is present throughout the disease as appendicular 
symptoms tend to develop unilaterally; however, it is common for the side of onset to 
remain more severe for axial and appendicular symptoms. For instance, tremor may 
develop unilaterally but disease progression elicits bilateral tremor manifestation with the 
side of onset exhibiting greater tremor severity. In addition, gait commonly presents with 
a greater reduction of arm swing of the more affected side (Karádi et al., 2015; Lizarraga 
et al., 2017). Furthermore, the presentation and severity of cardinal symptoms differs 
across patients; therefore, three subtypes are often described: tremor dominant PD, which 
presents with minimal manifestation of other motor symptoms and non-tremor dominant 
PD, which can be further categorized into an akinetic and rigid or postural and gait 
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instability subtype (Kalia & Lang, 2015; Marras & Lang, 2012). In addition, a mixed 
phenotype with multiple symptoms of similar severity may manifest (Marras & Lang, 
2012).  
Clinical presentation of PD is not limited to motor symptoms despite manifesting 
as a movement disorder; in fact, non-motor symptoms are common and reduce overall 
health and quality of life (Duncan et al., 2014; Kalia & Lang, 2015; Khoo et al., 2013; 
Martinez-Martin, Rodriguez-Blazquez, Kurtis, Chaudhuri, & NMSS Validation Group, 
2011). Non-motor symptoms include sleep and psychiatric disorders, autonomic and 
olfactory dysfunction, cognitive deficits, pain, and fatigue (Duncan et al., 2014; Khoo et 
al., 2013; Magrinelli et al., 2016). Non-motor symptoms typically precede motor 
symptom onset during the period that is referred to as the pre-motor phase. Similar to 
motor symptom development, certain non-motor symptoms present at different stages; 
for instance, constipation and rapid eye movement sleep behaviour disorder manifest 
around 20 years and 10 years prior to motor symptom onset, respectively (Kalia & Lang, 
2015). On the other hand, excessive daytime sleepiness, anosmia, and depression tend to 
present immediately prior to motor symptom onset (Kalia & Lang, 2015).  
The clinical standard to assess symptom severity is the Movement Disorder 
Society-Unified Parkinson’s Disease Rating Scale (UPDRS); namely, part I and III assess 
non-motor and motor symptoms, respectively. The UPDRS is an ordinal scale ranging 
from zero to four to characterize a non-diseased and the most severe Parkinsonian state, 
respectively. Assessments rely on sensory judgements such as visual appraisals; thus, 
scores are highly subjective and easily influenced by examiner bias. UPDRS-III assesses 
various axial and appendicular motor symptoms; however, the scale exhibits a bias 
towards appendicular symptoms. Only four out of fourteen items solely represent axial 
motor symptoms, which include the speech, posture, gait, and postural instability sub-
scores.  
1.4 Therapeutic interventions for Parkinson’s disease 
Pharmacological therapy for Parkinsonian symptoms is the initial form of symptom 
management. Therapy is initiated once symptoms begin to interfere with daily function 
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and reduce quality of life; thus, patients may not necessarily begin treatment at the time 
of diagnosis (Connolly & Lang, 2014; Kalia & Lang, 2015). There is presently no cure 
for PD and no therapy reverses, stops, or slows neurodegeneration (AlDakheel, Kalia, 
Lang, 2014; Connolly & Lang, 2014; Kalia & Lang, 2015). Agonistic influence of 
dopamine receptors or augmentation of dopamine concentrations throughout the central 
nervous system are the primary dopaminergic mechanisms of pharmaceuticals (Kalia & 
Lang, 2015). Compounds commonly used to treat PD are as follows: dopamine 
precursors—L-DOPA, dopamine receptor agonists—apomorphine, monoamine oxidase 
type B (MAOB) inhibitors—rasagiline, and catechol-O-methyltransferase (COMT) 
inhibitors—entacapone (Kalia & Lang, 2015). These drugs may be prescribed in 
combination or independently; notably, the therapy plan is highly subject to change as the 
disease progresses with manifestation of long-term complications, worsening of pre-
existing symptoms, and induction of symptoms such as FOG. 
 L-DOPA is the direct dopamine precursor, which is utilized to treat PD for its 
ability to cross the blood brain barrier, unlike dopamine, to increase dopamine 
concentrations in the brain. L-DOPA is converted to dopamine in the central and 
peripheral nervous system by the enzyme aromatic L-amino acid decarboxylase (AAAD); 
therefore, L-DOPA is administered with a peripheral AAAD inhibitor to ensure sufficient 
concentrations cross the blood brain barrier (Dorszewska, Prendecki, Lianeri, & 
Kozubski, 2014). Dopamine receptor agonists activate dopamine receptors, which exhibit 
reduced activity in hypodopaminergic states. MAOB and COMT inhibitors are 
administered to interfere with physiological dopamine metabolism to prevent further 
depletion in PD (Kalia & Lang, 2015). Motor symptom severity determines which class 
of drugs are prescribed initially. Mild motor symptoms are usually treated with MAOB 
inhibitors to delay treatment of L-DOPA or a dopamine agonist, which are preserved for 
motor symptoms of greater severity because they are more potent but also associated with 
more long-term complications (Connolly & Lang, 2014; Kalia & Lang, 2015). Multiple 
large studies have reported that L-DOPA elicits the greatest improvement of 
Parkinsonian symptoms but is more associated with motor complications as compared to 
dopamine agonists (Connolly & Lang, 2014; Ferreira et al., 2013; Fox et al., 2011; 
Holloway et al., 2004; Rascol et al., 2000). On the other hand, psychiatric side effects 
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(hallucinations and impulse control disorders) are more common among dopamine 
agonists; however, nausea, edema, and daytime sleepiness are common to both drugs 
(Connolly & Lang, 2014; Kalia & Lang, 2015).  
Due to the progressive nature of PD, patients often develop long term 
complications due to reliance on drug therapies for many years; complications include: 
motor fluctuations, non-motor fluctuations, dyskinesia, and psychosis (Kalia & Lang, 
2015). Fluctuations describe periods of adequate and inadequate symptom alleviation, 
commonly referred to as “ON” and “OFF” periods, respectively; in addition, motor and 
non-motor fluctuations allude to motor and non-motor symptoms, respectively (Kalia & 
Lang, 2015). Dopamine agonists, MAOB inhibitors, and COMT inhibitors may be 
introduced to reduce fluctuations (Kalia & Lang, 2015). Dyskinesia refers to involuntary 
movements consisted of continuous or repetitive muscle contractions that manifest in 
twisting, spasmodic movements, or irregular postures, which most commonly occur at 
maximal L-DOPA concentrations termed as peak-dose dyskinesia (Kalia & Lang, 2015; 
Magrinelli et al., 2016). Dyskinesia may be addressed by non-dopaminergic compounds 
such as clozapine and amantadine (Kalia & Lang, 2015). Furthermore, dopaminergic 
drug induced psychosis commonly presents as visual hallucinations, which may be also 
addressed by clozapine (Kalia & Lang, 2015). In addition, surgical interventions may 
address long-term complications such as deep brain stimulation (DBS) or direct 
administration of L-DOPA to the duodenum through a surgically implanted tube (Kalia & 
Lang; 2015; Olanow et al., 2014).  
1.5 Basal ganglia and associated nuclei 
The basal ganglia (BG) are a collection of subcortical nuclei with extensive connections 
including but not limited to the brainstem, limbic system, thalamus, and cerebral cortex 
(Takakusaki, Tomita, & Yano, 2008; Takakusaki, 2013). Core components are situated in 
the telencephalon and include the striatum and globus pallidus (GP) (Fazl & Fleisher, 
2018). The striatum serves as the main input and is divided into dorsal and ventral 
regions, which are further subdivided into the caudate nucleus and putamen, and the 
nucleus accumbens and olfactory tubercle, respectively (Fazl & Fleisher, 2018). The 
caudate nucleus and putamen are implicated with motor learning and planning and 
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movement execution, respectively (Alexander, DeLong, & Strick, 1986; Fazl & Fleisher, 
2018). Associated nuclei of the BG include the subthalamic nucleus (STN) and the SN, 
which are in the diencephalon and mesencephalon, respectively (Fazl & Fleisher, 2018). 
The internal globus pallidus (GPi) and substantia nigra pars reticulata (SNr) are 
functionally categorized as the output nuclei, which directly project to the thalamus and 
brainstem (Figure 1a) (Fazl & Fleisher, 2018). The external globus pallidus (GPe) and the 
STN serve as intermediary nuclei, and the SNc exerts dopaminergic projections onto the 
striatum (Fazl & Fleisher, 2018). The BG nuclei are all predominantly Gamma-
Aminobutyric Acid (GABA)ergic except for the STN, which is predominantly 
glutamatergic (Hamani et al., 2017; Lanciego, Luquin, & Obeso, 2012).  
1.5.1 The subthalamic nucleus—a valuable investigative region 
The STN is a major regulator of BG output and is postulated to be implicated in PD 
pathophysiology; appropriately, the STN is the most common target for DBS therapy of 
motor symptoms (Hamani, Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004; Larson, 2014). In 
humans, the STN is dense and lens-shaped with an approximate volume of 240 mm3 
encompassing about 560 000 neurons, heavily surrounded by many white-matter fibre 
tracts such as the internal capsule, the fields of forel, and the zona incerta (Zi) (Hamani et 
al., 2004; Hamani et al., 2017). The thalamus is dorsal to the STN; however, non-
contiguous due to the positioning of the Zi and the SN is ventral to the STN (Fazl & 
Fleisher, 2018; Hamani et al., 2017).  
The STN exhibits functional organization subdivided into a sensorimotor, 
associative, and limbic region (Tewari, Jog, & Jog, 2016). The sensorimotor region is 
situated in the dorsolateral portion of the STN and receives projections from the primary 
motor cortex (MI) and supplementary motor area (SMA) (Hartmann-von Monakow, 
Akert, & Künzle, 1978; Tewari et al., 2016). The MI and SMA projections to the 
sensorimotor region are somatotopically organized (Nambu, 2011; Romanelli et al., 
2004; Tankus et al., 2017). Leg, arm, and face representations project from the MI and 
SMA with mirroring innervations of the lateral and medial STN, respectively (Hamani et 
al., 2004; Nambu, 2011; Tewari et al., 2016). Tankus et al. (2017) investigated 
somatotopy using spike recordings and found an overrepresentation of the lower limb and 
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additional subdivisions representing joint regions (Tankus et al., 2017). Following 
standard targeting for STN-DBS procedures, spike recordings displayed that neurons 
within the STN encoding ankle movements were represented more superior-medially and 
those facilitating wrist movements to be situated more inferior-laterally (Tankus et al., 
2017).  
In contrast to other BG nuclei, the STN is predominantly glutamatergic with only 
7.5% of its composition containing GABAergic interneurons (Hamani et al., 2017; 
LLévesque & Parent, 2005). Within the BG, majority of projections innervating the STN 
arise from the GPe, which is part of the canonical indirect pathway. For motor control, 
cortical fibres directly innervate the dorsal STN and arise from the MI, SMA, pre-motor 
cortex, and pre-SMA (Hamani et al., 2017; Nambu, 2011). A greater proportion of STN 
efferents project to the GPi compared to the SNr with the GP exhibiting a greater 
representation in the BG motor circuit (Hamani et al., 2004).  In addition, projections 
between the STN and PPN and dopaminergic interconnections between the STN and SNc 
have been found, which may highlight the role of the STN in locomotion and 
dopaminergic modulation, respectively (Carpenter, Carleton, Keller, & Conte, 1981; 
François et al., 2000; Hamani et al., 2017).  
1.5.2 Dopaminergic modulation in the basal ganglia  
Majority of the striatum is composed of GABAergic medium-sized spiny neurons 
(MSNs), which receive glutamatergic cortical projections and dopaminergic projections 
from the SNc (Fazl & Fleisher, 2018). The A9 dopaminergic cell group of the SNc 
projects to the dorsal striatum to facilitate voluntary movement control (Hegarty, 
Sullivan, & O’Keeffe, 2013). Dorsal striatal MSNs projecting to the output nuclei and 
GPe express dopamine subtype 1 receptor (D1) and dopamine subtype 2 receptor (D2), 
respectively (Fazl & Fleisher, 2018). Classically, two circuitries encompassing the 
cortical-BG-thalamus-cortical loop are postulated to modulate BG activity and to be 
functionally altered in PD (Lanciego et al., 2012). The direct pathway is suggested to 
facilitate initiation and execution of voluntary movement through dopaminergic 
excitation of striatal D1 receptors, which exert direct GABAergic projections to the 
output nuclei (Fazl & Fleisher, 2018) (Figure 1a). In PD, decreased excitation of D1 
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receptors reduces the direct inhibition of the output nuclei (Figure 1b). The indirect 
pathway is proposed to counteract undesirable movement that would impede proper 
execution of voluntary movements (Fazl & Fleisher, 2018). Dopaminergic excitation of 
the striatal D2 receptors decreases the activity of the D2 expressing MSNs that project to 
the GPe. The GPe projects to the STN, which exerts glutamatergic projections to the 
output nuclei (Figure 1a) (Fazl & Fleisher, 2018). In PD, reduced dopamine elicits a 
greater inhibition of the GPe and a hyperactive STN; thus, increasing the GABAergic 
effect of the output nuclei (Figure 1b). More recently, direct glutamatergic modulation of 
the STN from the cortex has been postulated and termed the hyperdirect pathway, which 
is suggested to quickly restrict an action or decision (Figure 1a) (Fazl & Fleisher, 2018; 
Nambu, Tokuno, & Takada, 2002). Greater GABAergic modulation from the output 
nuclei in PD results in greater inhibition of the thalamus and reduced excitation of the 
cortex, which diminishes the hyperdirect pathway (Figure 1b).   
 In physiological states, the executed motor plan will exert a net dominance of the 
direct pathway over the indirect pathway compared to the various competing motor 
programs (Fazl & Fleisher, 2018). In PD, over inhibition of the thalamo-cortical and 
thalamo-brainstem projection is postulated to elucidate bradykinesia and gait deficits 
(Magrinelli et al., 2016). However, the validity of the classical model of BG circuitry has 
been disputed in the literature (Lanciego et al., 2012). Fundamentally, it fails to account 
for the array of neurotransmitters influencing the BG and pathological neuronal firing 
patterns observed in PD (Brown, 2003; Magrinelli et al., 2016). In addition, the model is 
well suited to explain bradykinesia but only partially addresses tremor and rigidity 
(Magrinelli et al., 2016). Furthermore, BG lesions should induce involuntary movements 
or hyperkinesia through a drastic reduction of inhibition exerted by the output nuclei; 
however, clinically implemented lesions of the STN and GPi greatly reduce dyskinesia 
(Lanciego et al., 2012; Lozano et al., 1995).  
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a) 
 
b) 
 
Figure 1: Summary of the BG circuitry.  
Summary of proposed circuitry in the cortical-BG-thalamus-cortical loop, representations 
are not anatomically correct. Sharp and blunt arrows represent excitatory and inhibitory 
projections, respectively. Inhibitory projections depicted are GABAergic. Excitatory 
projections from STN, cortex, and thalamus constitute glutamatergic projections while 
excitatory output of the SNc is dopaminergic. Arrow thickness represents the magnitude 
of activity for the projection. a) & b) Direct pathway constitutes dopaminergic 
modulation of the D1 receptors to the GPi and SNr; indirect pathway constitutes 
dopaminergic modulation of the D2 receptors to the GPe; and hyperdirect pathway 
constitutes the cortical to STN projection. a) Depiction of the physiological state. b) 
Parkinsonian state—loss of dopaminergic neurons in the SNc results in the augmented 
activity of the output nuclei due to a hyperactive STN compared to physiological states. 
11 
 
1.5.3 Motor function lateralization  
Dominance of the left hemisphere has been associated with motor control while 
dominance of the right hemisphere has been associated with spatial and proprioceptive 
processing (Hugdahl, 2011; Serrien, Ivry & Swinnen, 2006). Accordingly, lateralization 
of motor control has been postulated to be based on handedness due to the greater 
frequency of executed movements with the dominant side (Scholz et al., 2000; Serrien et 
al., 2006; Volkmann, Schnitzler, Witte & Freund, 1998). Stroke patients with left sided 
lesions have been reported to exhibit greater impairment of voluntary movement as 
depicted by gait impairments of greater severity with longer recovery periods compared 
to right sided stroke patients (Voos & Ribeiro do Valle, 2008). In addition, left 
hemispheric dominance has been depicted using functional magnetic resonance imaging, 
Barber et al. (2011) found a strong correlation between the magnitude of the motor 
circuit connectivity of the left hemisphere (M1, SMA, thalamus, putamen, and 
cerebellum) and motor abilities of right-handed children (Barber et al., 2011). Notably, 
the magnitude of connectivity on average was not different between the hemispheres but 
the correlation to the motor abilities for the left hemisphere was more robust and 
statistically significant (Barber et al., 2011).  
More recently, dominance related activation was reported in the BG with a 
stronger left-sided lateralization than the motor cortex, which is also postulated to be 
associated with handedness (Scholz et al., 2000). Asymmetry of the nigrostriatal network 
may allude to lateralization of motor control and performance (de la Fuente-Fernández, 
Kishore, Calne, Ruth, & Stoessl, 2000). Post-mortem analysis found that the left GP 
exhibits higher dopamine concentrations than the right among a sample predominantly 
composed of right-handed individuals (Glick, Ross & Hough, 1982). In addition, the 
magnitude of right-handedness was positively correlated with dopaminergic left-sided 
lateralization of the putamen (de la Fuente-Fernández et al., 2000). Both the putamen and 
GPi have a direct role in facilitating movement amplitude, direction, speed, and timing; 
notably, the putamen to thalamus projection of the left hemisphere was found to exhibit 
dominance for regulation of movement speed (Barber et al., 2011; O’boyle, Freeman, & 
Cody, 1996; Turner & Desmurget, 2010; Yin, 2014). 
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1.6 Deep brain stimulation  
1.6.1 History of deep brain stimulation  
DBS originated as a technique to confirm the localization of deep cerebral nuclei in 
stereotactic lesioning neurosurgery; however, observations suggested that stimulation 
could be used therapeutically as well (Guiot et al., 1962; Gildenberg, 2005; Sironi, 2011). 
Subsequent investigations found that low frequency stimulation (5-10 Hz) exacerbated 
symptoms like tremor but high frequency stimulation (50-100Hz) resulted in symptom 
reduction (D FESSARD et al., 1963; Blomstedt & Hariz, 2010; Schwalb & Hamani, 
2008; Sironi, 2011). However, the introduction of L-DOPA, in the late 60s, drastically 
reduced the practice of surgical interventions; thus, therapeutic stimulation was not 
reconsidered until Benabid et al. (1987) accounted the alleviation of tremor in PD 
patients with high frequency stimulation of the ventral intermediate nucleus (Benabid, 
Pollak, Louveau, Henry, & De Rougemont, 1987). Side effect elimination once the 
stimulation was turned off provided a considerable benefit over lesioning techniques; 
thus, the safety, non-permanency, and efficacy of DBS prompted the transition to the 
predominant use of stereotactic stimulation over lesioning for PD therapy (Sironi, 2011).  
1.6.2 Mechanism of deep brain stimulation  
In general, DBS is considered a therapy of neuromodulation that alleviates various 
symptoms over a respective time course, which is attributed to several mechanisms— 
neuro-electrical (excitatory or inhibitory) effects, neuro-chemical (neurotransmitter) 
effects, regulation of oscillatory activity, synaptic plasticity, and neurogenesis (Ashkan, 
Rogers, Bergman & Ughratdar, 2017; Herrington, Cheng, & Eskandar, 2015). The exact 
mechanism of DBS remains elusive; thus, traditional hypotheses of an excitatory and 
inhibitory effect will be namely discussed (Chiken & Nambu, 2016; Montgomery, 2010). 
DBS excites or inhibits local neuronal elements according to the excitation and inhibition 
hypothesis, respectively (Chiken & Nambu, 2016). Accordingly, the excitation 
hypothesis states that DBS will depolarize the neuronal membrane to facilitate action 
potential generation and the inhibition hypothesis suggests that neuronal membrane 
hyperpolarization or counter depolarization impedes action potential formation. Majority 
of research investigating the mechanism of DBS focuses on the local influence of DBS 
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and addresses the firing rate and pattern model, which are commonly used to elucidate 
PD pathophysiology (Chiken & Nambu, 2016; Montgomery & Gale, 2008). The firing 
rate model proposes that dopamine depletion elicits an increased firing rate on average of 
the BG output nuclei, which decreases activity of the cortical-BG-thalamus-cortical loop 
(Chiken & Nambu, 2016). The firing pattern model suggests that dopamine reduction in 
PD increases the synchrony of neuronal firing patterns, which disrupts the processing and 
relaying of signals necessary for motor function (Chiken & Nambu, 2016). Greater 
synchrony presents as neural oscillations in the ß frequency range (13-30 Hz), which are 
enhanced and present throughout the cortical-BG-thalamus-cortical loop in PD (Brown, 
2003; Bergman, Wichmann, Karmon, & DeLong, 1994; Little & Brown, 2014). 
Amelioration of bradykinesia has been correlated with a reduction of the augmented ß 
oscillatory activity in the STN and cortex (Brown, 2007).    
 The inhibition hypothesis follows that DBS may suppress excessive output and 
pathologically synchronized oscillations of the BG, which addresses the firing rate and 
pattern models, respectively (Chiken & Nambu, 2016). Initially, the inhibition hypothesis 
was supported due to similar clinical outcomes of DBS and surgical lesioning therapies; 
furthermore, studies reported a reduction in firing rates of neurons surrounding the 
electrodes of STN-DBS in Parkinsonian patients, monkeys, and rats (Benabid et al., 
1994; Benazzouz, Gross, Féger, Boraud, & Bioulac, 1993; Chiken & Nambu, 2016; 
Filali, Hutchison, Palter, Lozano, & Dostrovsky, 2004; Moran, Stein, Tischler, 
Belelovsky, & Bar-Gad, 2011; Shi, Luo, Woodward, & Chang, 2006). However, the 
findings are open to speculation due to accounts of residual STN neuronal activity and 
full termination of firing exhibited by only a minute population (Meissner et al., 2005; 
Tai et al., 2003).  
 More recent research supports the excitation hypothesis, which states that DBS 
functions through activation of neural elements, particularly axons (Montgomery, 2010). 
Studies have reported increased neuronal firing in the GPi in Parkinsonian monkeys and 
the GP and SNr in PD patients during STN-DBS (Galati et al., 2006; Hashimoto, Elder, 
Okun, Patrick, & Vitek, 2003; Montgomery & Gale, 2008; Reese et al., 2011). 
Furthermore, Windels et al. (2003) found that high frequency stimulation in the STN 
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increased glutamate levels in the GP and SNr suggesting activation of the STN upon 
stimulation (Windels et al., 2003). In addition, evidence from in vitro studies suggest that 
stimulation activates afferent axons within the target nucleus and the net effect depends 
on the composition of the neurotransmitters of the axon terminal (Chiken & Nambu, 
2016; Lee, Chang, Roberts, & Kim, 2004). Lee et al. (2004) applied high frequency 
stimulation to rat STN neurons and reported excitatory and inhibitory postsynaptic 
potentials but attributed this to the net effect of neurotransmitter release (Lee et al., 
2004). A substantial number of findings demonstrate DBS to antidromically (along the 
axon towards the soma) excite axons that pass near or terminate in the target (Chiken & 
Nambu, 2016; Montgomery, 2010). Parkinsonian rodent studies have demonstrated 
symptom improvement following antidromic activation; furthermore, activity of evoked 
potentials of STN-DBS suggest antidromic activation of cortical projections to the STN 
(Gradinaru, Mogri, Thompson, Henderson, & Deisseroth, 2009; Montgomery, 2010).  
1.6.3 Neurological targets for deep brain stimulation  
The two standard targets for the treatment of PD are the GPi and STN; however, STN-
DBS is more common (Follett & Torres-Russotto, 2012; Fox et al., 2011; Mahlknecht, 
Limousin, & Foltynie, 2015). Several studies have compared the efficacy of these nuclei 
as a therapeutic target for DBS; both targets consistently reduce UPDRS scores, 
dyskinesia severity, dyskinesia duration, and improve quality of life (Anderson, Burchiel, 
Hogarth, Favre, & Hammerstad, 2005; Follett et al., 2010; Mahlknecht et al., 2015; 
Odekerken et al., 2013; Okun et al., 2009; Zahodne et al., 2009). However, unique to 
STN stimulation is the significantly greater reduction of the L-DOPA dose with some 
patients ceasing L-DOPA therapy; in addition, STN-DBS elicits slightly greater 
improvements of bradykinesia and rigidity as assessed with UPDRS-III (Anderson, 
Burchiel, Hogarth, Favre, & Hammerstad, 2005; Follett et al., 2010; Mahlknecht et al., 
2015; Odekerken et al., 2013). For alleviation of cardinal motor symptoms, electrodes are 
localized to the sensorimotor-dorsolateral STN, which exhibits somatotopic organization 
(Bot et al., 2018; Kuncel & Grill, 2004; Tewari et al., 2016; Wagle Shukla, Zeilman, 
Fernandez, Bajwa, & Mehanna, 2017). Notably, current spread into surrounding fibre 
tracts such as the Zi and the fields of forel have been reported to relieve tremor, rigidity, 
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and dyskinesia; however, paradoxically induces FOG and gait hypokinesia (Blomstedt et 
al., 2018; Saint-Cyr et al., 2002; Fleury et al., 2016; Hamel et al., 2003).  
1.6.4 Therapeutic practicality of deep brain stimulation  
DBS is a therapeutic intervention that requires surgical implantation of an impulse 
generator (IPG), extension, and macroelectrodes. Treatment relies on delivery of 
electrical pulses carried by wires that are implanted into target brain regions using 
stereotactic neurosurgery. The leads are insulated coiled wires that contain multiple 
macroelectrodes, which consist of non-insulated regions, termed as contacts, that allow 
charge to traverse into the surrounding neural tissue. Commonly, two leads are inserted 
bilaterally; however, one lead may be inserted for unilateral treatment. The IPG is sub-
dermally embedded in the chest and serves as the source of electrical pulses and contains 
the battery to run the system. The IPG is connected to the therapeutic leads through an 
extension, which is entirely insulated and traverses subdermally from the chest, up the 
neck posteriorly, through a cranial burr hole and into the brain (Figure 2). Therefore, 
electrical pulses are carried to the brain by the extension and can only traverse into target 
nuclei through the contacts. Electrode geometry and stimulation parameters are set using 
an external programmer, which communicates with the IPG to coordinate the selected 
features to yield stimulation accordingly.  
Electrode geometries dictate cathode and anode designations, which exhibit a 
negative and positive electric potential, respectively. Current is drawn towards the 
cathode from the anode; thus, the cathode and anode are considered the current sink and 
source, respectively. Among all geometries, only the contacts serve as the cathode for 
therapeutic stimulation but the IPG or an active contact can be assigned as the anode. 
Only unipolar configurations consist of the IPG set as the anode with one or more active 
contacts set as the cathode. Other geometries such as bipolar, tripolar, quadrapolar, and 
quintipolar consist of two, three, four, and five active contacts, respectively, with one of 
the contacts being set as the anode (Kuncel & Grill, 2004).  A unipolar electrode 
geometry is most commonly implemented followed by the bipolar geometry. Bipolar 
geometries are implemented when unipolar configurations inadequately improve 
symptoms, especially if side effects are induced at low amplitudes (Wagle Shukla et al., 
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2017; Volkmann, Moro, & Pahwa, 2006). The bipolar electrode geometry programs one 
contact as the cathode and another as the anode; commonly, the contact most effective for 
symptom relief is set as the cathode and the adjacent contact serves as the anode (Wagle 
Shukla et al., 2017).  
DBS relies on the delivery of electrical pulses, which is approximated to represent 
a square wave; therefore, the stimulation amplitude fluctuates between peaks and troughs 
(Montgomery, 2010; Wagle Shukla et al., 2017). The square shaped pulse is described to 
exhibit a short-duration stimulation phase with a peak amplitude and a long-duration 
recharge phase to minimize tissue damage associated with a trough amplitude (Figure 3) 
(Wagle Shukla et al., 2017). The stimulation phase delivers charge to the contact(s) 
designated as the cathode, which is associated with cathodal current; however, the 
recharge phase returns charge back to the IPG, which is associated with anodal current 
(Montgomery, 2010). Since the stimulation amplitude fluctuates over time, impedance is 
used to describe the opposition to electrical charge flow in DBS (Montgomery, 2010; 
Wagle Shukla et al., 2017). Frequency, pulse width, and current are the stimulation 
parameters that can be programmed to regulate stimulation. Current dictates the 
stimulation intensity measured in milliamperes (mA), frequency is the rate of stimulation 
measured in Hz or the inverse of the period of the electric pulse, and the pulse width 
encompasses the period when the electrical pulse is delivered measured in μs (Figure 3) 
(Wagle Shukla et al., 2017).  For treatment of PD, the clinical standard is to program 
STN-DBS with a frequency of 130 Hz and a pulse width of 60 s. Current amplitude is 
set within a range that is below the side effect threshold but above the efficacy threshold, 
referred to as the therapeutic window (TW); accordingly, the side effect threshold is the 
minimal intensity that elicits side effects and the efficacy threshold is the minimal 
intensity to elicit symptom alleviation.  
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Figure 2: Diagram of the DBS hardware.  
a) Image provided courtesy of Boston Scientific (MA, USA) portraying the sub-dermal 
implantation of the IPG below the clavicle and the attachment of two leads bilaterally to 
the IPG. The extension runs up the neck posteriorly through a cranial burr hole into target 
deep brain structures. b) Scout view obtained from a computed tomography displaying 
the insulated extension that runs up the neck posteriorly, which connects to an adaptor 
allowing the contacts to localize to target brain structures. 
 
Figure 3: Schematic of the electric pulses delivered with DBS.  
Cathodal current refers to the charge delivery to the cathode(s) designated as the 
contact(s) for the therapeutic application of DBS. Anodal current refers to charge 
delivery to the anode, which is set as the IPG. Charge moves away from the source 
(anode) and towards the current sink (cathode(s)); the peak is associated with the 
stimulation phase and the trough is associated with the longer re-charge phase. Pulse 
width measured in s defines the period that the electrical pulse is delivered; current 
amplitude measured in mA indicates the stimulation intensity; and frequency measured in 
Hz refers to the rate of the pulse delivery or inverse of the period.  
1.6.5 Total electrical energy delivered and the relation to power 
consumption and the IPG battery life  
The total electrical energy delivered (TEED) represents an overall measure of 
stimulation. The concept was first introduced by Moro and colleagues in their 
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investigation of DBS as a therapy for Huntington’s disease (Moro et al., 2004). However, 
it was later modified by Koss and colleagues using derivations with standard physics 
equations such as Ohm’s law (Koss, Alterman, Tagliati, & Shils, 2005). TEED is 
established by the voltage, frequency, pulse width, and impedance, and represents the 
total amount of energy delivered in a given time period of stimulation. Notably, power is 
the amount of energy transferred per unit time; thus, TEED may be used to allude to 
power consumption. The TEED calculation has been reported as:  
TEED1sec = 
(𝑣𝑜𝑙𝑡𝑎𝑔𝑒)2× (𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦) × (𝑝𝑢𝑙𝑠𝑒 𝑤𝑖𝑑𝑡ℎ)
𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒
 ×  1𝑠𝑒𝑐𝑜𝑛𝑑. 
TEED has been studied in the context of practicality through investigations of its effect 
on battery life, which influences the need and frequency of IPG replacements (Bin-
Mahfoodh, Hamani, Sime, & Lozano, 2003; Helmers et al., 2018; Niemann, Schneider, 
Kühn, Vajkoczy, & Faust, 2018; van Riesen et al., 2016). Pulse width and TEED have 
been reported to directly correlate with the IPG battery drainage rate (van Riesen et al., 
2016). Therefore, stimulation with smaller values of TEED delay battery depletion and 
need for surgical replacement of the IPG battery. 
 Faster drainage results in an earlier and more probable need for initial and 
subsequent re-implantations, which introduces two primary risks—inadequate or unstable 
symptom control and infection risk (Allert, Kirsch, Weirich, & Karbe, 2009; Pepper et 
al., 2013). Allert and colleagues reported that 20% of patients experience inadequate 
symptom alleviation despite accurate restoration of the hardware and programming with 
previous parameters that provided alleviation before IPG replacement (Allert et al., 
2009). Re-programming may require diligent re-selection of optimal stimulation 
parameters, which is laborious and may not be feasible in large busy centres or in small 
centres that are limited in resources (Allert, et al., 2009; Wagle Shukla et al., 2017).  In 
addition, Pepper et al. (2013) reported that the infection rate associated with the IPG 
replacement surgery was more than three times greater than the initial DBS implantation 
procedure (Pepper et al., 2013). TEED values are also useful to represent various 
stimulation parameters as a uniform measure during clinical investigations; for instance, 
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inadequate axial improvement with low frequency stimulation was attributed to the 
reduced TEED of the investigative stimulation (Dayal, Limousin, & Foltynie, 2017).  
1.6.6 Factors affecting the clinical outcome of deep brain stimulation  
The ideal clinical outcome is achieved by maximizing symptom alleviation and 
minimizing side effects, power usage, and tissue damage risk, which is influenced by the 
electrode geometry, electrical characteristics of the tissue encompassing the contact, 
contact localization, and stimulation parameter selection (Butson, Maks, & McIntyre, 
2006; Kuncel & Grill, 2004). Maximal symptom alleviation with minimal side effect 
manifestation is best controlled with optimizing current spread; on the other hand, battery 
life is related to power usage; therefore, minimal power usage is also pursued to reduce 
the IPG battery drainage rate (Kuncel & Grill, 2004). Post-mortem studies depict minor 
tissue damage following chronic STN-DBS when stimulus parameters are programmed 
with a charge density that is considerably lower than recommended values (Kuncel & 
Grill, 2004). Reported neural tissue changes are caused by immune responses such as 
gliosis, which introduces lymphocytes, microglia, and macrophages to the neural tissue 
surrounding the electrode (Haberler et al., 2000; Henderson et al., 2002). Gliosis is the 
proliferation or hypertrophy of various glial cells serving as a non-specific response to 
central nervous system damage; notably, extreme gliosis may lead to scar formation, 
which impedes axonal regeneration resulting in loss of function (Yiu & He, 2006).  
Unipolar geometries elicit a broader electric field since current spreads from the 
brain to the chest region compared to the confinement of the field within the brain with 
bipolar configurations. The unipolar electric field is approximated to exhibit a spherical 
shape around the active contact due to diffuse, radial current spread (Butson, Cooper, 
Henderson, &, McIntyre, 2007; Deli et al., 2011; McIntyre, Mori, Sherman, Thakor, & 
Vitek, 2004). Unipolar stimulation is programmed conventionally and bipolar 
configurations are utilized when unipolar stimulation is inadequate for symptom 
alleviation or induces side effects at low amplitudes (Kuncel & Grill, 2004). Unipolar 
configurations are associated with a lower efficacy threshold; thus, symptom alleviation 
is elicited at lower stimulation amplitudes, which is favourable for reduced power 
consumption and maintenance of the IPG battery life (Deli et al., 2011; Volkmann et al., 
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2006). Therefore, unipolar stimulation is preferred because symptom alleviation is 
elicited at higher amplitudes with bipolar configurations, which increases power 
consumption and expedites the IPG battery drainage rate (Deli et al., 2011; 
O’suilleabhain, Frawley, Giller, & Dewey, 2003; Volkmann et al., 2006).  
Electrical characteristics of the neural tissue encompassing the electrode also 
influence the spatial distribution of the stimulation field (Kuncel & Grill, 2004). For 
instance, grey matter has a lower conductivity; therefore, contact localizations in white 
matter fiber tracts such as the Zi exhibit broader electric fields (Li, Bak, & Parker, 1968; 
Kuncel & Grill, 2004). Furthermore, large diameter myelinated axons are activated at the 
lowest stimulation amplitudes compared to dendrites and the soma (Wagle Shukla et al., 
2017). Nonetheless, the actual neuroanatomical location of the active contact also 
influences the success of the clinical outcome. It is generally agreed that the ideal target 
for motor symptom alleviation is the dorsolateral STN (Bot et al., 2018; Kuncel & Grill, 
2004; Tewari et al., 2016; Wagle Shukla et al., 2017).  
The combination of frequency, pulse width, and current amplitude influences 
current spread and power consumption, which ultimately affects symptom relief and the 
risk of side effects and tissue damage (Kuncel & Grill, 2004). Magnitudes of the 
stimulation parameters must be programmed with a compromise between symptom 
alleviation and power usage. For instance, frequency is directly related to power 
consumption and the IPG battery drainage rate; however, the frequency cannot be 
programmed too low (Kuncel & Grill, 2004; Volkmann, Herzog, Kopper, &, Deuschl, 
2002; Moro et al., 2002). Frequencies below 100 Hz have been reported to be inadequate 
for symptom alleviation and frequencies of 13-30 Hz have been found to aggravate 
bradykinesia (Kuncel & Grill, 2004; Volkmann et al., 2002; Moro et al., 2002). Similarly, 
shorter pulse widths reduce the charge density of stimulation, which lowers the risk of 
tissue damage (Kuncel & Grill, 2004). In addition, shorter pulse widths increase the 
therapeutic window; thus, shorter pulse widths are preferred in clinical practice (Rizzone 
et al., 2001). However, depending on the impedance of the DBS system, pulse widths 
may need to be increased from the clinical standard. Furthermore, the stimulation 
amplitude required for symptom alleviation is directly related to the distance of the active 
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contact from appropriate neural elements, which emphasizes the importance of accurate 
contact localizations (McNeal, 1976) Notably, high amplitudes are associated with 
greater power consumption; thus, lower efficacy thresholds are more ideal because lower 
amplitudes reduce power consumption and subsequently, the side effect and tissue 
damage risk.  
1.6.7 Technological development of deep brain stimulation  
The emergence of DBS systems arose as voltage-controlled (VC) devices, which 
established the design of all DBS devices until the production of current-controlled (CC) 
systems. VC devices are adequate for symptom alleviation in straightforward cases; 
however, these systems are not ideal when addressing cases that require more 
programming. Overall, VC systems exhibit limited ability to regulate and fine-tune 
stimulation making programming laborious especially since there are no established 
protocols (Wagle Shukla et al., 2017). VC devices are associated with inconsistent charge 
delivery due to the lack of regulation of inherent impedance fluctuations at the 
contiguous border between the electrode and neural tissue (Butson et al., 2006; Butson & 
McIntyre, 2008; Wagle Shukla et al., 2017). For several weeks following implantation, 
increased impedance is attributed to an encapsulation layer generated from the body’s 
reaction to the foreign electrode through protein and immune cell deposition (Polikov, 
Tresco, & Reichert, 2005). Impedance is reported to settle around a month post-
implantation; however, impedance also invariably decreases with stimulation changes 
(Lempka, Johnson, Miocinovic, Vitek, & McIntyre, 2010; Lempka, Miocinovic, Johnson, 
Vitek, McIntyre, 2009). Consequently, VC devices commonly over or under stimulate the 
intended target due to impedance fluctuations deviating the stimulation from programed 
parameters, which prompted the development of CC systems with multiple independent 
current control (Butson et al., 2006). In multiple independent current control technology, 
each contact acts as a resistor in its own circuit; therefore, the voltage is manipulated to 
address the impedance fluctuations and ensure that current delivery is consistent from 
each active contact and matches programmed parameters (Figure 4). CC systems with 
multiple current sources has increased the degrees of freedom for programming through 
stimulation techniques termed as current steering (CS) (Barbe, Maarouf, Alesch, & 
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Timmermann, 2014). CS can be implemented in the axial or coronal plane, which 
employs directional and vertical CS, respectively.  
 Directional CS can only be employed with segmented electrodes that are designed 
with two segmented contacts. Each segmented contact is divided into three sections that 
together span the electrode circumference in contrast to exhibiting the conventional ring-
shape (Figure 4b). Directional CS activates contact segments, instead of stimulating from 
the entire circumference, to specifically target or avoid neural structures in the axial 
plane. Neuroanatomical variations and imprecise contact localizations can be addressed 
by activating only one or two segments of the contact. Steigerwald et al. (2016) 
performed a pilot study among seven patients with bilateral STN implantation and 
reported the feasibility of directional CS, which increased the TW in a patient specific 
manner compared to ring style contact activation (Steigerwald, Müller, Johannes, 
Matthies, & Volkmann, 2016).  
Vertical CS divides the current delivery between multiple active contacts to 
manipulate the stimulation field shape. Thus, current fractionation is employed in the 
coronal plane along the dorsal-ventral axis. The percentage or proportion of current 
stimulation is directly related to the electric field spread; therefore, contacts receiving a 
greater percentage will exhibit a broader spread than those receiving a smaller 
percentage. Vertical CS allows for manipulation of the conventional unipolar spherical 
electric field to fine-tune stimulation, which maximizes targeted stimulation and 
minimizes unintended current spread into surrounding neural tissue. This technique 
systematically associates current fractionations with contact localizations to improve the 
overall efficiency and feasibility of programming; however, the technique is particularly 
beneficial for inadequate symptom alleviation that demands repetitive re-programming 
(Barbe et al., 2014). In addition, multiple programs can be employed; therefore, different 
combinations of stimulation parameters may be implemented for different symptoms, 
which ultimately reduces the need for surgical re-implantation. Simulations have depicted 
the ability of vertical CS to improve the precision of influencing targeted neural 
structures to maximize symptom alleviation and minimize side effects (Chaturvedi, 
Foutz, & McIntyre, 2012). Similarly, the first human report fractionated the current 
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between four active contacts to yield a tear-drop shaped electric field to elicit symptom 
alleviation without dyskinesia at the same amplitude that single-contact stimulation 
induced dyskinesia and failed to alleviate symptoms (Barbe et al., 2014). Furthermore, 
the most extensive investigation to date with the assessment of 40 individuals with 
moderate to severe idiopathic PD across six European countries also found a substantial 
clinical benefit of utilizing vertical CS (Timmermann et al., 2015). Timmermann and 
colleagues reported the utility of vertical CS to alleviate motor symptoms, improve 
quality of life, increase the “ON” period, and reduce the L-DOPA equivalent dose 
(Timmermann et al., 2015). Notably, majority of patients initiated programming with 
single-contact stimulation; however, 82% of patients shifted to CS (unipolar stimulation 
with multiple contacts) by the third month following implantation and this remained for 
the majority at six months and one year following implantation (Timmermann et al., 
2015). Promising results from clinical observations and studies have prompted the use of 
vertical CS in more clinical settings (Barbe et al., 2014; Chaturvedi et al., 2012; Wagle 
Shukla et al., 2017; Timmermann et al., 2015).  
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Figure 4: Schematic of the multiple independent current control technology utilized. 
Images of leads adapted by the design of Boston Scientific (MA, USA). Simplified 
diagram of the electric circuitry associated with the a) VerciseTM lead and b) Vercise 
CartesiaTM Directional lead, which has two segmented levels such that the conventional 
ring electrode is divided into three segments that are individually controlled. Both leads 
are designed with multiple independent current control; therefore, each contact acts as a 
resistor in an individual circuit and consistent current delivery is maintained by adjusting 
the voltage to account for impedance fluctuations.  
1.6.8 Implementation of vertical current steering  
The Boston Scientific DBS systems (Valencia, CA) orchestrate vertical CS since they 
are designed as CC devices with multiple independent current sources. Boston Scientific 
offers segmented and non-segmented leads to operate with the multiple independent 
current control technology; the VerciseTM DBS lead contains eight non-segmented 
contacts and the CartesiaTM Directional lead consists of 8 contacts with the two middle 
levels segmented into 3 portions (Figure 4). The eight contacts of the VerciseTM DBS 
lead span 15.5 millimetres (mm); however, the eight contacts of the CartesiaTM 
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Directional lead span 7.5 mm (Figure 4). In both leads, the contact length is 1.5 mm 
with a separation distance of 0.5 mm between contacts and are designed with an overall 
diameter of 1.3 mm (Figure 4). Additionally, the two middle levels of the CartesiaTM 
Directional lead are segmented into 3 portions that approximately span 120 degrees 
(Steigerwald et al., 2016). Vertical CS is implemented with a unipolar electrode 
geometry; thus, the IPG is set as the anode and at least two contacts are assigned a 
cathodic designation to allow for current to be fractionated between the active contacts.  
1.7 Gait  
1.7.1 Role of the central nervous system in gait facilitation  
Gait encompasses the bilateral coordination of sequential limb movements for 
locomotion, which most commonly manifests as walking. An external or visceral 
stimulus initiates volitionally or emotionally primed locomotion through downward 
projections from the cerebral cortex and limbic system, respectively (Takakusaki, 2008). 
Namely, emotionally primed movements may be reactive such as a fight-or-flight 
response (Takakusaki, 2017). Gait execution relies on the correct degree of postural 
muscle tone and the rhythmicity of limb movements facilitated by subconscious 
processing of the brainstem and spinal cord. Processing of higher order brain regions is 
necessary for adaptation to address changes in the ambulation environment such as for 
obstacle avoidance (Takakusaki, 2013).  
Descending projections from the cortex and brainstem reticular formation 
constituting the corticospinal and reticulospinal tracts, respectively, influence -motor 
neurons in the spinal cord to control locomotion and posture (Takakusaki, 2013). 
Automatic posture regulation maintains the body upright throughout ambulation; 
however, dynamic postural control, facilitates adjustments to maintain steady-state 
walking in response to environmental disturbances (Takakusaki, 2013). The latter relies 
on additional cortical processing and integration of visual, vestibular, and proprioceptive 
input; however, the former is predominantly maintained through subconscious processing 
in the brainstem and spinal cord (Collomb-Clerc & Welter, 2015; Massion, 1992; 
Takakusaki, 2017). Execution of steady-state locomotion occurs with automatic 
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processes as with all learned behaviours. The critical role of the brainstem and spinal 
cord in facilitating steady-state locomotion was deduced by induced locomotion from 
electrical stimulation of locomotor centres in the midbrain of decerebrate cats (Hinsey, 
Ranson, & McNattin, 1930). Three locomotor regions are postulated to exist—the 
midbrain locomotor region (MLR), subthalamic locomotor region (SLR), and cerebellar 
locomotor region (CLR), which have been identified in humans using magnetic 
resonance imaging (Jahn et al., 2008). The MLR is postulated to encompass the area in 
the mesopontine tegmentum, which includes the cuneiform nucleus (CN) and the PPN, 
and the SLR and CLR are situated in the lateral hypothalamus and the mid-cerebellum, 
respectively (Mori et al., 1999). 
 The MLR was discovered in 1966 through stimulation of a region between the 
midbrain and hindbrain in cats but is now postulated to be conserved across all vertebrate 
classes (Grillner, Georgopoulos, & Jordan, 1997; Shik, Orlovskiĭ, & Severin, 1966). Gait 
and posture are controlled with the MLR through afferents from the cerebellum and 
motor cortex, outward projections to the reticulospinal tract and thalamo-cortical 
pathway, and reciprocal connections with the BG (Magrinelli et al., 2016; Takakusaki, 
2017). The MLR has been postulated to regulate central pattern generators in the spinal 
cord, which maintain locomotor rhythm, facilitate adaptations, and coordinate the correct 
degree of postural control for gait execution (Takakusaki, 2013).   
 The spinal cord is predominantly involved in the rhythm and pattern generation of 
locomotion through projections from the MLR acting on spinal interneurons termed as 
the central pattern generators. The central pattern generators exist as two separate 
networks for regulation of flexor and extensor muscles that are reciprocally active during 
ambulation (Takakusaki, 2013). Central pattern generators subsequently project to second 
order interneurons, which shape the pattern of locomotion and ultimately to motor 
neurons of the ipsilateral limb (Takakusaki, 2013). The left-right alterations of limb 
movements are facilitated by interneurons in lamina VIII that project to motor neurons of 
the contralateral limb (Takakusaki, 2013). Sensory feedback from proprioceptive 
receptors relay signals upward for adaptation to environment changes through tracts such 
as the spino-reticular and spino-cerebellar (Takakusaki, 2013).   
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The cerebellum and BG exert downward and upward projections to serve as relay 
structures to facilitate automatic features and aspects influenced by the cortex, 
respectively (Figure 5) (Takakusaki, 2013). The BG exhibits reciprocal connections with 
the cortex, and projects to the brainstem and hypothalamus to coordinate volitional, 
automatic, and emotional locomotor processes, respectively; similarly, the cerebellum 
also projects to the brainstem and cortex (Figure 5) (Takakusaki, 2013). Cortical circuitry 
coordinates planning, learning, and adaptive processes, which is facilitated through 
cortical projections to the spinal cord, brainstem, BG, and cerebellum (Figure 5) 
(Takakusaki, 2013; Takakusaki, 2017). Precise limb movement is programmed and 
planned with the premotor area and the SMA while execution is facilitated with the MI 
and corticospinal tract (Takakusaki, 2013). Modifications to maintain steady-state 
ambulation heavily rely on visuo-motor processing and the generation and constant 
update of body schema information; thus, involving integration of somatosensory, 
vestibular, and visual information in the occipital, temporal, parietal, and motor cortices 
(Stuart, Lord, Hill, & Rochester, 2016; Takakusaki, 2013). Subsequently, the MI and 
somatosensory cortex employ body schemas to generate motor programs to execute 
ambulation addressing perturbations (Takakusaki, 2013).   
 
Figure 5: Neural control in the central nervous system for gait facilitation.   
Gait facilitation involving the spinal cord, sub-cortex, and cortex. Schematic does not 
represent actual anatomical locations, adapted from Takakusaki, 2013. 
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1.7.2 Dopamine responsive versus non-dopamine responsive 
postural and gait deficits in Parkinson’s disease  
Reduced dopamine levels in PD are postulated to augment GABAergic activity of the BG 
output nuclei, which increases inhibition of the thalamo-cortical projection and the 
brainstem (Fazl & Fleisher, 2018; Magrinelli et al., 2016). Alterations in dopaminergic 
and cholinergic projections are postulated to impair sensorimotor integration, motor 
programming, and motor execution facilitated predominantly by the brainstem and cortex 
necessary for the regulation of gait and posture (Magrinelli et al., 2016). The cardinal 
Parkinsonian gait is characterized by a stooped posture; increased flexion at the hip and 
knee joints; and reduced limb swing, ground clearance, speed, and step magnitude 
(Magrinelli et al., 2016). Postural and gait deficits tend to manifest later as opposed to 
appendicular symptoms, which have an earlier onset and are typically present at 
diagnosis (Kalia & Lang, 2015). Postural and gait deficits may be further categorized 
based on the stage of onset, predominant underlying mechanism, and response to L-
DOPA and STN-DBS (Lubik et al., 2006; McNeely & Earhart, 2013; Welter et al., 2002). 
A correlation between axial motor symptom response to L-DOPA and the clinical 
outcome of STN-DBS has been reported in several accounts; therefore, clinicians rely on 
an adequate response to L-DOPA as a prerequisite for DBS (Fasano, Aquino, Krauss, 
Honey, & Bloem, 2015; Pötter-Nerger & Volkmann, 2013; Welter et al., 2002).  
 Gait and postural deficits of earlier manifestation tend to be attributed to limb 
rigidity and bradykinesia, which contribute to a hypokinetic gait with reduced limb 
swing, step size, and gait velocity (Collomb-Clerc & Welter, 2015). Gait measures of 
amplitude, rhythm, and velocity tend to improve with L-DOPA and STN-DBS; thus, are 
postulated be predominantly facilitated by dopaminergic modulation of the BG and 
subsequent influence of the CN in the MLR (Collomb-Clerc & Welter, 2015; 
Krystkowiak et al., 2003; Lubik et al., 2006; Magrinelli et al., 2016; Takakusaki, Chiba, 
Nozu, & Okumura, 2016). Namely, the subthalamo-pallidal-MLR pathway has been 
proposed to regulate spatio-temporal gait parameters particularly through the CN or the 
cholinergic neurons in the laterodorsal tegmental nucleus of the MLR that project to the 
spinal cord (Collomb-Clerc & Welter, 2015; Takakusaki et al., 2016). Accordingly, post-
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mortem assessment found that the magnitude of neuronal loss in the CN was not 
significantly different between those with a tendency to fall and those without; in 
contrast, cholinergic neuronal loss in the PPN varied between spontaneous fallers and 
non-fallers (Karachi et al., 2010).  
FOG, spontaneous falls, and postural sway are suggested to be controlled by non-
dopaminergic pathways in the brainstem that typically manifest following 10 years of 
diagnosis and exhibit a variable responsiveness to L-DOPA and STN-DBS (Collomb-
Clerc & Welter, 2015; Kalia & Lang, 2015; Takakusaki, 2017). Non-dopamine 
responsive postural and gait dysfunction are influenced by the inability to produce 
anticipatory and compensatory postural adjustments; thus, are more representative of 
balance deficits (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Namely, the 
subthalamo-nigro-PPN circuit has been implicated in postural control as the lateral SNr 
regulates muscle tone through GABAergic projections to the PPN, which is a MLR 
nuclei implicated with balance regulation (Collomb-Clerc & Welter, 2015; Takakusaki, 
Habaguchi, Ohtinata-Sugimoto, Saitoh, & Sakamoto, 2003). Cholinergic-based deficits 
have been supported through lesioning studies of PPN neurons in primates, which elicited 
L-DOPA resistant gait and postural deficits (Grabli et al., 2013). In addition, a correlation 
between reduction of cholinergic PPN neuronal size and quantity with FOG presentation 
and fall frequency was confirmed post-mortem (Zweig, Jankel, Hedreen, Mayeux, & 
Price, 1989; Rinne, Ma, Lee, Collan, & Röyttä, 2008).  
1.7.3 Spatio-temporal gait parameters  
Spatio-temporal gait parameters may be analyzed for disease or injury diagnosis, fall risk 
evaluation, and assessment of the efficacy of various therapies such as DBS (Egerton, 
Thingstad, & Helbostad, 2014). Quantitative gait descriptions are often expressed with 
respect to a stride or step. A stride is the distance between the initial heel contact to the 
consecutive heel contact of the ipsilateral foot. A stride is composed of two steps; thus, 
one step is the distance between the initial heel strike to the consecutive heel strike of the 
contralateral foot. Step based expressions are preferred over stride expressions because 
steps reveal the potential right-left asymmetry of gait, which is indicative of an irregular 
gait pattern common in PD (Johnsen, Sunde, Mogensen & Østergaard, 2010).  
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Gait parameters are categorized into respective domains, which may elucidate 
separate neural circuits facilitating various gait features—namely spatio-temporal or 
postural measures. A spatial (length), temporal (time and double support time), and 
spatiotemporal domain (velocity) often model the cardinal Parkinsonian gait as step 
length and gait velocity reductions and step time and total double support time (TDST) 
increases (Morris, Iansek, Matyas, & Summers, 1994). Definitions for the 
aforementioned parameters follow: step length—distance between consecutive heel 
strikes of opposite feet measured parallel to the advancement trajectory (measured in 
cm); step time—period to advance from one foot contact to the consecutive heel strike of 
the opposite foot (measured in seconds); stride velocity—ratio of stride length to time 
(measured in cm/sec); and TDST—sum of all time periods during which, both feet are 
supporting the body and making direct contact with the ambulation surface (measured in 
seconds) (Huxham, Gong, Baker, Morris, & Iansek, 2006). Notably, TDST is a postural 
measure but may be assessed in the temporal domain (Collomb-Clerc & Welter, 2015).  
 Step length, step time, and gait velocity reflect the amplitude, rhythm or timing, 
and velocity of locomotion, respectively; thus, reflecting spatio-temporal gait features, 
which are regulated by BG such as the striatum (Alexander et al. 1986). On the other 
hand, TDST is more representative of postural control and has been correlated to FOG 
and spontaneous fall risk, which are axial deficits that manifest later in PD and tend to be 
less responsive to L-DOPA and STN-DBS (Collomb-Clerc & Welter, 2015; Hausdorff et 
al., 2003; Plotnik, Giladi, Dagan, & Hausdorff, 2011). Therefore, TDST is postulated to 
be regulated by cholinergic networks in the brainstem that involve the spinal cord, 
cerebellum, BG, and cortex (Collomb-Clerc & Welter, 2015; Takakusaki, 2017).  
1.7.4 Technology utilized for gait research  
Gait can be recorded using pressure sensitive mats embedded with sensors to record foot 
falls, which are subsequently extracted as spatio-temporal gait parameters using analysis 
software. The GAITRite (NJ, USA) and ZenoTM (PA, USA) walkways are utilized 
alongside GAITRite and ProtoKinetics Movement Analysis Software (PKMAS), 
respectively. GAITRite is a more established program while PKMAS and the ZenoTM 
walkway are a newer system (Egerton et al., 2014). Vallabhajosula et al. (2017) reported 
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an acceptable validity of the recording ability of both walkway systems with differences 
only reported with fast pace walking; however, differences in surface texture, walkway 
dimensions, and walking assessment protocol were not accounted for and could address 
differences (Vallabhajosula, Humphrey, Cook, & Freund, 2017). Egerton et al. (2014) 
demonstrated that there was no difference between the outputs of PKMAS and the 
GAITRite analysis software except for base width and foot angle, which requires further 
validation of the PKMAS calculation (Egerton et al., 2014). In addition, gait analysis 
softwares calculate the functional ambulation performance (FAP) score, which is an 
overall measure of gait used to assess ambulation at self-selected paces (Gouelle, 2014). 
The score is calculated by deducting points from a maximal score of 100 for deviations 
from a healthy gait; notably, scores between 95 to 100 represent gait in a non-diseased 
adult population (Gouelle, Mégrot, Presedo, Penneçot, & Yelnik, 2011; Gouelle, 2014).  
1.7.5 Literature investigating the effect of deep brain stimulation on 
Parkinsonian gait   
Improvement of appendicular symptoms elicited by DBS has been consistently replicated 
in scientific investigations; however, axial symptom response is more variable in the 
clinical realm and literature. Stimulation may worsen or have no effect on axial 
symptoms postulated to be predominantly regulated by non-dopaminergic mechanisms 
such as FOG (Adams, Keep, Martin, McVicker, & Kumar, 2011; Collomb-Clerc & 
Welter, 2015; Cossu & Pau, 2017; Ferraye et al., 2008; Fleury et al., 2016; van Nuenen et 
al., 2008; Stolze et al., 2001). Gait dysfunction that is dopamine responsive typically 
improves upon initial stimulation but in a more variable degree than appendicular 
symptoms; in addition, these improvements may fail to maintain over time (Anderson et 
al., 2005; Collomb-Clerc & Welter; Cossu & Pau, 2017; Fasano et al., 2010; Ferrarin et 
al., 2005; Krystkowiak et al., 2003; Moro et al., 2010; Rodriguez-Oroz et al., 2005). In 
present clinical practice, patients with axial symptoms that are non-responsive to L-
DOPA or exhibit severe postural and gait instabilities are excluded from DBS. 
 Many studies investigate the effect of DBS on gait using quantitative analyses of 
spatio-temporal gait parameters. Significant improvements in gait velocity and length are 
most commonly reported (Allert et al., 2001; Cantiniaux et al., 2009; Faist et al., 2001; 
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Ferrarin et al., 2002; Ferrarin, Rizzone, Lopiano, Recalcati, & Pedotti, 2004; Ferrarin et 
al., 2005; Krystkowiak et al., 2003; Stolze et al., 2001; Vallabhajosula et al., 2015; Xie, 
Krack, Benabid, & Pollak, 2001). Improvements in TDST are also often reported and 
expressed as the reduction of dual stance support during the gait cycle (Faist et al., 2001; 
Ferrarin et al., 2002; Johnsen et al., 2010; Krystkowiak et al., 2003; Xie et al., 2001). 
However, effects on step time are much more variable with accounts reporting no effect, 
an increase, or a decrease to step time following DBS (Allert et al., 2001; Krystkowiak et 
al., 2003; Lubik et al., 2006). Altogether, STN-DBS tends to improve amplitude and 
velocity gait features; however, FOG and postural instability tend to be aggravated or 
inadequately improved (Collomb-Clerc & Welter, 2015; Cossu & Pau, 2017).   
 In addition, gait response is substantially affected by contact localization 
(Collomb-Clerc & Welter, 2015; Cossu & Pau, 2017; Fleury et al., 2016; Johnsen et al., 
2010; Tommasi et al., 2007). Johnsen et al. (2010) used magnetic resonance imaging to 
confirm contact localization and found that contacts targeted to the dorsal STN 
significantly improved UPDRS motor scores and quantitative measures of step length, 
step velocity, and gait balance compared to ventral STN stimulation (Johnsen et al., 
2010). In addition, adverse effects such as FOG and gait hypokinesia were induced with 
current spread into dorsal and anterior regions of the STN influencing the Zi and the 
fields of forel, which paradoxically improved tremor, rigidity, and dyskinesia (Cossu & 
Pau, 2017; Fleury et al., 2016; Tommasi et al., 2007). Improvement of dyskinesia may be 
attributed to the influence of the pallidofugal fibres, which have been implicated with 
dyskinesia relief (Hamani et al., 2004).  
DBS has also been reported to elicit poor clinical outcomes of Parkinsonian gait; 
for instance, the frequency of falling increases following DBS, especially when 
comparing STN-DBS to GPi-DBS (Hausdorff, Gruendlinger, Scollins, O’herron, & 
Tarsy, 2009). In rare and severe cases, DBS was reported to induce freezing or postural 
deficits in patients with no history of these symptoms such as a dystonia patient, which 
suggests an underlying cause directly related to DBS (Cossu & Pau, 2017; Tommasi et 
al., 2007; Zauber, Watson, Comella, Bakay, & Metman, 2009). In less severe cases, 
worsening of axial symptoms may be attributed to disease progression (Cossu & Pau, 
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2017). Axial symptoms manifest in later stages and DBS is not disease protective; 
therefore, induction or worsening of axial symptoms is plausible (Cossu & Pau, 2017; 
Kalia & Lang, 2015). Inadequate alleviation of gait symptoms may also arise from 
standard clinical practices that bias improvement of upper limb symptoms during DBS 
implementation procedures such as contact selection. Furthermore, another profound 
clinical enigma is the worsening or resistance of gait deficits that initially improved 
following stimulation around five years following surgical implantation (Fasano et al., 
2010; Rodriguez-Oroz et al., 2005).  
 Unsatisfactory and inconsistent clinical outcomes of gait following DBS has 
motivated researchers to explore different applications such as altering stimulation 
parameters and assessing various targets. Commonly, frequency reduction is investigated 
as reports state that low frequency stimulation may be beneficial for axial symptoms; 
however, results have been inconsistent (Ramdhani, Patel, Swope, & Kopell, 2015; 
Sidiropoulos et al., 2013). Among five patients, stimulation of 60 Hz improved the 
worsening of L-DOPA responsive gait dysfunction that was worsened by stimulation at 
130-185 Hz in all patients but one (Ramdhani et al., 2015). However, the largest sample 
to date investigated the switch from 130 Hz to 80 Hz and did not find significant 
differences in the total motor UPDRS scores or within the gait sub-score (Sidiropoulos et 
al., 2013). In addition, the PPN is commonly investigated due its involvement in 
locomotion (Fasano et al., 2015; Mazzone et al., 2005; Plaha & Gill, 2005; Stefani et al., 
2007; Takakusaki, 2017). Stefani et al. (2007) reported that PPN-DBS, STN-DBS, and 
STN & PPN DBS provided significant reductions in the UPDRS motor scores compared 
to “OFF” stimulation; however, PPN-DBS elicited significantly smaller reductions 
compared to STN-DBS and simultaneous STN and PPN DBS (Stefani et al., 2007). In 
addition, all three stimulation conditions elicited significant reductions in the axial sub-
scores; however, no target was superior (Stefani et al., 2007). Overall, studies suggest 
that PPN-DBS is unfeasible due to the difficulty of localizing the target and the 
associated mild improvement of L-DOPA resistant gait deficits (Fasano, et al., 2015; 
Mazzone et al., 2005; Plaha & Gill, 2005; Stefani et al., 2007). 
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1.8 Rationale 
The response of Parkinsonian gait deficits to STN-DBS is more variable compared to 
other motor symptoms such as tremor. This phenomenon extends to L-DOPA responsive 
gait symptoms as well, which are expected to improve. The variable responsiveness may 
be attributed to the physiological and pathological features of gait. Physiologically, gait 
facilitation relies on multiple interacting circuits within the musculoskeletal and nervous 
system; namely, the cerebral cortex, basal ganglia, thalamus, cerebellum, brainstem, and 
spinal cord. Pathologically, other Parkinsonian motor symptoms such as rigidity and 
bradykinesia influence gait. Furthermore, clinical implementation procedures of DBS 
including intraoperative contact localization and postoperative contact selection bias the 
improvement of upper limb symptoms leading to an oversight of gait improvement. The 
paradoxical worsening of gait despite improvement of tremor and dyskinesia when 
current spreads into the anterior zona incerta and fields of forel with STN stimulation 
demonstrates the difficulty of achieving gait alleviation in present clinical practice 
(Fleury et al., 2016). Altogether this reasonably suggests that Parkinsonian gait therapy is 
more sensitive to the contact localization and the resultant stimulation area.  
The variable outcome of L-DOPA responsive gait deficits may be addressed by 
CS, which fractionates current to fine-tune the stimulation field shape to provide more 
regulatory control to improve neuroanatomical targeting. Current fractionations may be 
tailored to contact localizations to systemize programming. Therefore, the spherical field 
shape exhibited by unipolar stimulation can be shaped to reduce the radial spread to 
improve the efficacy of the practical and clinical outcome. In a practical context, CS 
reduces the TEED to each contact, which yields stimulation that is associated with the 
reduction of power consumption, the IPG battery drainage rate, and tissue damage risk. In 
a clinical context, CS should reasonably improve Parkinsonian gait deficits to a greater 
degree compared to conventional single-contact stimulation through the improved 
accuracy of neuroanatomical targeting and reducing tissue damage risk. The feasibility of 
CS has been reported in the literature; the first human case study exhibited the ability of 
CS to lower the efficacy threshold by providing symptom alleviation at the same 
amplitude that single-contact stimulation yielded dyskinesia and inadequate symptom 
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relief (Barbe et al., 2014). In addition, the first multicentre study reported that majority of 
patients that initiated programming with single-contact stimulation switched to CS by the 
one year follow up (Timmermann et al., 2015). However, a direct comparison of vertical 
CS and conventional single-contact stimulation has yet to be performed especially in 
context of practical and clinical effectiveness at the level of individual gait parameters 
and overall ambulation using gait recording technology.  
1.9 Hypothesis 
It is hypothesized that CS is an effective programming technique that improves the 
efficacy of the clinical outcome of Parkinsonian gait deficits and practical utility of the 
DBS system compared to conventional, single-contact DBS.  
1.10 Objectives 
1. Chapter 1—To compare the clinical and practical efficacy of CS versus conventional 
stimulation for Parkinsonian gait therapy by determining the differential effect on the 
FAP score and the TEED value and to assess the correlation between the two measures. 
2. Chapter 2—To determine the differential effect on individual gait parameters, as 
measured by percent changes from baseline when comparing various stimulation settings 
and models encompassing unilateral CS, bilateral CS, or non-CS (conventional single-
contact) DBS across increasing amplitudes in the TW.  
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Chapter 2  
2 Assessing the clinical and practical efficacy of 
vertical current steering in deep brain stimulation 
for Parkinsonian gait therapy   
2.1  Introduction   
2.1.1 Parkinson’s disease & deep brain stimulation 
Following Alzheimer’s, Parkinson’s disease (PD) is the second most common 
neurodegenerative disease (Bertram & Tanzi, 2005). Family history of PD or tremor 
increases PD risk and age serves as the greatest risk factor as PD manifests with adult 
onset (Kalia & Lang, 2015). When accounting for age, approximately 30% of neuronal 
degeneration in the substantia nigra is associated with motor symptom onset, which 
typically coincides with time of diagnosis (Cheng, Ulane, & Burke, 2010; Fearnley & 
Lees, 1991). PD is characterized by the cardinal motor symptoms—bradykinesia, rigidity, 
rest tremor, and postural and gait instability; the latter represents axial symptoms that 
manifest later in disease and the remainder constitute appendicular symptoms that are 
usually present around diagnosis (Gibb & Lees, 1988; Kalia & Lang, 2015).  
Deep brain stimulation (DBS) is a secondary therapy to address disabling 
dyskinesia and motor fluctuations from long-term use of Levodopa (L-DOPA) through 
chronic transmission of electrical pulses to neural tissue through stereotactic localized 
electrodes (Kalia & Lang, 2015; Tran, Vo, Frei, & Truong, 2018). DBS does not reverse 
or cure disease pathology; however, it consistently relieves appendicular symptoms but 
its effect on axial symptoms remains more elusive and variable (Cossu & Pau, 2017). The 
dorsolateral subthalamic nucleus (STN) is somatotopically organized and associated with 
sensorimotor function; suitably, it is the most common target for treating motor 
symptoms. STN-DBS consistently alleviates appendicular symptoms and substantially 
decreases the L-DOPA dose with some ceasing L-DOPA therapy, which is a unique 
feature compared to other common targets such as the internal globus pallidus (Anderson, 
Burchiel, Hogarth, Favre, & Hammerstad, 2005; Follett et al., 2010; Mahlknecht, 
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Limousin, & Foltynie, 2015; Odekerken et al., 2013; Okun et al., 2009; Tankus et al., 
2017; Tewari, Jog, & Jog, 2016; Zahodne et al., 2009).  
In present clinical practice, patients with severe or L-DOPA resistant postural and 
gait instabilities are often excluded from DBS. Gait deficits attributed to rigidity and 
bradykinesia such as reduced step size and gait velocity tend to respond to L-DOPA and 
STN-DBS; however, deficits such as freezing of gait tend to worsen or manifest no 
change (Allert et al., 2001; Cantiniaux et al., 2009; Collomb-Clerc & Welter, 2015; 
Follett et al., 2010; Stolze et al., 2001; Vallabhajosula et al., 2015). Nonetheless, L-
DOPA responsive gait deficits still exhibit a more variable responsiveness to STN-DBS 
compared to appendicular symptoms. Parkinsonian gait is influenced by bradykinesia and 
rigidity and requires the extensive physiological integration of the musculoskeletal 
system and the spinal cord, brainstem, cerebellum, basal ganglia, and cerebral cortex to 
facilitate gait (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Thus, the variable 
responsiveness may be attributed to a greater sensitivity of gait therapy to the resultant 
stimulation area and the clinical bias towards upper limb symptom improvement during 
intraoperative contact localization and postoperative contact selection. Thus, gait 
improvement may require greater regularity of the resultant stimulation field.  
2.1.2 Advances in deep brain stimulation technology  
Until recently, DBS systems have been conventionally voltage-controlled (VC), which 
inconsistently deliver charge due to impedance fluctuations at the contiguous border 
between the neural tissue and contact (Butson, Maks, & McIntyre, 2006; Miocinovic et 
al., 2007). Thus, charge delivery may not match the programmed value, which renders 
frequent programming adjustments due to inadequate stimulation of the target (Wagle 
Shukla, Zeilman, Fernandez, Bajwa, & Mehanna, 2017). Notably, variable stimulation 
may additionally account for the elusive effect of DBS on gait since its improvement may 
be particularly sensitive to the resultant stimulation area.  
Inadequate improvement of symptoms and the difficulty with programming in 
complex cases prompted the development of current-controlled (CC) systems with 
multiple independent current control (Butson et al., 2006; Lempka, Miocinovic, Johnson, 
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Vitek, McIntyre, 2009; Wagle Shukla et al., 2017). CC devices adjust the voltage to 
account for impedance fluctuations to ensure that charge distribution is consistent and the 
current amplitude matches the programmed value (Butson et al., 2006; Wagle Shukla et 
al., 2017). Multiple independent current control allows for individual manipulation of 
current delivery from each contact as a separate entity; thus, the current distribution can 
be divided among multiple contacts or contact segments of segmented leads to facilitate 
vertical current steering (CS) (Butson & McIntyre, 2008). Division of the current 
distribution is referred to as vertical CS or CS for short and serves as a systemized 
technique to fine-tune the stimulation field for accurate neuroanatomical targeting 
(Chaturvedi, Foutz, & McIntyre, 2012). Current division shapes the stimulation field 
since the percentage of current stimulation is directly related to the electric field spread; 
therefore, contacts stimulating with a greater percentage will exhibit a broader spread. In 
addition, divisions are quantifiable; thus, algorithms associating divisions to contact 
localizations may replace present, empirical approaches to DBS programming (Wagle 
Shukla et al., 2017).  
 Presently, single-contact, unipolar stimulation is programmed in standard clinical 
care; the resultant stimulation produces an approximate spherical field around the active 
contact due to diffuse, radial current spread. The broad distribution of the electric field 
increases side effect risk, which is particularly problematic for sub-optimally localized 
electrodes but poses a risk regardless of localization at high amplitudes (Butson, Cooper, 
Henderson, &, McIntyre, 2007; Deli et al., 2011; McIntyre, Mori, Sherman, Thakor, & 
Vitek, 2004). Therefore, CS can reduce radial spread of conventional stimulation fields to 
optimize neuroanatomical targeting to potentially address inadequate symptom 
alleviation with present systems.  
2.1.3 Therapeutic practicality of deep brain stimulation  
In addition to adequate symptom alleviation, effective programming requires the 
minimization of tissue damage risk and power consumption to prolong battery life of the 
impulse generator (IPG). Tissue damage risk is based on charge density levels and is 
calculated by dividing the product of current and pulse width by the surface area of the 
contact (Kuncel & Grill, 2004). Thus, charge density is directly related to the current 
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amplitude. Tissue damage associated with chronic DBS is minimal when the charge 
density is considerably below recommended levels (Haberler et al., 2000; Kuncel & Grill, 
2004). Minimal tissue damage is often a result of gliosis, which constitutes the 
proliferation or hypertrophy of glial cells as a response to central nervous system damage. 
In extreme cases, gliosis may result in scarring, which impedes axonal regeneration (Yiu 
& He, 2006). Moreover, power usage is directly related to the IPG battery drainage rate, 
which is influenced by programming factors such as the electrode geometry and 
magnitude of stimulation parameters. Factors such as the system impedance, frequency of 
programming changes, and total duration of stimulation also influence the battery life but 
are harder to regulate. Nonetheless, minimal power consumption is pursued to maintain 
battery life since need for IPG replacement may arise as early as three to five years post-
implantation in non-rechargeable systems (Kuncel & Grill, 2004). 
Unipolar electrode geometries designate the IPG as the anode and typically one 
contact as the cathode; however, multiple contacts can serve as the cathode, which is 
implemented with CS. Unipolar configurations are associated with a lower side effect and 
therapeutic threshold; therefore, lower amplitudes provide symptom alleviation, which is 
beneficial to reduce tissue damage risk and power consumption (Kuncel & Grill, 2004). 
Bipolar configurations are conventionally implemented when single-contact, unipolar 
stimulation is ineffective for symptom alleviation. At higher amplitudes, bipolar 
configurations may be less likely to induce side effects since the stimulation field is more 
confined. Both the anode and cathode are situated in the brain since one contact is set as 
the anode and another is set as the cathode. However, power consumption is higher with 
bipolar stimulation; thus, unipolar stimulation is still preferred to prolong battery life 
(Butson et al., 2007; Deli et al., 2011; Kuncel & Grill, 2004; Volkmann, Moro, & Pahwa, 
2006). Furthermore, frequency, pulse width, and current magnitudes must be 
programmed with a compromise between adequate symptom alleviation and minimized 
tissue damage risk and power usage to prolong battery life. For instance, low frequency 
stimulation between 13-130 Hz may worsen bradykinesia and increasing the current 
amplitude within the therapeutic window provides greater symptom alleviation but 
stimulation at higher amplitudes expedites drainage of the IPG battery (Moro et al., 
2002).  
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2.1.4 Total electrical energy delivered 
The total electrical energy (TEED) delivered is an integrative measure incorporating 
stimulation parameters and impedance, which are variables that influence the electric 
field (Butson et al., 2006; Kuncel & Grill, 2004). The concept was first introduced by 
Moro and colleagues; however, it was later modified by Koss and colleagues using 
derivations with standard physics equations such as Ohm’s law (Koss, Alterman, Tagliati, 
& Shils, 2005; Moro et al., 2004). The TEED equation suggested by Koss and colleagues 
is as follows: 
TEED1sec = 
(𝑣𝑜𝑙𝑡𝑎𝑔𝑒)2× (𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦) × (𝑝𝑢𝑙𝑠𝑒 𝑤𝑖𝑑𝑡ℎ)
𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒
 ×  1𝑠𝑒𝑐𝑜𝑛𝑑. 
TEED has been studied in the context of practical efficacy through its effect on 
IPG battery life (Bin-Mahfoodh, Hamani, Sime, & Lozano, 2003; Helmers et al., 2018; 
Niemann, Schneider, Kühn, Vajkoczy, & Faust, 2018; van Riesen et al., 2016). In 
addition, the TEED measure integrates stimulation parameters such as current and pulse 
width, which are used to calculate the charge density of stimulation that is associated 
with tissue damage risk (Kuncel & Grill, 2004). Therefore, the TEED measure may be 
used to reflect tissue damage risk as well. Pulse width and TEED are directly related to 
the IPG battery drainage rate; therefore, stimulation with lower TEED and pulse width 
values delay battery depletion and need for surgical replacement of the IPG (van Riesen 
et al., 2016). Faster drainage results in an earlier and more probable need for re-
implantation, which is a minor surgical procedure; however, surgical replacements of the 
IPG are an elective procedure; thus, are often delayed due to availability of surgical staff 
and operating rooms. In addition, risk of inadequate symptom alleviation following IPG 
replacement is common and requires tedious, manual re-selection of stimulation 
parameters, which is laborious due to the lack of established protocols (Allert, Kirsch, 
Weirich, & Karbe, 2009; Wagle Shukla et al., 2017). Allert and colleagues reported that 
around 20% of cases of inadequate symptom alleviation, following IPG replacement, are 
attributed to idiopathic reasons that are not related to evident reasons such as errors in 
hardware restoration, which makes programming particularly difficult (Allert et al., 
2009). In addition, Pepper et al. (2013) reported that the infection rate was more than 
three times higher than the initial implantation (Pepper et al., 2013).  
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2.1.5 Rationale 
CS is a stimulation technique that may account for clinical and practical logistics of DBS. 
CS shapes the stimulation field, which reduces the diffuse radial spread of the 
conventional spherical field to improve neuroanatomical targeting and the resultant 
clinical outcome. In addition, CS should reduce the TEED through current fractionation, 
which ultimately decreases power consumption and the IPG battery drainage rate to 
improve the practical outcome. Reducing the TEED additionally improves the clinical 
outcome by decreasing the side effect and tissue damage risk. Altogether, it is reasonable 
to suggest that CS may address the variable improvement of L-DOPA responsive gait 
deficits in a feasible systemized manner.  
L-DOPA responsive gait deficits exhibit a more inconsistent response to STN-
DBS compared to other motor symptoms such as tremor. The varying response may be 
attributed to the extensive integration that facilitates gait physiologically, the influence of 
bradykinesia and rigidity in PD, and the bias of upper limb symptom improvement during 
DBS implementation. Thus, tailoring current fractionations to contact localizations may 
minimize current spread and improve the accuracy of targeting the array of interacting 
circuits that regulate gait within the cerebral cortex, thalamus, basal ganglia, brainstem, 
cerebellum, and spinal cord. In addition, the ability to employ separate fractionation 
programs may be implemented to alleviate appendicular and axial symptoms to overcome 
the bias towards upper limb symptom improvement during intraoperative contact 
localization and postoperative contact selection. The predicted clinical benefit should be 
accompanied by an improved practicality of the DBS system through reduction of the 
TEED value.  
The feasibility of CS has already been reported in the literature; the first human 
case study found that CS reduces the efficacy threshold and the first multicentre study 
reported that majority of patients initiated programming with single-contact stimulation 
but switched to CS by the one year follow up (Barbe, Maarouf, Alesch, & Timmermann, 
2014; Timmermann et al., 2015). However, comparisons of CS to conventional single-
contact stimulation regarding the outcome of Parkinsonian gait deficits and the practical 
outcome of the DBS system in the context of power consumption measured by the TEED 
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have yet to be investigated. In addition, distinct to other studies, the present investigation 
assesses gait with quantitative measures provided by gait recording technology and 
analysis software, which eliminates examiner bias and variation associated with the 
Unified Parkinson’s Disease Rating Scale (UPDRS)—the clinical standard that provides 
ordinal measures.    
2.1.6 Objectives 
1. To assess the effect of CS and conventional single-contact stimulation on 
functional ambulation performance (FAP) scores and TEED values individually. 
2. To determine and compare the correlation between FAP and TEED in CS and 
conventional single-contact stimulation.  
2.1.7 Hypotheses 
For the first objective, it is hypothesized that CS will improve FAP scores to a greater 
degree and TEED values will be reduced when compared to single-contact stimulation. 
For the second objective, it is hypothesized that TEED values and FAP scores will be 
more positively correlated when implementing CS, which exhibits greater practical and 
clinical efficacy through yielding higher FAP scores at lower TEED values. 
2.2 Methods 
2.2.1 Study sample & inclusion and exclusion criteria  
The present investigation was approved by the Human Subjects Research Ethics Board 
(REB) at Western University (REB #108453). Patients were selected based on clinical 
standards. Inclusion criteria included: diagnosis of idiopathic PD with L-DOPA 
responsive motor symptoms as assessed with the standard L-DOPA challenge test, 
disabling motor fluctuations and dyskinesia, and absence of dementia or psychiatric 
abnormalities confirmed by neuropsychological testing (Albanese et al., 2001). 
Additionally, participants were excluded based on: history of brain surgery, previous 
implantation of a cardiac pacemaker, overall poor health, and tendency to exhibit lack of 
compliance. Ultimately, nine participants provided informed consent; however, two 
patients were withdrawn for adverse health concerns unrelated to the study or ineligibility 
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due to implantation with a DBS system unable to perform CS. The analyzed sample of 
seven were diagnosed with idiopathic PD for an average duration of 12.5 years and 
included three males and four females with an average age of 61.  
2.2.2 Clinical Procedures—surgical implantation and contact 
selection  
All DBS devices were implanted by a surgeon trained in functional neurosurgery 
practicing at University Hospital, London Health Sciences Centre (London, ON, CA); 
electrodes and the IPG were implanted within the same day unless complications arose. 
All participants were implanted with the VerciseTM PC IPG and the CartesiaTM 
Directional leads or the VerciseTM IPG and the associated leads, which are equipped with 
multiple independent current control (Boston Scientific, Valencia, CA, USA). Local 
anesthesia was utilized for electrode implantation; however, the participant was 
subsequently under general anesthesia for IPG implantation. Pre-surgical magnetic 
resonance imaging identified the neuroanatomical positioning of the STN through 
standard stereotactic coordinates based on the anterior commissure (AC) and posterior 
commissure (PC). Standardly the dorsolateral STN is targeted following these 
guidelines—4.0 mm ventral to the AC-PC plane, 2.0 mm posterior to the mid-
commissural point, and 12.0 mm lateral to the midline of the plane (Rabie, Verhagen 
Metman, & Slavin, 2016). Intraoperatively, a stereotactic Leksell frame mounted the 
head and a computed tomography scan was used to merge stereotactic coordinates from 
the magnetic resonance image to the surgical computer. The STN positioning in the 
dorsal to ventral axis was confirmed with recordings from five microelectrodes 
temporarily implanted to denote a central, anterior, posterior, medial, and lateral channel. 
Each microelectrode detected spike potentials denoting signatures of nuclei as it traversed 
ventrally in the dorsal to ventral axis. In addition, the microelectrodes provided 
stimulation to assess the clinical outcome based on localization. The implantation 
trajectory of the therapeutic electrode was determined by the microelectrode that 
exhibited the most extensive STN spike signature and provided the greatest improvement 
of tremor and rigidity. 
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Two contact reviews were performed to select two contacts in the left and right 
STN for implementation of CS. The initial contact review was performed when the IPG 
was turned on, approximately one month following surgical implantation and the second 
review was performed around two weeks after the initial contact review. A unipolar 
contact review of all contacts was performed for the initial review to identify the 
individual contact eliciting the widest TW; however, the second contact review paired the 
initial contact, determined by the previous review, with all the other contacts to find the 
pair of contacts that elicited the widest TW. During the second contact review, each 
contact of the pair was stimulated with 50% of the current. The TW was defined by the 
upper and lower limit or the side effect and efficacy threshold, respectively. To determine 
the TW, the current amplitude was increased with increments of 0.5 mA until side effect 
manifestation. Subsequently, the previous amplitude was programmed and increments of 
0.1 mA confirmed the exact side effect threshold. UPDRS motor items including: finger 
taps, upper limb rigidity, and rest tremor served as the primary measures of symptom 
improvement but postural tremor was assessed additionally for some patients. Blurry 
vision, face pulling, dystonia, dysarthria, and any uncomfortable, intolerable sensations 
were noted as side effects. Namely, dystonia describes twisting or atypical fixed postures 
attributed to continuous or repetitive muscle contractions (Magrinelli et al., 2016). After 
the IPG was turned on, the patient accustomed to stimulation with an amplitude of 0.5 
milliamperes (mA) until the start of the CS investigations. The frequency and pulse width 
were consistent throughout the entire investigation as 130 Hz and 60 µs, respectively. 
Notably, one patient was stimulated with a pulse width of 90 µs. 
2.2.3 Study Design 
CS investigations began immediately after the second contact review, which was 
approximately six weeks following surgical implantation. Bilateral applications of CS 
were compared to conventional, single-contact stimulation among eight investigational 
settings that represented bilateral CS or bilateral non-CS stimulation models (Table 1). 
CS was implemented with unipolar stimulation with current divisions of 50/50 and 70/30 
between two contacts. Notably, segmented leads (CartesiaTM Directional leads) were 
always stimulated in the ring mode; therefore, all three segments were active and current 
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was divided equally. All investigational settings were repeated over four consecutive 
weeks such that the amplitude was increased by approximately 20% each week (Table 2). 
Investigational settings were randomized across patients; however, the order remained 
consistent throughout the consecutive weeks for each participant. Following the 
programming of each investigational setting, a 25-minute washout period was enforced 
before the subsequent gait assessment.  
 Table 1: Investigational settings of bilateral CS and bilateral non-CS stimulation.  
A) represents the ventral contact and B) represents the dorsal contact. 
Setting Number Stimulation Model Left STN Right STN 
1 Bilateral non-CS A): 100% B): 0% A): 100% B): 0% 
2 Bilateral non-CS A): 100% B): 0% A): 0% B): 100% 
3 Bilateral non-CS A): 0% B): 100% A): 100% B): 0% 
4 Bilateral non-CS A): 0% B): 100% A): 0% B): 100% 
5 Bilateral CS A): 70%   B): 30% A): 70%   B): 30% 
6 Bilateral CS A): 70%   B): 30% A): 50%   B): 50% 
7 Bilateral CS A): 50%   B): 50% A): 70%   B): 30% 
8 Bilateral CS A): 50%   B): 50% A): 50%   B): 50% 
 
Table 2: Stimulation amplitudes with respect to the CS investigational week.  
Week refers to the CS investigational week.   
Week Current Amplitude 
1 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.2) 
2 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.4) 
3 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.6) 
4 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.8) 
 
2.2.4 Gait Assessments  
Gait assessments were recorded using a 0.61 metre by 6.1 metre ZenoTM walkway 
(ProtoKinetics, Peekskill, NY) without shoes, assistive walking devices (verbal cues, 
splints, or orthoses), or ambulatory aids (canes, crutches, or walkers) (Gouelle, 2014). 
Standard, non-skid hospital socks were worn to reduce fall risk when walking adjacent to 
the ZenoTM walkway. Forwards walking was assessed at a self-selected pace, as 
participants were instructed to walk at their daily ambulatory pace. Subjects arose from a 
seated position to walk for five continuous loops in a clockwise direction to maintain 
speed through gradual turns and to allow recordings in a uniform direction. Ambulation 
away from the initial seated position was always recorded on the pressure sensitive 
walkway; however, walking towards the start position was exercised off the walkway.  
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2.2.5 Extraction and calculation of the TEED value  
TEED value calculations for each investigational setting at each stimulation amplitude 
required extraction of the associated current amplitude and impedance. Frequency and 
pulse width remained at 130 Hz and 60 s (and 90 s for one patient)— respectively. 
Current amplitude corresponded to the investigational week with an increasing magnitude 
throughout the consecutive weeks as displayed in Table 2. Impedance values for each 
active contact were retrieved from a single time point at least nine weeks following 
surgical implantation to ensure that impedance values were relatively consistent. The 
impedance between each individual contact and the IPG was recorded since a unipolar 
electrode geometry was implemented. Notably, impedance values for each individual 
segment and the IPG were obtained for segmented levels of directional leads.  
TEED values were calculated for each individual contact following the 
International System of Units; therefore, current was converted from milliamperes to 
amperes and pulse width was converted from microseconds to seconds. Using Ohm’s 
law, the voltage component was replaced with current and all TEED calculations 
followed this equation: 
TEED1sec = (𝑐𝑢𝑟𝑟𝑒𝑛𝑡)2 × (𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒) ×  (𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦) ×  (𝑝𝑢𝑙𝑠𝑒𝑤𝑖𝑑𝑡ℎ).  
The current amplitude for each contact was computed based on the current 
fractionations for each respective setting. For instance, if the current division was 50/50, 
the amplitude was divided equally among the two contacts. Furthermore, stimulation in 
the ring mode approximated all segmented contacts to receive equal percentages of 
current. Therefore, 50% of the current stimulating a segmented level would approximate 
each segment to be stimulated with 50% of the amplitude divided by 3. TEED for the 
segmented levels of the CartesiaTM Directional lead required summation of individual 
TEED values for each segmented contact. For instance, the TEED value for the 
segmented level of contacts 13,14, and 15 was calculated as TEED131415 = TEEDcontact 13 + 
TEEDcontact 14 + TEEDcontact 15. Following this rule, setting TEED values were calculated 
by summating TEED values of both contacts of the left and right lead (Setting TEED = 
TEEDLEFTContactA + TEEDLEFTContactB + TEEDRIGHTContactA + TEEDRIGHTContactB).  
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2.2.6 Functional ambulation performance calculation 
The ZenoTM walkway recorded foot falls during the walking assessments with embedded 
sensors sensitive to pressure. The ProtoKinetics Movement Analysis Software (PKMAS, 
Havertown, PA) automatically calculated the FAP score. The ZenoTM walkway and 
PKMAS are validated through comparisons to the established GAITRite system 
(Egerton, Thingstad, & Helbostad, 2014; Vallabhajosula, Humphrey, Cook, & Freund, 
2017). Overall ambulation was assessed with the FAP score, which was computed 
automatically by PKMAS. The score was calculated by deducting points for deviations 
from a healthy gait from a maximal score of 100 among four categories (Gouelle, 2014). 
For the left and right step functions category, 22 points were subtracted for abnormal 
values of step time and abnormal ratios of step length and velocity to leg length for the 
left and right side separately (Gouelle, 2014). The step length to leg length ratio 
differentials category assessed differences between the left and right ratios to identify 
abnormal step length asymmetries, which warranted deductions up to eight points 
(Gouelle, 2014). A maximum of eight points were deducted for a base that was too wide 
or narrow compared to the clinically deemed healthy range for the dynamic base of 
support category, and five points were deducted for use of ambulatory aids and assistive 
devices (Gouelle, 2014). Notably, scores between 95 to 100 represent gait in a non-
diseased adult population (Gouelle, Mégrot, Presedo, Penneçot, & Yelnik, 2011).  
2.2.7 Data and Statistical Analyses  
All statistical analyses were performed by GraphPad Prism 6.00 (La Jolla, CA, USA) 
using an alpha criterion of ≤ 0.05. Data were removed if found to be below the difference 
of the first quartile and the interquartile range multiplied by 1.5, above the sum of the 
third quartile and the interquartile range multiplied by 1.5, or based on clinical discretion.  
Three clinical outliers were identified as gait was skewed by dyskinesia or dystonia. 
Normality was assessed using the Shapiro—Wilk test and a two-tailed, Wilcoxon 
matched-pairs signed-rank test assessed the differential effect on FAP and TEED 
individually. A Spearman, two-tailed, correlation was performed to identify the potential 
correlation between the FAP and TEED values with the FAP score set as the dependent 
variable. Lastly, slopes of the linear trend (line of best fit) of the regression between FAP 
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and TEED values in both stimulation conditions were extracted sing Excel. Subsequently, 
means of the slopes for each participant in both stimulation models were assessed for 
differences using a two-tailed, paired, Student’s t-test.  
2.3 Results 
Significant differences were found between the average TEED values elicited by the two 
stimulation models (p < 0.0001) (Figure 6a); however, the FAP score means of both 
stimulation models were not significantly different (p = 0.7861) (Figure 6b). TEED 
values elicited by bilateral CS stimulation were significantly lower than those elicited by 
stimulation without CS (Figure 6a). Furthermore, no correlation was found between the 
FAP and TEED values in the bilateral non-CS stimulation condition (r = 0.132, p = 
0.053) (Figure 7a). However, a positive correlation was found between FAP and TEED in 
the bilateral CS stimulation condition (r = 0.174, p = 0.011) (Figure 7b). The slope for the 
linear trend line of the correlation was steeper in the bilateral CS stimulation condition; 
specifically, the values were found to be 0.1839 and 0.428 for the bilateral non-CS and 
bilateral CS stimulation condition, respectively (Figure 7). The slopes averaged across all 
patients were significantly lower with the bilateral CS stimulation model; specifically 
averages of 0.0639 and 0.5683 in the bilateral non-CS and bilateral CS stimulation model 
were found, respectively (p = 0.0435) (Figure 8; Table 3). 
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Figure 6: The effect of CS and non-CS stimulation on FAP and TEED values. 
Means of the a) TEED values multiplied by 100000 and b) FAP values evaluated during 
normal pace walking in bilateral non-CS and bilateral CS stimulation conditions 
including all stimulation amplitudes (around 20%, 40%, 60%, and 80% of the TW). 
Boxplots with N=7; solid horizontal lines represent the median and the upper and lower 
whiskers represent the maximum and minimum values, respectively. a) TEED values on 
average were significantly lower in the bilateral CS stimulation condition compared to 
the bilateral non-CS stimulation condition (****, p < 0.0001; two-tailed, Wilcoxon 
matched-pairs signed rank test) b) FAP scores on average were not significantly different 
in the two stimulation conditions (p = 0.7861; two-tailed, Wilcoxon matched-pairs signed 
rank test). 
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Figure 7: Correlation between FAP and TEED for CS and non-CS stimulation. 
Correlation between TEED and FAP as the independent and dependent variable, 
respectively; evaluated during normal pace walking and stimulation a) without CS and b) 
with CS at all investigative amplitudes (around 20%, 40%, 60%, and 80% of the TW) 
with N=7. TEED values represented were multiplied by 100000. a) No correlation was 
found; the slope of the linear trend line was found to be 0.1839 (p = 0.0530, r =0.1320; 
two-tailed, Spearman correlation). b) Positive correlation was found with the slope of the 
linear trend line being 0.428 (*, p<0.05, r =0.1740; two-tailed, Spearman correlation). 
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Figure 8: Comparison of the slope of the linear trend of the correlation between 
FAP and TEED in CS and non-CS stimulation.  
Slope of the correlation between FAP and TEED with FAP as the dependent variable; 
evaluated during normal pace walking with and without CS across all investigative 
amplitudes (around 20%, 40%, 60%, and 80% of the TW). Means represented  SD with 
N=7. Slope of the bilateral CS condition was significantly greater than the slope of the 
bilateral non-CS condition (*, p<0.05; two-tailed, Paired student’s t-test). 
 
Table 3: Slopes of the linear trend line of the correlation between FAP and TEED.  
Participant Code Bilateral non-CS Bilateral CS 
BSC-01 0.0633 0.1686 
BSC-02 -0.1647 1.0886 
BSC-03 -0.0416 0.1565 
BSC-05 0.483 1.4016 
BSC-06 -0.0599 -0.0194 
BSC-07 0.1749 0.2115 
BSC-08 -0.0077 0.971 
AVERAGE 0.0639 0.5683 
2.4 Discussion 
TEED was minimized when CS was employed but no differential effect was found on the 
FAP score when comparing the two stimulation types, which partially supports the 
hypothesis (Figure 6). The average TEED elicited by the bilateral CS stimulation settings 
was significantly lower than the average TEED elicited by the non-CS settings (Figure 
6a); however, there was no significant difference between the FAP values in the two 
stimulation conditions (Figure 6b). CS minimizes the TEED to an individual contact 
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through current fractionation; thus, the TEED and charge delivery is divided between 
multiple active contacts rather than involving a single-contact. Raw TEED values 
exhibited lower magnitudes with CS; for instance, 1.83 x 10^-4 (A2•  • Hz • s) and 
9.03 x 10^-5 (A2•  • Hz • s) yielded TEED scores of setting one and six, a bilateral 
non-CS and bilateral CS setting, respectively (Table 1). TEED reduction may suggest the 
benefit of employing CS to reduce power consumption, which prolongs battery life and to 
minimize risk of current spread into non-intended neural structures that may induce side 
effects or tissue damage (Kuncel & Grill, 2004; Henderson et al., 2002; Yiu & He, 2006; 
van Risen et al., 2016).  
TEED was reported to be inversely related to the drainage rate of the IPG battery; 
therefore, reduced TEED helps delay the need for surgical IPG re-implantation, which 
has been reported to elicit a higher infection rate compared to the initial implantation and 
often requires a greater frequency of programming changes to address inadequate 
symptom alleviation (Allert et al., 2009; Pepper et al., 2013). Allert and colleagues 
reported that 20% of patients experience sub-optimal symptom alleviation despite 
accurate restoration of the hardware and programming with parameters that provided 
alleviation before IPG replacement (Allert et al., 2009). Notably, this may not be a 
substantial issue for multiple independent current controlled systems since it was 
postulated that inadequate programming may be attributed to a change in the electrode 
impedance, which conventional VC systems poorly address (Lempka et al., 2009; Wagle 
Shukla et al., 2017). In addition, tissue damage risk has been associated with charge 
density levels, which is directly related to the current amplitude stimulating the contact 
(Kuncel & Grill, 2004). Therefore, the reduced TEED to each contact additionally 
decreases the charge density and tissue damage risk since current fractionations reduce 
the current delivered to each contact. Arguably, charge delivery from multiple contacts 
may interact and superimpose; however, the present methodology cannot confirm this. In 
addition, severe dyskinesia that interfered with gait assessment manifested with single-
contact stimulation rather than CS. Nonetheless it is necessary to reduce the charge 
density because chronic stimulation below the limit can still induce gliosis, which in 
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extreme cases may result in inhibition of axonal regeneration and loss of function 
(Kuncel & Grill, 2004; Yiu & He, 2006).  
The FAP and TEED values in the bilateral non-CS stimulation condition 
exhibited no correlation (Figure 7a); however, a positive correlation was reported for the 
bilateral CS stimulation condition (Figure 7b). FAP scores were directly related to TEED 
values when CS was implemented; thus, gait performance improved as the current 
amplitude increased within the patients’ TW. This supports the hypothesis that TEED 
values would be correlated to FAP scores with CS. The positive correlation may be 
attributed to all the administered amplitudes being within the TW. The enhanced 
therapeutic effect associated with amplitude increases within the TW acts synonymously 
to a higher dosage of oral pharmacotherapy within the patients’ tolerance. Lack of 
correlation exhibited by non-CS stimulation may represent the response variability when 
stimulating from one contact (Wagle Shukla et al., 2017). Conventional stimulation is 
more sensitive to contact localization and the resultant stimulation area since single-
contact stimulation is associated with a greater radial spread that arises from a single part 
of the electrode (Kuncel & Grill, 2004). However, radial current spread is reduced with 
CS since the electric field is more elongated as a result of current fractionation between 
multiple active contacts. Therefore, this suggests that CS requires less programming 
adjustments compared to single-contact stimulation, which is particularly laborious since 
there are no established protocols for programming (Wagle Shukla et al., 2017). Thus, the 
positive correlation of FAP and TEED depicts the clinical effectiveness of CS to improve 
gait as current amplitude increases within the TW, which opposes the more variable 
outcome of gait with non-CS stimulation, which failed to exhibit a correlation between 
FAP and TEED (Figure 7).  
Furthermore, the slope for the linear trend line between the FAP and TEED values 
was steeper with CS, which means that higher FAP scores were elicited at lower TEED 
values (Figure 7). On average, implementing CS bilaterally elicited a significantly steeper 
slope compared to stimulation without CS (Figure 8; Table 3). The slope reflects the 
clinical and practical efficacy; therefore, a steeper slope suggests that CS is more 
effective in clinical and practical terms because higher FAP scores—better gait 
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performance—were elicited at lower TEED values. TEED reduction exhibits practical 
efficacy since it is associated with reduced power consumption, side effect risk, tissue 
damage risk, and IPG battery drainage rate. However, as previously mentioned, CS 
cannot be concluded to improve gait to a greater degree compared to stimulation without 
CS since FAP scores were not significantly different when comparing the two stimulation 
types (Figure 6b).  
The FAP score integrates gait velocity and step length as ratios of leg length and 
measures of dynamic support; in the literature, gait velocity, step/stride length, and total 
double support time are commonly reported to improve following STN-DBS (Allert et 
al., 2001; Cantiniaux et al., 2009; Faist et al., 2001; Ferrarin et al., 2002; Ferrarin, 
Rizzone, Lopiano, Recalcati, & Pedotti, 2004; Ferrarin et al., 2005; Gouelle, 2014; 
Johnsen, Sunde, Mogensen, & Østergaard, 2010; Krystkowiak et al., 2003; Stolze et al., 
2001; Vallabhajosula et al., 2015; Xie, Krack, Benabid, & Pollak, 2001). Accordingly, 
the FAP score improvement elicited by CS is comparable to conventional DBS, which is 
an established therapy for L-DOPA responsive gait parameters (Collomb-Clerc & Welter, 
2015; Wagle Shukla et al., 2017).  
These findings support the utility of CS regarding its clinical and practical 
effectiveness since it can elicit the same FAP scores but at lower TEED values; therefore, 
gait improvement was achieved at lower current amplitudes with reduced power 
consumption. The first case study of CS reported similar findings; in particular, symptom 
alleviation without side-effect induction was elicited at the same amplitude single-contact 
stimulation elicited dyskinesia with sub-optimal symptom alleviation (Barbe et al., 2014). 
Thus, among patients with L-DOPA responsive gait, CS may be implemented to improve 
ambulation with lower TEED values, which minimizes power consumption, tissue 
damage and side effect risk, IPG battery drain rate, and need for IPG replacement.    
2.4.1 Limitations 
The primary limitation to this scientific investigation is the lack of a direct measure of 
battery life. All participants were subject to both types of stimulation; therefore, 
recruitment of novel participants subdivided into those strictly receiving CS or non-CS 
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stimulation should be compared for the time it takes for the battery to drain for a more 
accurate assessment. Another major limitation of the study is related to the integrated 
analysis of segmented contacts and non-segmented contacts. TEED values for segmented 
contacts compared to conventional ring-style contacts were inherently smaller because 
current is additionally fractionated between the segments. Thus, segmented contacts 
stimulate with a lower current and exhibit a lower TEED value especially since the 
current component of the TEED equation is squared. However, due to the small sample 
all types of electrodes were analyzed together; to address this limitation, future analysis 
should analyze segmented contacts and non-segmented contacts separately.  
Notably, conventional stimulation was modelled with single-contact stimulation 
with CC devices; thus, non-CS stimulating settings may not be a true representative of 
conventional stimulation, which employs single-contact stimulation with VC devices that 
are susceptible to variable charge delivery. Furthermore, TEED values may not precisely 
reflect the administration of the setting at the given time point since impedance measures 
were obtained from a single time point following the end of the investigation. The 
literature suggests that impedance may decrease during stimulation; therefore, the 
impedance utilized for the calculation may not accurately reflect the impedance during 
each stimulation setting (Lempka et al., 2009).  
In addition, a 25-minute washout period was implemented based on the 
recommendation of the supervising movement disorder specialist; however, the literature 
states that the period required for adequate wash-out of STN-DBS varies across 
participants and is inversely related with disease duration (Cooper, McIntyre, Fernandez, 
& Vitek, 2013). Therefore, the wash-out period implemented in the present investigation 
may not be adequate for some patients. Furthermore, unequal fractionations of 70%/30% 
modelled CS but the counterpart was not investigated; therefore, the more ventrally 
located contact was biased with a greater proportion of current. Thus, future studies 
should personalize fractionations to contact localizations allowing for fewer sessions 
spread out by a greater amount of time allowing for a more appropriate wash-out period, 
which reduces the confound of residual effects induced by other settings.  
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2.4.2 Conclusions 
CS was concluded to exhibit greater practical efficacy through TEED reduction; 
however, CS exhibited a similar clinical outcome for improvement of Parkinsonian gait 
deficits compared to conventional DBS. Thus, CS may be applied to DBS to reduce 
TEED values and to improve L-DOPA responsive gait parameters to a degree that is 
comparable to present clinical standards of DBS. The ability to stimulate with lower 
TEED values reduces power consumption, tissue damage and side effect risk, IPG battery 
drainage rate, and need for IPG replacement.   
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Chapter 3  
3 Assessing the clinical outcome of spatio-temporal 
gait parameters when utilizing vertical current 
steering in deep brain stimulation for Parkinsonian 
gait therapy 
3.1 Introduction 
3.1.1 Parkinson’s disease  
With a prevalence of two per one thousand individuals affected, Parkinson’s disease (PD) 
is the second most common neurodegenerative disease of adult onset (Tysnes & 
Storstein, 2017). Pesticide exposure, age, and family history of PD or tremor serve as the 
greatest environmental, non-environmental, and genetic risk factors for PD (Kalia & 
Lang, 2015; Noyce et al., 2012). When accounting for age, motor symptom onset is 
associated with an approximate neuronal loss of 30% in the substantia nigra and 
neurodegeneration is postulated to also occur in the pedunculopontine nucleus (PPN) 
(Cheng, Ulane, & Burke, 2010; Fearnley & Lees, 1991; Rinne, Ma, Lee, Collan, & 
Röyttä, 2008; Zweig, Jankel, Hedreen, Mayeux, & Price, 1989). Appendicular symptoms 
such as bradykinesia, tremor, and rigidity are usually present around diagnosis; however, 
axial symptoms—including speech, postural, and gait deficits— tend to manifest in later 
disease stages (Kalia & Lang, 2015). Dopaminergic degeneration manifests 
asymmetrically; thus, appendicular symptoms commonly develop unilaterally and disease 
progression elicits bilateral presentation of appendicular and axial symptoms 
(Hornykiewicz, 1966; Kalia & Lang, 2015). However, it is common for motor symptoms 
of the side of onset to remain more severe, even axial symptoms may present 
asymmetrically as gait deficits typically manifest with a greater reduction of ground 
clearance or arm swing of the more affected side (Karádi et al., 2015).  
Deep brain stimulation (DBS) provides chronic delivery of electrical pulses 
through stereotactic localization of electrodes, which addresses disabling dyskinesia and 
motor fluctuations from long-term use of Levodopa (L-DOPA) (Kalia & Lang, 2015). 
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The dorsolateral region of the subthalamic nucleus (STN) associated with sensorimotor 
function is most commonly targeted for PD therapy since it consistently alleviates 
appendicular symptoms, addresses motor complications,, and substantially decreases the 
L-DOPA dose with some ceasing L-DOPA use (Anderson, Burchiel, Hogarth, Favre, & 
Hammerstad, 2005; Follett et al., 2010; Mahlknecht, Limousin, & Foltynie, 2015; 
Odekerken et al., 2013; Okun et al., 2009; Tankus et al., 2017; Tewari, Jog, & Jog, 2016; 
Zahodne et al., 2009). DBS consistently relieves appendicular symptoms but its effect on 
gait deficits remains more elusive and variable (Collomb-Clerc & Welter, 2015; Cossu   
& Pau, 2017). 
3.1.2 Motor control involving the basal ganglia  
Dominance of the left hemisphere has been associated with motor control while 
dominance of the right hemisphere has been associated with spatial and proprioceptive 
processing (Hugdahl, 2011; Serrien, Ivry, &, Swinnen, 2006). Left cerebral hemispheric 
dominance in motor control has been reported during assessments of unilateral and 
bilateral movements (Barber et al., 2011; Scholz et al., 2000; Volkmann, Schnitzler, 
Witte & Freund, 1998). A functional magnetic resonance imaging study demonstrated a 
correlation between the magnitude of connectivity of the motor circuit in the left 
hemisphere (motor cortex, thalamus, putamen, cerebellum, and supplementary motor 
cortex) and motor abilities of right-handed children (Barber et al., 2011). In addition, 
Voos and colleagues reported that stroke patients with left sided lesions exhibit gait 
impairments of greater severity with longer recovery periods compared to patients with 
right sided lesions (Voos & Ribeiro do Valle, 2008).  
The predominant role of the left hemisphere in motor control has also been 
exhibited in the basal ganglia (BG), which is postulated to be attributed to handedness 
(Scholz et al., 2000). Assessments of unilateral and bilateral movements of the upper and 
lower limbs exhibited greater activation of the BG and motor cortex in the left 
hemisphere with the BG exhibiting a greater asymmetric activation (Scholz et al., 2000). 
Accordingly, it has been suggested that asymmetry of the nigrostriatal dopaminergic 
network and the globus pallidus (GP) in healthy individuals and PD patients may allude 
to lateralization of motor control and performance (de la Fuente-Fernández, Kishore, 
81 
 
Calne, Ruth, & Stoessl, 2000; Glick, Ross & Hough, 1982; Kish, Shannak, & 
Hornykiewicz, 1988). Namely, the putamen and internal globus pallidus (GPi) have been 
implicated in facilitating movement amplitude, direction, speed, and timing (O’boyle, 
Freeman, & Cody, 1996; Yin, 2014). 
3.1.3 Parkinsonian Gait 
In present clinical practice, patients with severe or L-DOPA resistant postural and gait 
deficits are often excluded from DBS. Gait deficits may be categorized based on stage of 
onset and responsiveness to L-DOPA and STN-DBS, which are therapeutic interventions 
that elicit similar clinical outcomes (Welter et al., 2002). Axial motor symptoms that are 
non-responsive to L-DOPA develop around 10 to 15 years post-diagnosis and include 
freezing of gait (FOG) and spontaneous falls that tend to worsen or exhibit no change 
following STN-DBS (Kalia & Lang, 2015). L-DOPA resistant gait deficits are postulated 
to be predominantly controlled by cholinergic brainstem locomotor regions such as the 
PPN (Collomb-Clerc & Welter, 2015; Rinne et al., 2008; Takakusaki, 2017; Zweig et al., 
1989). On the other hand, rigidity and bradykinesia contribute to a hypokinetic gait that 
manifests earlier than L-DOPA resistant gait deficits (Magrinelli et al., 2016). A 
hypokinetic gait yields reductions in amplitude, rhythm, timing, and velocity, which are 
gait features that tend to be L-DOPA responsive and associated with at least initial 
improvement following STN-DBS (Beradelli, Rothwell, Thompson, & Hallett, 2001; 
Collomb-Clerc & Welter, 2015). For instance, significant improvements in gait velocity 
and step or stride length are most commonly reported in analyses of the effect of STN-
DBS on spatio-temporal gait parameters (Allert et al., 2001; Cantiniaux et al., 2009; Faist 
et al., 2001; Ferrarin et al., 2002; Ferrarin, Rizzone, Lopiano, Recalcati, & Pedotti, 2004; 
Ferrarin et al., 2005; Johnsen, Sunde, Mogensen, & Østergaard, 2010; Krystkowiak et al., 
2003; Stolze et al., 2001; Vallabhajosula et al., 2015; Xie, Krack, Benabid, & Pollak, 
2001). Nonetheless, gait improvement exhibits a more variable responsiveness to STN-
DBS compared to appendicular symptoms, which may be attributed to the complex 
integration required for gait facilitation (Cossu & Pau, 2017).  
Gait in PD has a physiological and pathological context unlike motor symptoms 
such as tremor, which manifests solely due to pathology. In PD, gait deficits are 
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influenced by other symptoms including bradykinesia and rigidity (Collomb-Clerc & 
Welter, 2015). However, gait facilitation additionally relies on the physiological 
integration between the musculoskeletal system and the spinal cord, brainstem, 
cerebellum, BG, and the cortex to regulate postural muscle tone to sustain an upright 
position and to bilaterally coordinate rhythmic, sequential movements of the upper and 
lower limbs (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Two regions of the 
midbrain locomotor region (MLR); namely, the cuneiform nucleus (CN) and PPN are 
postulated to predominantly facilitate spatio-temporal gait parameters and balance, 
respectively (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). Post-mortem 
assessment found that the magnitude of neuronal loss in the CN was not significantly 
different between those with a tendency to fall and those without; however, a correlation 
was found between the reduction of size and quantity of PPN cholinergic neurons and the 
presentation of spontaneous falls and FOG (Rinne et al., 2008; Zweig et al., 1989). 
Therefore, reduced dopamine in PD may elicit STN hyperactivity, which subsequently 
augments Gamma-Aminobutyric Acid (GABA)ergic output to the thalamo-cortical 
projection and CN accounting for gait deficits influenced by bradykinesia and rigidity 
that manifest earlier and tend to be L-DOPA responsive (Fazl & Fleisher, 2018; 
Magrinelli et al., 2016). Consequently, gait therapy may be inherently more sensitive to 
the stimulation area; therefore, the bias towards improvement of upper limb rigidity and 
rest tremor during intraoperative contact localization and postoperative contact selection 
may additionally lead to a variable inadequate response of L-DOPA responsive gait 
deficits to STN-DBS.  
3.1.4 Factors influencing the clinical outcome of DBS  
The clinical outcome of DBS is directly related to the electric field distribution and 
resultant neuroanatomical structures influenced. The electric field is influenced by 
programmed features—electrode geometry and stimulation parameters; and non-
programmed features—contact localizations, neural tissue properties, and impedance of 
the contact and tissue interface (Butson, Maks, & McIntyre, 2006; Kuncel & Grill, 2004). 
Unipolar electrode geometries are initially programmed in standard clinical care due to 
the lower efficacy and side effect thresholds; however, the radially diffuse distribution of 
83 
 
the electric field increases risk of un-intended stimulation (Butson, Cooper, Henderson, 
&, McIntyre, 2007; Deli et al., 2011; McIntyre, Mori, Susumu, Sherman, Thakor, & 
Vitek, 2004). Furthermore, an optimal combination of frequency, pulse width, and 
amplitude stimulates appropriate neural elements at a necessary magnitude to maximize 
symptom alleviation and minimize side effect manifestation and power usage to prolong 
battery life (Kuncel & Grill, 2004). Increasing the amplitude within the therapeutic 
window (TW) elicits greater symptom alleviation until the side effect threshold is reached 
(Kuncel & Grill, 2004). The stimulation amplitude influences the electric field spread; 
accordingly, higher amplitudes are subject to greater current spread that may be 
associated with side effects particularly with single-contact stimulation that elicits spread 
radially (Deli et al., 2011). Side effect induction is more pronounced with poorly 
localized contacts but is more likely at high amplitudes regardless of contact localization 
(Kuncel & Grill, 2004). 
Slight variations in contact localizations are inherent due to neuroanatomical 
variation and brain shift induced by air entering the burr hole intraoperatively (Nambu, 
2011; Romanelli et al., 2004; Tankus et al., 2017; Tewari et al., 2016). In addition, DBS 
is complicated by neural tissue properties that influence current spread (Kuncel & Grill, 
2004). Following that DBS mechanisms are excitatory, axon diameter is inversely related 
to the amount of charge required to produce an action potential (Montgomery, 2010). The 
greater surface area associated with a larger diameter allows for greater charge 
accumulation; therefore, large myelinated axons are activated at lower magnitudes 
compared to the soma or dendrites (Wagle Shukla, Zeilman, Fernandez, Bajwa, & 
Mehanna, 2017). Accordingly, contacts localized to white matter fiber tracts exhibit 
broader electric fields compared to those in grey matter suggesting a higher conductance 
(Li, Bak, & Parker, 1968; Kuncel & Grill, 2004). Therefore, stimulation spread may elicit 
variable effects depending on the neural tissue influenced, which is less regulated and 
predictable in centres that program solely based on clinical improvement using the 
Unified Parkinson’s Disease Rating Scale (UPDRS) rather than additionally relying on 
imaging techniques. In addition, impedance fluctuations inherent to the contact and tissue 
interface inversely influence the charge delivery and are poorly regulated with 
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conventional voltage-controlled (VC) systems, which has prompted the development of 
current-controlled (CC) DBS systems that regulate impedance changes. 
3.1.5 Advances in deep brain stimulation technology   
DBS systems have been traditionally VC, which inconsistently deliver charge due to 
impedance fluctuations (Butson et al., 2006; Miocinovic et al., 2007). VC systems have 
been adequate for alleviating symptoms in straightforward cases; however, variable 
charge delivery often under or over stimulates the target. In addition, deviations between 
the programmed and actual stimulation render a greater need for programming changes, 
which is tedious and laborious since there are presently no established protocols (Wagle 
Shukla et al., 2017). These inefficiencies prompted the development of CC systems, 
which allow for consistent charge delivery through voltage manipulations to account for 
impedance fluctuations; thus, the actual stimulation matches the programmed value 
(Butson et al., 2006; Lempka, Miocinovic, Johnson, Vitek, McIntyre, 2009; Wagle 
Shukla et al., 2017). Multiple independent current control associated with CC devices 
allows for manipulation of charge delivery from each contact as a separate entity; thus, 
current distribution may be divided among multiple contacts or segments of a contact to 
facilitate vertical current steering (CS) (Butson & McIntyre, 2008). The substantial 
benefit of implementing vertical CS, or CS for short, is the ability to fine-tune the 
stimulation field shape to improve the precision of neuroanatomical targeting 
(Chaturvedi, Foutz, & McIntyre, 2012). The current fractionation associated with a 
particular contact is proportional to the spread of the electric field; therefore, contacts 
receiving a greater percentage of current will exhibit a broader spread than those 
receiving a smaller percentage. Thus, CS can reduce the radial spread of conventional 
stimulation fields by elongating and shaping the field across multiple active contacts 
(Kuncel & Grill, 2004). The first reported human application of CS divided the current 
between four contacts to alleviate motor symptoms at an amplitude that failed to improve 
symptoms and induced dyskinesia with single-contact stimulation; thus, CS lowered the 
efficacy threshold (Barbe, Maarouf, Alesch, & Timmermann, 2014). Furthermore, CS 
can address contact localization deviations, neuroanatomical variations, and the varying 
influence of particular neural structures such as the soma versus the axon through 
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systematic programming that fine-tunes the stimulation field, which avoids surgical re-
implantation. Current fractionations may be tailored to the patients’ contact localizations 
to increase programming efficiency and reduce the empirical nature of programming; in 
addition, different fractionations may be employed to address appendicular and axial 
symptom improvement separately if necessary. The efficacy of CS has been exhibited in 
a multicentre European study that reported the improvement of motor symptoms and 
quality of life and reduction of motor fluctuations and the L-DOPA equivalent dose 
(Timmermann et al., 2015). Notably, the majority switched to CS by the one year follow 
up despite initiating programming with single-contact conventional stimulation 
(Timmermann et al., 2015).  
3.1.6 Rationale  
Optimal DBS programming maximizes symptom alleviation with minimal side effects; 
however, improving both appendicular and axial motor symptoms with conventional 
DBS systems has been particularly difficult. Gait therapy may be particularly sensitive to 
the resultant stimulation area since gait deficits in PD are influenced by bradykinesia and 
rigidity. In addition, an array of neural circuitries is postulated to be affected by PD 
pathology to elicit Parkinsonian gait deficits. The ability to employ various current 
fractionations to fine-tune the stimulation field shape would provide more regulatory 
control to improve the variable outcome of L-DOPA responsive gait deficits. Tailoring 
current fractionations to contact localizations should systematically improve 
neuroanatomical targeting, which may address the variable improvement that potentially 
arises from a bias for upper limb symptom improvement during DBS implementation and 
a greater sensitivity of gait therapy to the stimulation area. In addition, CS may be 
implemented unilaterally to address disease asymmetry or to elucidate hemispheric 
dominance in motor control (Scholz et al., 2000). The actual comparison between the 
effect of conventional stimulation, unilateral and bilateral applications of CS, and L-
DOPA at the level of individual gait parameters has yet to be investigated. Thus, we will 
investigate the potential difference between the aforementioned therapies utilizing 
quantitative measures recorded with gait analysis software, which provides a more 
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detailed comparison in contrast to clinical ordinal scales such as the UPDRS, which is 
subject to examiner bias and variation.    
3.1.7 Objectives 
1. To compare the differential effect of stimulation with unilateral and bilateral 
applications of CS and single-contact conventional stimulation at various TW 
amplitudes on gait variable changes representing amplitude—step length; 
representing timing—step time; representing velocity—stride velocity; 
representing balance—total double support time (TDST); and an overall measure 
of gait— functional ambulation performance (FAP) score. 
a. Gait variable changes assessed from a non-therapeutic state (“OFF” 
stimulation, OFF L-DOPA—OFF-therapy baseline). 
b.  Gait variable changes assessed from a therapeutically compatible state 
(OFF L-DOPA, “ON” stimulation) within the same period following 
surgical implantation (weekly baseline). 
2. To assess the difference of implementing CS unilaterally that may be attributed to 
hemispheric differences or disease asymmetry using hemispheric stimulation 
models (right CS and left CS) and laterality stimulation models (more affected 
side and less affected side) at various TW amplitudes on gait variable changes— 
FAP score, step length, step time, stride velocity, and TDST. 
3. To compare the effects of L-DOPA with unilateral and bilateral applications of 
CS and single-contact conventional stimulation at various TW amplitudes on gait 
variable changes— FAP score, step length, step time, stride velocity, and TDST. 
3.1.8 Hypotheses 
For the first objective, it is hypothesized that unilateral or bilateral applications of CS to 
the STN will elicit greater improvements of overall ambulation and spatio-temporal gait 
measures but may not elicit a differential effect on balance as compared to conventional, 
single-contact stimulation, which highlights the feature specific neural facilitation of the 
BG. Therefore, step length, step time, stride velocity and the FAP score are predicted to 
improve to a greater degree with CS; however, TDST is expected to respond similarly 
with CS or conventional stimulation due to its predominant regulation by cholinergic 
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midbrain nuclei such as the PPN. For the second objective, it is hypothesized that 
unilateral applications of CS will differentially affect gait measures based on hemispheric 
dominance of the motor cortex and BG or asymmetry of symptom severity. For the third 
objective, it is hypothesized that L-DOPA and all stimulation types will not exhibit a 
differential effect on gait variable changes. All patients in the sample were responsive to 
L-DOPA and the outcome of conventional STN-DBS has been correlated with the L-
DOPA response; thus, it is predicted that the CS will be comparable to L-DOPA (Fasano, 
Aquino, Krauss, Honey, & Bloem, 2015; Welter et al., 2002). 
3.2 Methods 
3.2.1 Study Sample 
The present investigation was approved by the Human Subjects Research Ethics Board 
(REB) at Western University (REB #108453). Patients were selected based on clinical 
standards intended to maximize symptom alleviation and minimize side effects. Inclusion 
criteria encompassed: diagnosis of idiopathic PD with L-DOPA responsive motor 
symptoms as assessed with a standard L-DOPA challenge test and motor complications 
(Albanese et al., 2001). Exclusion criteria included: overall poor health, previous brain 
surgery or implantation of a cardiac pacemaker, diagnosis of dementia and severe 
psychiatric symptoms (notably, hallucinations and depression) according to the 
Diagnostic and Statistical Manual of Mental Disorders –V, and tendency to exhibit lack 
of compliance. All participants analyzed were diagnosed with idiopathic PD for an 
average duration of 12.5 years and included four females and three males with an average 
age of 61. Nine participants provided informed consent; however, one patient withdrew 
from the study for adverse health reasons unrelated to the study and another patient was 
no longer eligible following implantation of a DBS device incapable of performing CS.  
3.2.2 Experimental Timeline and Study Design 
Overall, the experiment included the pre-assessment that was performed at least one 
week prior to surgical implantation, the initial contact review that was conducted 
approximately one month following surgical implantation, the second contact review that 
was executed at least two weeks following the initial review, and the CS investigations 
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that were performed immediately after the second contact review (Figure 9). Notably, the 
contact reviews will be described in detail in the following section. The pre-assessment 
was performed pre-surgically to confirm an adequate response to L-DOPA and the OFF-
L-DOPA condition was used as a baseline condition to assess improvement from a non-
therapeutic state. Bilateral and unilateral applications of CS were compared to stimulation 
without CS utilizing 16 investigational settings that represented bilateral CS, right CS, 
left CS, and bilateral non-CS stimulation models (Table 4). CS was investigated using 
unipolar, dual contact configurations with current divisions of 50/50 and 70/30. 
Stimulation without CS was implemented through single-contact stimulation; thus, 
represented as divisions of 0/100 or 100/0. Non-CS stimulation was intended to model 
conventional clinical standards. Notably, segmented leads (CartesiaTM Directional leads) 
always employed ring mode stimulation; therefore, all three segments were active to 
stimulate as a ring-shaped contact. All investigational settings were repeated at four 
various stimulation amplitudes over four consecutive weeks, which increased in 
amplitude by 20% of the TW (Table 5). Amplitude was increased gradually to allow for 
the patient to accustom to stimulation; however, amplitudes always remained in the TW. 
Each participant was subject to all 16 investigational settings over a period of four days; 
thus, four settings were tested each day. Order of application was randomized for each 
patient; however, the order remained consistent when settings were repeated at higher 
amplitudes across weeks. 
A 25-minute washout period was enforced prior to the gait assessments after each 
setting was programmed. Gait was assessed with every setting, in addition to, a baseline 
walk that was performed prior to implementation of the settings. Therefore, each CS 
investigational day consisted of five testing sessions categorized into one baseline session 
and four investigational sessions, with 25-minute washout periods in between (Figure 
10). The baseline walk was performed with a lower amplitude than the subsequent 
investigational sessions with a setting that was deemed optimal for symptom alleviation 
by the supervising movement disorders specialist. Baseline walks served as a state of 
comparison (weekly baseline) for how the patient performs in a clinically stable state at 
that given time point following surgical implantation with a matching therapeutic 
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protocol. Thus, the baseline walks matched the CS investigational sessions as both were 
performed with stimulation but without L-DOPA. 
 
Figure 9: Experimental timeline. 
* denotes the earliest time point that event would occur. Time in reference to the 
electrode implantation surgery. 
 
Figure 10: Summary of testing sessions within one week of the CS investigation.  
Summary schematic of the testing session schedule within one week during the CS 
investigation protocol (~Week 6-9 post-surgical implantation). Baseline sessions 
preceded investigational setting sessions each day and a 25-minute washout period was 
enforced before each investigational setting session. During a given week, stimulation 
amplitudes of baseline sessions and investigational setting sessions were consistent with 
each other, represented by squares and circles, respectively. However, baseline 
amplitudes were lower than investigational amplitudes. 
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Table 4: Investigational settings with single-contact stimulation and bilateral and 
unilateral applications of CS.     
    A) represents the ventral contact and B) represents the dorsal contact. 
Setting 
Number 
Stimulation Model Left  
STN 
Right 
STN 
1 Bilateral non-CS A): 100% B): 0% A): 100% B): 0% 
2 Right sided, unilateral CS A): 100% B): 0% A): 70%   B): 30% 
3 Right sided, unilateral CS A): 100% B): 0% A): 50%   B): 50% 
4 Bilateral non-CS A): 100% B): 0% A): 0%    B):100% 
5 Left sided, unilateral CS A): 70%   B): 30% A): 100% B): 0% 
6 Bilateral CS A): 70%   B): 30% A): 70%   B): 30% 
7 Bilateral CS A): 70%   B): 30% A): 50%   B): 50% 
8 Left sided, unilateral CS A): 70%   B): 30% A): 0%    B):100% 
9 Left sided, unilateral CS A): 50%    B):50% A): 100% B): 0% 
10 Bilateral CS A): 50%    B):50% A): 70%   B): 30% 
11 Bilateral CS A): 50%    B):50% A): 50%   B): 50% 
12 Left sided, unilateral CS A): 50%    B):50% A): 0%    B):100% 
13 Bilateral non-CS A): 0%    B):100% A): 100% B): 0% 
14 Right sided, unilateral CS A): 0%    B):100% A): 70%   B): 30% 
15 Right sided, unilateral CS A): 0%    B):100% A): 50%   B): 50% 
16 Bilateral non-CS A): 0%    B):100% A): 0%    B):100% 
Table 5: Stimulation amplitudes with respect to the CS investigational week.   
   Week refers to the CS investigational week.   
Week Stimulation Amplitude 
1 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.2) 
2 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.4) 
3 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.6) 
4 (Therapeutic windowminimum) + (Therapeutic windowdifference *0.8) 
3.2.3 Clinical Procedures—surgical implantation and contact 
selection  
Therapeutic macroelectrodes and the impulse generator (IPG) were implanted on the 
same day, unless complications arose, by a surgeon trained in functional neurosurgery 
91 
 
practicing at University Hospital, London Health Sciences Centre (London, ON, CA). 
Investigational devices consisted of the VerciseTM IPG and associated DBS leads or the 
VerciseTM PC IPG and the CartesiaTM Directional leads, which are Boston Scientific DBS 
systems equipped with multiple independent current control (Boston Scientific, Valencia, 
CA, USA). Local anesthesia was utilized for neuro-targeting and macroelectrode 
implantation; however, general anesthesia was administered subsequently for IPG 
implantation. Pre-surgically, the neuro-targeting portion began with magnetic resonance 
imaging to locate the STN based on positioning of the anterior commissure (AC), and 
posterior commissure (PC). The STN was targeted using standard stereotactic coordinates 
based on AC-PC positioning—2.0 mm posterior to the mid-commissural point, 12.0 mm 
lateral to the midline, and 4.0 mm ventral to the AC-PC plane (Rabie, Verhagen Metman, 
& Slavin, 2016). Intraoperatively, a stereotactic Leksell frame was mounted to the head 
and a computed tomography scan was used to merge stereotactic coordinates from the 
magnetic resonance image to the surgical computer. Recordings from five 
microelectrodes temporarily implanted to denote a central, anterior, posterior, medial, and 
lateral channel confirmed the STN positioning in the dorsal to ventral axis through the 
associated spike signature. Microelectrodes provided intra-operative stimulation to 
associate symptom alleviation and localization. Thus, the most extensive STN spike 
signature and the greatest improvement of tremor and rigidity upon intra-operative 
stimulation determined the implantation trajectory of the therapeutic macroelectrode.  
The IPG was turned on approximately one month following surgical implantation, 
upon which the initial contact review was performed. The initial contact review selected 
the first contact and the second review selected the second contact for a total of two 
investigational contacts in each hemisphere; contact selection was based on the 
extensiveness of the TW. A single-contact unipolar review identified the first contact; 
however, the second contact review paired the most clinically efficacious contact 
(determined by the initial review) with every other contact to find the pair of contacts that 
elicited the widest TW with each contact stimulated with 50% of the current. The TW 
was defined by the upper and lower limit or the side effect and efficacy threshold, 
respectively. For all TW assessments, current amplitude was increased with increments 
of 0.5 milliamperes (mA) until side effects were elicited; subsequently, the previous 
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amplitude was programmed and increments of 0.1 mA confirmed the exact side effect 
threshold. UPDRS items including: finger taps, upper limb rigidity, and upper limb rest 
tremor served as primary measures of symptom improvement. Dysarthria, blurry vision, 
face pulling, dystonia, and any uncomfortable, intolerable sensations were markers for 
the upper limit. Namely, dystonia is characterized by irregular fixed postures or 
contortions as a result of consistent or repetitive muscle contractions (Magrinelli et al., 
2016). Upon turning on the IPG, the patient accustomed to stimulation at 0.5 mA until the 
start of the CS investigations and the frequency and pulse width remained at 130 Hertz 
(Hz) and 60 µs, respectively for the entire study. For one patient, a pulse width of 90 µs 
was used.  
3.2.4 Changes to medication dosages throughout the experimental 
investigation and stimulation changes  
The CS investigations and TW assessments were performed in an OFF-L-DOPA state to 
reduce potential confounding effects of L-DOPA. Discontinuation of L-DOPA for at least 
12 hours was enforced prior to CS investigations, TW assessments, and the pre-
assessment (Albanese et al., 2001). The pre-assessment followed the standard protocol 
for the L-DOPA challenge test; therefore, patients took a suprathreshold dose compared 
to their regular morning dose (typically 130 % of the standard dosage) for the “ON” 
assessments (Albanese et al., 2001). Patients were able to take Parkinsonian medications 
following the CS investigational sessions while adhering to the approximate 12-hour 
withdrawal prior to initiation of the subsequent CS investigation.  
As the stimulation amplitude increased throughout the study, the Parkinsonian 
medications including L-DOPA taken outside of testing hours were also reduced. 
Reduction in quantity and frequency of consumption was prescribed by the supervising 
movement disorders specialist to optimize symptom alleviation while avoiding 
dyskinesia to titrate concurrent Parkinsonian therapies. The protocol did not demand a 
strict withdrawal schedule for other Parkinsonian medications such as amantadine or 
dopamine agonists. Instead, the supervisor monitored and regulated a gradual reduction 
of these medications to avoid adverse side effects.  
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3.2.5 Technology assessing gait variables—spatio-temporal 
parameters and functional ambulation performance score 
The ZenoTM walkway (ProtoKinetics, Peekskill, NY) recorded foot falls during walking 
assessments with embedded sensors sensitive to pressure and recordings were analyzed 
with respect to spatio-temporal gait parameters using ProtoKinetics Movement Analysis 
Software (PKMAS, Havertown, PA). The ZenoTM walkway and PKMAS have been 
validated in the literature particularly with comparisons to the more traditional GAITRite 
system (Egerton, Thingstad, & Helbostad, 2014; Vallabhajosula, Humphrey, Cook, & 
Freund, 2017). Spatio-temporal gait parameters representing spatial (length), temporal 
(time and TDST), and spatiotemporal (velocity) domains were expressed as a stride or 
step. A step is defined as the distance between the initial heel contact to the consecutive 
heel contact of the contralateral foot, and a stride is composed of two steps. Accordingly, 
step length, step time, stride velocity, TDST, and the FAP score were extracted using 
PKMAS. Reduction of TDST and step time, and increases in step length, gait velocity, 
and the FAP score modeled improvements compared to the bradykinetic, Parkinsonian 
gait (Morris, Iansek, Matyas, & Summers, 1994; Nelson et al., 2002). 
Step length was measured in cm as the distance between consecutive heel strikes 
of opposite feet measured parallel to the advancement trajectory; the step time was 
recorded in seconds as the period to advance from one heel strike to the consecutive heel 
strike of the opposing foot; stride velocity was quantified as the ratio of stride length to 
time in cm/sec; and TDST in reference to seconds was the sum of all time periods during 
which, both feet were supporting the body and making direct contact with the ambulation 
surface (Huxham, Gong, Baker, Morris, & Iansek, 2006). Notably, TDST was assessed in 
the temporal domain but is more representative of balance. The FAP score is an 
integrative measure, which assesses overall ambulation at a self-selected pace (Gouelle, 
2014). The FAP score was automatically calculated by PKMAS through subtracting 
points from a maximal score of 100 for aberrations from a healthy gait (Gouelle, 2014). 
The left and right step functions category accounted for abnormal step time values and 
ratios of step length and velocity to leg length, which warranted subtractions up to 22 
points for each respective side (Gouelle, 2014). The step to leg length ratio differentials 
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category identified abnormal asymmetries, which warranted deductions up to eight points 
(Gouelle, 2014). The dynamic base of support category deducted up to eight points for a 
base of support that was too wide or narrow (Gouelle, 2014). Lastly, five points were 
deducted for use of ambulatory aids (canes, crutches, or walkers) or assistive devices 
(verbal cues, splints, or orthoses) (Gouelle, 2014).  
3.2.6 Gait Assessments 
All gait assessments were recorded using a 0.61 m by 6.1 m ZenoTM walkway without 
shoes, ambulatory aids, or assistive walking devices; however, standard, non-skid socks 
were worn to reduce fall risk. Forwards walking was assessed at a self-selected pace, as 
participants were instructed to ambulate consistently at their daily pace. Five continuous 
loops in a clockwise direction were performed for execution of gradual turns with a 
consistent speed. Ambulation away from the initial seated position was always recorded 
on the ZenoTM walkway; however, walking towards the start position was exercised off 
the walkway. Therefore, straight walking was always recorded away from the starting 
point. PKMAS averaged the five passes on the walkway to yield the means of the FAP 
score, step length, step time, stride velocity, and TDST.  
3.2.7 Data and Statistical Analyses  
All gait measures were calculated based on equations stated in the PKMAS 
Measurements & Definitions document developed by ProtoKinetics, LLC; all analyzed 
gait measures have been validated with the established GAITRite software (Egerton et 
al., 2014; Vallabhajosula et al., 2017). Prior to statistical analyses, step length, step time, 
stride velocity, TDST, and the FAP score were normalized and assessed for outliers, 
which were all included for analysis due to the small sample size unless categorized as a 
clinical outlier. For instance, three data points were omitted for gait interference due to 
dyskinesia and dystonia. Utilizing equations established by Hof (1996), gait parameter 
(step length, step time, stride velocity, and TDST) means were normalized to leg length 
(Table 5) (Hof, 1996). Subsequently, FAP scores and normalized gait parameter means 
were expressed as % changes from baseline with respect to two conditions—the weekly 
baseline or the OFF-therapy baseline. The weekly baseline represented the gait variable 
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on average during the given week of investigation with a matching therapeutic protocol; 
therefore, the weekly baseline value was calculated by averaging across all baseline 
walks within the week to constitute the baseline mean using the % change from baseline 
equation (Table 6). However, outliers among the baseline walks were removed, which 
were performed for each individual week and gait variable. Data were removed if found 
to be below the difference of the first quartile and the interquartile range multiplied by 
1.5 or above the sum of the third quartile and the interquartile range multiplied by 1.5. 
The OFF-baseline mean was obtained from the OFF- L-DOPA condition during the pre-
assessment. Therefore, gait parameter means and FAP scores expressed as % changes 
from the weekly baseline or the OFF-therapy baseline were assessed for differences 
among the treatment groups being set as the stimulation models or individual settings. 
Analysis with the stimulation models utilized means of the constituent settings. Unilateral 
applications of CS were categorized for the hemisphere of application or the hemisphere 
facilitating motor control for the side of greater or less symptom severity. The former 
reference designated right and left CS stimulation models referred to as hemispheric 
stimulation models, while the latter designated unilateral CS-less severe side or unilateral 
CS-more severe side stimulation models, referred to as laterality stimulation models.  
All statistical analyses were performed by GraphPad Prism 6.00 (La Jolla, CA, 
USA) or an open-source statistical platform, R (version 3.5.1, Boston, MA, USA) using 
an alpha criterion of ≤ 0.05. Normality was assessed with the Shapiro—Wilk test 
utilizing GraphPad Prism 6.00; ultimately, non-parametric tests were applied to all data 
sets due to the inconsistency in normality and the small sample size. All non-parametric 
multiple comparisons and associated post-hoc tests were performed using R (version 
3.5.1, Boston, MA, USA). Differences were assessed using the Friedman test but the 
Skillings—Mack test was used for incomplete data sets due to clinical outliers. The 
blocking factor was set as the various stimulation amplitudes or the various participants 
to assess differences at particular stimulation amplitudes (Table 5). The Nemenyi post-
hoc test was utilized following the Friedman and Skillings—Mack test to perform pair-
wise comparisons to account for family wise error in a conservative manner; therefore, no 
p-value adjustments were performed (Nemenyi, 1962). The Friedman and Nemenyi post-
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hoc test utilized the package “PMCMRplus”, and the Skillings—Mack test was 
conducted with the package “Skillings.Mack”. 
Table 6: Summary of equations utilized for analysis.  
Normalizing gait parameters for the effects of leg length and gravity expressed as 9.81 
m/s2, modified by Hof AL, 1996.  
Analysis Variable Equation 
Step length 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑆𝑡𝑒𝑝 𝐿𝑒𝑛𝑔𝑡ℎ =  
𝑢𝑛𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑙𝑒𝑛𝑔𝑡ℎ
𝑙𝑒𝑔 𝑙𝑒𝑛𝑔𝑡ℎ
 
Step Time 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝑆𝑡𝑒𝑝 𝑇𝑖𝑚𝑒 𝑜𝑟 𝑇𝑜𝑡𝑎𝑙 𝐷𝑜𝑢𝑏𝑙𝑒 𝑆𝑢𝑝𝑝𝑜𝑟𝑡 𝑇𝑖𝑚𝑒
=  
𝑢𝑛𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑡𝑖𝑚𝑒
(
𝑙𝑒𝑔 𝑙𝑒𝑛𝑔𝑡ℎ
𝑔𝑟𝑎𝑣𝑖𝑡𝑦
)
^(
1
2
)
 
Double Support 
Time 
Stride Velocity 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑆𝑡𝑟𝑖𝑑𝑒 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦
=  
𝑢𝑛𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦
(𝑙𝑒𝑔 𝑙𝑒𝑛𝑔𝑡ℎ ∗ 𝑔𝑟𝑎𝑣𝑖𝑡𝑦)^(
1
2
)
 
% Change from 
Baseline 
% 𝑐ℎ𝑎𝑛𝑔𝑒 =  [
 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑚𝑒𝑎𝑛 –𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑚𝑒𝑎𝑛 
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑚𝑒𝑎𝑛 
]*100 
3.3 Results 
3.3.1 Effect on step length  
Significant differences in the percent change of step length from the OFF-therapy and 
weekly baseline between hemispheric stimulation models were found during a 
stimulation amplitude around 80% of the TW (Figure 11). The average stimulation 
amplitude across all participants at the given stage was 3.39 mA and 3.56 mA for the left 
and right STN, respectively (Table 7). Significantly greater increases in the percent 
change in step length from the OFF-therapy baseline were elicited by the bilateral CS 
stimulation model compared to the bilateral non-CS stimulation model (p = 0.02) (Figure 
11a). In addition, significant differences in the percent change in step length from the 
weekly baseline were elicited between the bilateral CS and non-CS stimulation model (p 
= 0.02) (Figure 11b). The percent change in step length elicited by the bilateral non-CS 
stimulation model was negative on average (Figure 11b).  
3.3.2 Effect on step time 
Significant differences in the percent change of step time from the OFF-therapy baseline 
were found between hemispheric stimulation models when administered across 
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stimulation amplitudes (p = 0.031) (Figure 12a). In particular, significant differences 
were found around 60% and 80% of the TW, which stimulated with an average amplitude 
of 2.90 mA and 2.99 mA and 3.39 mA and 3.56 mA for the left and right STN, 
respectively (Table 7). At these stimulation amplitudes, significantly greater reductions in 
the % change in step time were elicited with the right CS stimulation model compared to 
the bilateral CS stimulation model (p60% = 0.02 & p80% = 0.01) (Figure 12b & 12c). 
Notably, no significant differences were found between the laterality stimulation models 
at the same amplitude stages (Figure 13). For the more affected side, the average 
stimulation amplitude across participants was 3.10 mA and 3.70 mA and for the less 
affected side, the average stimulation amplitude was 2.80 mA and 3.30 mA; listed for 
stimulation around 60% then 80% of the TW (Table 8).  
3.3.3 Effect on stride velocity 
Significant differences in the percent change of stride velocity from the weekly baseline 
were found between stimulation settings when administered across various amplitudes (p 
= 0.032) (Figure 14). In particular, significantly greater increases in the percent change in 
stride velocity were elicited by setting 8 compared to setting 1 (Figure 14).  Setting 8 
implemented CS unilaterally to the left hemisphere and setting one consisted of bilateral 
single-contact stimulation. However, no significant differences were found in the percent 
change in stride velocity between hemispheric and laterality stimulation models with 
slight differences between the means and medians (Figure 15).  
3.3.4 Effect on the FAP score 
Significant differences in the percent change of the FAP score from the OFF-therapy and 
weekly baseline between hemispheric stimulation models were found during a 
stimulation amplitude around 80% of the TW (poff = 0.048 & pweek= 0.048) (Figure 16). 
The average stimulation amplitude across all participants at the given stage was 3.39 mA 
and 3.56 mA for the left and right STN, respectively (Table 7).  Significant differences 
were elicited between the percent change in FAP scores between the left CS stimulation 
model and the bilateral non-CS stimulation model (Figure 16). In particular, the percent 
change of the FAP score from the weekly baseline elicited by the bilateral non-CS 
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stimulation model averaged around zero (Figure 16b). No significant differences were 
found between the laterality stimulation models when the percent change in the FAP 
score was assessed from the OFF-therapy and weekly baseline at stimulation around 80% 
of the TW (Figure 17). At this stimulation stage, amplitudes averaged at 3.70 mA and 
3.30 mA for the more and less affected side, respectively (Table 8).  
3.3.5 Effect on total double support time 
 No significant differences were found between the percent changes in TDST elicited by 
various stimulation settings and models applied across all amplitudes (Figure 18). All 
averages of the percent change in TDST from the weekly baseline or OFF-therapy 
baseline exhibited negative changes; therefore, less time was spent in double support 
following stimulation (Figure 18).  
3.3.6  Comparison of stimulation with L-DOPA  
Significant differences were found between the effect of L-DOPA and stimulation for the 
percent change in step time and step length from the OFF-therapy baseline (Figure 19-
22). At stimulation around 20% of the TW, L-DOPA had a differential effect on the 
percent change in step length from the OFF-therapy baseline compared to implementing 
CS unilaterally to the more symptomatically severe side (p =0.02) (Figure 19). The 
average stimulation amplitude across all participants at the given stage was 1.90 mA and 
1.60 mA for the more and less severe side, respectively (Table 8). On average, 
significantly smaller increases in the percent change in step length were implemented by 
the unilateral CS stimulation model compared to L-DOPA (Figure 19).  
At particular stimulation amplitudes, the use of L-DOPA had a differential effect 
on the percent change in step time compared to various stimulation settings, hemispheric 
stimulation models, and laterality stimulation models (Figure 20-22). L-DOPA elicited a 
positive mean percent change in step time compared to the OFF-therapy baseline; 
however, the median indicated no change (Figure 20-22). Regarding stimulation settings, 
the percent change in step time was significantly different between L-DOPA and setting 
16 (bilateral non-CS) at stimulation around 40% of the TW, which averaged 2.36 mA and 
2.33 mA to the left and right STN, respectively (p = 0.013) (Figure 20a). At stimulation 
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around 60% and 80% of the TW, significant differences were elicited between L-DOPA 
and settings constituting bilateral non-CS, right CS and left CS (Figure 20b & 20c). The 
average stimulation amplitude around 60% and 80% of the TW was 2.90 mA and 2.99 
mA and 3.39 mA and 3.56 mA for the left and right STN, respectively (Table 7). In 
particular, at stimulation around 60% of the TW, differences were found among settings 
4, 13, and 16 (bilateral non-CS), setting 14 (right CS), and setting 12 (left CS) 
(pLDvs.setting4 = 0.00806, pLDvs.setting13 = 0.00075, pLDvs.setting16 = 0.02867, pLDvs.setting14 = 
0.00806, pLDvs.setting12 = 0.00894) (Figure 20b). At stimulation around 80% of the TW, 
differences were found among settings 4 and 16 (bilateral non-CS), settings 14 and 15 
(right CS), and setting 8 (left CS) (pLDvs.setting4 = 0.00894, pLDvs.setting16 = 0.00059, 
pLDvs.setting14 = 0.03435, pLDvs.setting15 = 0.03140, pLDvs.setting8 = 0.03435) (Figure 20c). 
 At all stimulation amplitudes, L-DOPA affected the percent change in step time in 
a significantly different manner compared to the right CS stimulation model (p20% = 
0.012, p40% = 0.00096, p60% = 0.00096, p80% = 0.00096) (Figure 21). The average 
amplitude for stages in increasing order were 1.83 mA and 1.69 mA; 2.36 mA and 2.33 
mA; 2.90 mA and 2.99 mA; and 3.39 mA and 3.56 mA for the left and right STN, 
respectively (Table 7). At stimulation amplitudes around 60% and 80% of the TW, 
significant differences between L-DOPA and the bilateral non-CS stimulation on the 
percent change in step time were found (p60% = 0.01987, p80% = 0.01154) (Figure 21c & 
21d). In addition, certain stimulation amplitudes elicited a differential effect between L-
DOPA and particular laterality stimulation models on the percent change in step time 
(Figure 22). At stimulation amplitudes around 40%, 60% and 80% of the TW, significant 
differences in the percent change in step time were elicited between L-DOPA and the 
unilateral implementation of CS to the electrode in the hemisphere controlling the less 
symptomatically severe side (p40% = 0.012, p60% = 0.0065, p80% = 0.0065) (Figure 22). 
The average amplitude for stages in increasing order were 2.50 mA and 2.20 mA; 3.10 
mA and 2.80 mA; 3.70 mA and 3.30 mA for the more affected and less affected side, 
respectively (Table 8). However, significant differences in the percent change in step 
time were elicited between L-DOPA and the unilateral implementation of CS to the 
electrode in the hemisphere controlling the more symptomatically severe at the higher 
stimulation amplitudes of around 60% and 80% of the TW (p60% = 0.0331, p80% = 0.0331) 
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(Figure 22b & 22c). In addition, at higher stimulation amplitudes of around 60% and 80% 
of the TW, significant differences were elicited in the percent change in step time 
between L-DOPA and bilateral non-CS stimulation (p60% = 0.0199, p80% = 0.0115) 
(Figure 22b & 22c). Among the settings and hemispheric and laterality stimulation 
models, no significant differences were found between L-DOPA and bilateral CS 
stimulation (Figure 20-22).  
 
Figure 11: % Change in step length from the OFF-therapy and weekly baseline with 
respect to the hemispheric stimulation model with stimulation around 80% of the 
TW.  
Data presented as box plots with solid horizontal lines representing the median, crosses 
representing the mean, the upper and lower whiskers representing the upper and lower 
fence—respectively, and closed circles representing outliers above or below the upper 
and lower fence, respectively. Step length normalized to the a) OFF-therapy baseline or 
b) weekly baseline and leg length with N=7, participants set as the blocking factor. 
Significant differences in the % change in step length were elicited by the bilateral CS 
stimulation model compared to the bilateral non-CS stimulation model (*, p < 0.05; 
Skilling—Mack, post-hoc Nemenyi). 
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Figure 12: % Change in step time from the OFF-therapy baseline with respect to 
the hemispheric stimulation model. 
Percent change in step time from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings assessed with respect to the 
hemispheric stimulation model a) across all stimulation amplitudes (around 20%, 40%, 
60% and 80% of the TW), b) around 60% of the TW, and c) around 80% of the TW. Data 
presented as box plots with solid horizontal lines representing the median, crosses 
representing the mean, the upper and lower whiskers representing the upper and lower 
fence—respectively, and closed circles representing outliers above or below the upper 
and lower fence, respectively. Step time normalized to the OFF-therapy baseline and leg 
length with N=7, a) various stimulation amplitudes or b) & c) participants set as the 
blocking factor. Significant differences in % change in step time were elicited with the 
bilateral CS stimulation model compared to the right CS stimulation model a) & c) (*, 
p<0.05; Skillings—Mack, post-hoc Nemenyi) and b) (*, p<0.05; Friedman, post-hoc 
Nemenyi). 
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Figure 13: % Change in step time from the OFF-therapy baseline with respect to 
the laterality stimulation model. 
Percent change in step time from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings assessed with respect to the 
laterality stimulation model at stimulation a) around 60% and b) around 80% of the TW. 
Data presented as box plots with solid horizontal lines representing the median, crosses 
representing the mean, the upper and lower whiskers representing the upper and lower 
fence—respectively, and closed circles representing outliers above or below the upper 
and lower fence, respectively. Step time normalized to the OFF-therapy baseline and leg 
length with N=7, participants set as the blocking factor. No significant differences in % 
change in step time were elicited a) (Friedman, post-hoc Nemenyi) and b) (Skillings—
Mack, post-hoc Nemenyi).  
 
Figure 14: % Change in stride velocity from the weekly baseline with respect to the 
setting across all stimulation amplitudes.  
Percent change in stride velocity from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings across all stimulation amplitudes 
(around 20%, 40%, 60%, and 80% of the TW). Data presented as box plots with solid 
horizontal lines representing the median, crosses representing the mean, the upper and 
lower whiskers representing the upper and lower fence—respectively. Stride velocity 
normalized to the weekly baseline and leg length with N=7, various stimulation 
amplitudes set as the blocking factor. Significant differences in the % change in stride 
velocity from baseline were elicited between setting 1(bilateral non-CS) and setting 8 
(left CS) (*, p<0.05; Skillings—Mack, post-hoc Nemenyi).  
B
IL
A
T
E
R
A
L
 N
O
N
-C
S
B
IL
A
T
E
R
A
L
 C
S
U
ni
la
te
ra
l C
S
-L
es
s 
se
ve
re
 s
id
e
U
ni
la
te
ra
l C
S
-M
or
e 
se
ve
re
 si
de
-100
-75
-50
-25
0
25
50
75
100
125
150
%
 C
h
a
n
g
e
 i
n
 S
te
p
 T
im
e
Stimulation Model
B
IL
A
T
E
R
A
L
 N
O
N
-C
S
B
IL
A
T
E
R
A
L
 C
S
U
ni
la
te
ra
l C
S
-L
es
s 
se
ve
re
 s
id
e
U
ni
la
te
ra
l C
S
-M
or
e 
se
ve
re
 si
de
-100
-75
-50
-25
0
25
50
75
100
125
Stimulation Model
%
 C
h
a
n
g
e 
in
 S
te
p
 T
im
e
a) b)
S1 S4S1
3
S1
6 S6 S7S1
0
S1
1 S2 S3S1
4
S1
5 S5 S8 S9S1
2
-5
0
5
10
15
20
Stimulation Setting
%
 C
h
a
n
g
e 
in
 S
tr
id
e 
V
el
o
ci
ty
*
Bilateral Non-CS
Bilateral CS
Right CS
Left CS
103 
 
 
Figure 15: % Change in stride velocity from the weekly baseline with respect to the 
hemispheric and laterality stimulation models across all stimulation amplitudes.  
Percent change in stride velocity from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings assessed with respect to the a) 
hemispheric or b) laterality stimulation model across all stimulation amplitudes (around 
20%, 40%, 60%, and 80% of the TW). Data presented as box plots with solid horizontal 
lines representing the median, crosses representing the mean, the upper and lower 
whiskers representing the upper and lower fence—respectively, and closed circles 
representing outliers above or below the upper and lower fence, respectively. Stride 
velocity normalized to weekly baseline and leg length with N=7, various stimulation 
amplitudes set as the blocking factor. No significant differences found in the % change in 
stride velocity (Skillings—Mack, post-hoc Nemenyi).  
 
Figure 16: % Change in FAP from the OFF-therapy & weekly baseline with respect 
to the hemispheric stimulation model during stimulation around 80% of the TW.  
Percent change in FAP from baseline was calculated from normal pace walking following 
administration of 16 stimulation settings assessed with respect to the hemispheric 
stimulation model at an amplitude around 80% of the TW. Data presented as box plots 
with solid horizontal lines representing the median, crosses representing the mean, upper 
and lower whiskers representing the upper and lower fence—respectively, and closed 
circles representing outliers above or below the upper and lower fence, respectively. FAP 
scores normalized to a) OFF-therapy or b) weekly baseline with N=7, participants set as 
the blocking factor. Significant differences in the % change in FAP were elicited between 
the left CS and bilateral non-CS model (*, p<0.05; Skillings—Mack, post-hoc Nemenyi).  
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Figure 17: % Change in the FAP from the OFF-therapy and weekly baseline with 
respect to the laterality stimulation model during stimulation around 80% of the 
TW.  
Percent change in FAP from baseline was calculated from normal pace walking following 
administration of the 16 stimulation settings assessed with respect to the laterality 
stimulation model at a stimulation amplitude of around 80% of the TW. Data presented 
as box plots with solid horizontal lines representing the median, crosses representing the 
mean, the upper and lower whiskers representing the upper and lower fence—
respectively, and closed circles representing outliers above or below the upper and lower 
fence, respectively. FAP scores normalized to the a) OFF-therapy baseline or b) weekly 
baseline with N=7, participants set as the blocking factor. No significant differences in 
the % change in FAP from baseline were elicited (Skillings—Mack, post-hoc Nemenyi).  
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Figure 18: % Change in the TDST from the OFF-therapy and weekly baseline with 
respect to the setting and stimulation models including all stimulation amplitudes. 
Percent change in TDST from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings assessed with respect to the a) & 
b) setting, c) & d) hemispheric stimulation model or e) & f) laterality stimulation model 
across all stimulation amplitudes (around 20%, 40%, 60%, and 80% of the TW). Data 
presented as box plots with solid horizontal lines representing the median, crosses 
representing the mean, the upper and lower whiskers representing the upper and lower 
fence—respectively, and closed circles representing outliers above or below the upper 
and lower fence, respectively. TDST normalized to the a), c) & e) OFF-therapy baseline 
or b), d) & f) weekly baseline with N=7, various stimulation amplitudes set as the 
blocking factor. No significant differences in the % change in TDST were found 
(Skillings—Mack, post-hoc Nemenyi).   
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Figure 19: % Change in step length from the OFF-therapy baseline with respect to 
the laterality stimulation model and L-DOPA administration during stimulation 
around 20% of the TW.  
Percent change in step length from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings assessed with respect to the 
laterality stimulation model at an amplitude around 20% of the TW. Data presented as 
box plots with solid horizontal lines representing the median, crosses representing the 
mean, the upper and lower whiskers representing the upper and lower fence—
respectively. Step length normalized to the OFF-therapy baseline with N=7, participants 
set as the blocking factor. Significant differences in the % change in step length from 
baseline were elicited with L-DOPA compared to the unilateral CS stimulation model 
implementing CS to the electrode in the hemisphere controlling the side of greater 
symptom severity (*, p<0.05; Friedman, post-hoc Nemenyi).  
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Figure 20: % Change in step time from the OFF-therapy baseline with respect to 
the stimulation setting and L-DOPA administration. 
Percent change in step time from baseline was calculated from normal pace walking 
following administration of L-DOPA and the 16 stimulation settings at stimulation 
amplitudes of around a) 40% b) 60 % c) 80% of the TW. Data presented as box plots 
with solid horizontal lines representing the median, crosses representing the mean, the 
upper and lower whiskers representing the upper and lower fence—respectively, and 
closed circles representing outliers above or below the upper and lower fence, 
respectively. Step time normalized to the OFF-therapy baseline and leg length with N=7, 
participants set as the blocking factor. a) Significant differences in the % change in step 
time were elicited with setting 16 (bilateral non-CS) compared to the ON L-DOPA, OFF 
stimulation condition (*, p<0.05; Skillings—Mack, post-hoc Nemenyi). b) Significant 
differences in the % change in step time were elicited with settings 4, 13, and 16 
(bilateral non-CS), setting 14 (right CS), and setting 12 (left CS) compared to the ON L-
DOPA, OFF stimulation condition (*, p<0.05; **, p < 0.01; ***, p < 0.001; Friedman, 
post-hoc Nemenyi). c) Significant differences in the % change in step time were elicited 
with setting 4 and 16 (bilateral non-CS), setting 14 and 15 (right CS), and setting 8 (left 
CS) compared to the ON L-DOPA, OFF stimulation condition (*, p<0.05; **, p < 0.01; 
***, p < 0.001; Skillings—Mack, post-hoc Nemenyi). 
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Figure 21: % Change in step time from the OFF-therapy baseline with respect to 
the hemispheric stimulation model and L-DOPA administration.  
Percent change in step time from baseline was calculated from normal pace walking 
following administration of L-DOPA and the 16 stimulation settings assessed with 
respect to the hemispheric stimulation model at stimulation amplitudes around a) 20% b) 
40 % c) 60% d) 80 % of the TW. Data presented as box plots with solid horizontal lines 
representing the median, crosses representing the mean, the upper and lower whiskers 
representing the upper and lower fence—respectively, and closed circles representing 
outliers above or below the upper and lower fence, respectively. Step time normalized to 
the OFF-therapy baseline and leg length with N=7, participants set as the blocking factor. 
Significant differences in the % change in step time were elicited with L-DOPA 
compared to the right CS stimulation model a) & c) (*, p<0.05, ***, p < 0.001; 
Friedman, post-hoc Nemenyi) b) & d) (***, p < 0.001; Skillings—Mack, post-hoc 
Nemenyi). Significant differences in the % change in step time were elicited with L-
DOPA compared to the bilateral non-CS stimulation model c) (*, p<0.05; Friedman, 
post-hoc Nemenyi) d) (*, p<0.05; Skillings—Mack, post-hoc Nemenyi). 
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Figure 22: % Change in step time from the OFF-therapy baseline with respect to 
the laterality stimulation model and L-DOPA administration. 
Percent change in step time from baseline was calculated from normal pace walking 
following administration of the 16 stimulation settings assessed with respect to the 
laterality stimulation model around a) 40% b) 60% & c) 80% of the TW. Data presented 
as box plots with solid horizontal lines representing the median, crosses representing the 
mean, the upper and lower whiskers representing the upper and lower fence—
respectively, and closed circles representing outliers above or below the upper and lower 
fence, respectively. Step time normalized to the OFF-therapy baseline and leg length with 
N=7, participants set as the blocking factor. Significant differences in the % change in 
step time from baseline were elicited with L-DOPA compared to the bilateral non-CS 
stimulation model b) (*, p<0.05; Friedman, post-hoc Nemenyi) c) (*, p<0.05; Skillings—
Mack, post-hoc Nemenyi). Significant differences in the % change in step time from 
baseline were elicited with L-DOPA compared to the unilateral CS stimulation model 
implementing CS to the electrode in the hemisphere controlling the side of less symptom 
severity a) & c) (*, p<0.05; **, p<0.01; Skillings—Mack, post-hoc Nemenyi) b) (**, 
p<0.01; Friedman, post-hoc Nemenyi). Significant differences in the % change in step 
time from baseline were elicited with L-DOPA compared to the unilateral CS stimulation 
model implementing CS to the electrode in the hemisphere controlling the side of greater 
symptom severity b) (*, p<0.05; Friedman, post-hoc Nemenyi) c) (*, p<0.05; Skillings—
Mack, post-hoc Nemenyi). 
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Table 7: Stimulation amplitudes for the left and right STN for each participant 
across each investigative week.  
Week 1, 2, 3, and 4 represents current amplitudes around 20%, 40%, 60%, and 80%        
of the TW, respectively of the left STN (L) and right STN (R). Current amplitudes are 
expressed as milliamperes (mA).  
Participant 
Code 
Week 
1-L 
Week 
1- R 
Week 
2- L 
Week 
2-R 
Week 
3-L 
Week 
3-R 
Week 
4-L 
Week 
4-R 
BSC-01 2.8 1.8 3.6 2.8 4.4 3.9 4.8 4.4 
BSC-02 1.5 1.4 2 1.8 2.5 2.2 3 2.6 
BSC-03 1.7 1.8 2.4 2.6 3.1 3.4 3.8 4.2 
BSC-05 1 1.1 1.5 1.7 2 2.3 2.5 2.9 
BSC-06 1.9 1.6 2.3 2.2 2.7 2.8 3.1 3.4 
BSC-07 1.9 2.3 2.2 3.1 2.6 3.9 3 4.7 
BSC-08 2 1.8 2.5 2.1 3 2.4 3.5 2.7 
AVERAGE 1.83 1.69 2.36 2.33 2.9 2.99 3.39 3.56 
 
Table 8: Stimulation amplitudes for the more and less affected side for each 
participant across each investigative week.  
Week 1, 2, 3, and 4 represents current amplitudes around 20%, 40%, 60%, and 80%         
of the TW, respectively of the more affected (MA) and less affected (LA) side. Current 
amplitudes are expressed as milliamperes (mA).   
Participant 
Code 
Week 
1-MA 
Week 
1-LA 
Week 
2-MA 
Week 
2-LA 
Week 
3-MA 
Week 
3-LA 
Week 
4-MA 
Week 4-
LA 
BSC-01 2.8 1.8 3.6 2.8 4.4 3.9 4.8 4.4 
BSC-02 1.5 1.4 2 1.8 2.5 2.2 3 2.6 
BSC-03 1.7 1.8 2.4 2.6 3.1 3.4 3.8 4.2 
BSC-05 1.1 1 1.7 1.5 2.3 2 2.9 2.5 
BSC-06 1.9 1.6 2.3 2.2 2.7 2.8 3.1 3.4 
BSC-07 2.3 1.9 3.1 2.2 3.9 2.6 4.7 3 
BSC-08 2 1.8 2.5 2.1 3 2.4 3.5 2.7 
AVERAGE 1.9 1.6 2.5 2.2 3.1 2.8 3.7 3.3 
3.4 Discussion 
3.4.1 General Discussion 
Variable benefits were found for step length, step time, stride velocity, and the FAP score 
when applying CS unilaterally versus bilaterally (Figure 11, 12, 14 & 16). No significant 
differences were found between various stimulation settings and models for TDST 
(Figure 18). Notably, none of the investigated gait measures significantly benefited from 
conventional single-contact stimulation; cumulatively, these findings support the 
hypothesis of objective one. In addition, an apparent benefit on stride velocity and the 
FAP score arose from unilaterally applying CS to the left STN that appears to reflect 
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hemispheric dominance, which supports the hypothesis for objective two (Figure 14 & 
16). Furthermore, L-DOPA appeared to elicit a differential effect on step length 
compared to unilaterally applying CS to the more severe side at the lowest investigated 
amplitude, and L-DOPA elicited a differential effect compared to bilateral non-CS and 
unilateral hemispheric and laterality stimulation models, which does not support the 
hypothesis of objective three (Figure 19-22).  
Lack of significant improvements exhibited by conventional single-contact 
stimulation may allude to the variable clinical outcome of this practice due to limited 
regulation of the resultant stimulation area (Wagle Shukla et al., 2017). The variable 
response was best reflected by clinical extremes elicited by different single-contact 
stimulation settings within the same patient. Tolerable and adequate symptom alleviation 
was contrasted with the induction of severe, disabling dyskinesia that prevented proper 
gait assessment (clinical outliers) and voluntary refusal to proceed with gait assessments 
in around 40% of the participant sample. Disregarding variability, the non-significant 
improvements may reflect the inferiority of the conventional practice to CS. Since the 
protocol biased upper limb symptom improvement during contact localization and 
selection according to clinical standards, the non-significant improvements may depict 
the perils of the inability to regulate the stimulation field for gait therapy. As reported in 
the literature radial spread associated with single-contact stimulation may paradoxically 
improve tremor, rigidity, and dyskinesia but induce gait hypokinesia and freezing when 
the zona incerta (Zi) and fields of forel are influenced (Fleury et al., 2016; Tommasi et 
al., 2007).  
The benefit of CS appeared to be particularly substantial during higher 
stimulation amplitudes as depicted by unilateral or bilateral applications of CS benefiting 
the FAP score, step time, and step length at the highest investigated amplitude around 
80% of the TW (Figure 11, 12 & 16). Fine-tuning the stimulation field is more necessary 
at higher amplitudes during which, conventional stimulation exhibits greater current 
spread around the active contact (Kuncel & Grill, 2004). The red nucleus or cranial nerve 
III may be influenced medially, which potentially induces psychological (impulsivity) or 
ocular side effects (diplopia); the internal capsule laterally, anteriorly, dorsally and 
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ventrally, which potentially induces contralateral muscle contractions; the hypothalamus 
anteriorly, which potentially induces autonomic symptoms; the medial lemniscus 
posteriorly, which potentially induces paresthesia; the thalamus and Zi dorsally, which 
potentially worsens gait but paradoxically improves appendicular symptoms; and the 
substantia nigra pars reticulata (SNr) ventrally, which potentially induces mood changes 
(Wagle Shukla et al., 2017). Overall, there appears to be a benefit on gait from 
implementing CS unilaterally to the left STN or bilaterally; however, a few findings must 
still be addressed: the non-differential effect on TDST, the varying effect of unilaterally 
applying CS, and the differential effect of L-DOPA and stimulation on step length and 
time.  
3.4.2 Non-differential effect of implementing CS for total double 
support time 
Overall ambulation and gait measures of amplitude, timing and velocity yielded 
improvements with either unilateral or bilateral applications of CS as opposed to TDST, 
which elicited a negative percent change that was non-differential between all stimulation 
settings and models (Figure 11, 12, 14, 16 & 18). The negative percent change in TDST 
represents improvements that may be attributed to reductions in trunk flexion in the 
forward direction associated with stooped posture induced by axial muscle rigidity, which 
consistently improves with STN-DBS (Cossu & Pau, 2016; Crenna et al., 2006; Wagle 
Shukla et al., 2018). On the other hand, the responsiveness of step length, step time, and 
stride velocity to STN-DBS corresponds to the hypothesis that separate sub-cortical 
pathways predominantly facilitate amplitude, timing, and velocity of gait as compared to 
postural control portrayed by TDST (Collomb-Clerc & Welter, 2015). The MLR plays a 
substantial role in gait and postural control; however, the CN has been suggested to 
predominantly facilitate spatio-temporal gait parameters while the PPN has been 
implicated with balance regulation (Collomb-Clerc & Welter, 2015; Takakusaki, 2017). 
Collomb-Clerc et al. (2015) proposed that the subthalamo-pallidal-MLR pathway 
regulates gait features such as amplitude, rhythm, and velocity while the subthalamo-
nigro-PPN circuit facilitates balance but are related through functional projections to the 
frontal, parietal, and sensorimotor areas of the cortex (Collomb-Clerc & Welter, 2015).  
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In addition to stooped posture elicited by axial rigidity, TDST has been correlated 
with risk of spontaneous falls and FOG, which are axial symptoms that are typically 
resistant to L-DOPA and STN-DBS and manifest later in the disease (Collomb-Clerc & 
Welter, 2015; Plotnik, Giladi, Dagan, & Hausdorff, 2011; Takakusaki, 2017). Therefore, 
spontaneous falls and FOG are postulated to be predominantly elicited by cholinergic 
deficits in the brainstem and the interplay with the spinal cord, cerebellum, BG, and the 
cortex (Takakusaki, 2017). The role of cholinergic PPN neurons in postural control is 
highlighted through the correlation between reduced cholinergic PPN neuronal size and 
quantity with FOG and fall frequency (Rinne et al., 2008; Zweig et al.,1989). 
Furthermore, the lateral SNr has been suggested to regulate muscle tone through 
GABAergic projections to the PPN; thus, alluding to the predominant role of the 
subthalamo-nigro-PPN circuit in facilitating balance (Collomb-Clerc & Welter, 2015; 
Takakusaki, Habaguchi, Ohtinata-Sugimoto, Saitoh, & Sakamoto, 2003; Takakusaki, 
Obara, Nozu, & Okumura, 2011). In addition, cognitive decline of the frontal lobe, visuo-
spatial dysfunction of the occipital and parietal cortex, and motor programming 
deficiencies in the pre-motor area and SMA have been attributed to non-dopaminergic 
postural instabilities (Bartels & Leenders, 2008; Stuart, Lord, Hill, & Rochester, 2016).  
Thus, irrespective of the stimulation practice, targeting electrodes to the STN may 
not sufficiently influence critical brainstem and cortical regions associated with postural 
control. Step length and time, stride velocity, and FAP score improvements may be 
attributed to projections of the STN to the GPi and subsequently the CN or the 
laterodorsal tegmental nucleus (Takakusaki, Chiba, Nozu, & Okumura, 2016). The 
projection of the SNr to the PPN may not be predominantly influenced as primate studies 
portray a greater representation of STN axonal projections to the GPi compared to the 
SNr and a greater representation of the GPi in the BG motor circuit (Hamani, Saint-Cyr, 
Fraser, Kaplitt, & Lozano, 2004). On the other hand, the sample did not exhibit non-
dopamine responsive axial motor symptoms; therefore, the non-differential effect on 
TDST between conventional and CS stimulation may be due to the lack of substantial 
postural deficits. 
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3.4.3 Benefit of unilaterally implementing current steering 
The benefit of unilaterally applying CS to the left STN for stride velocity and FAP score 
improvement may be explained by the lateralized functional dominance of the brain. 
From a clinical standpoint, implementing CS unilaterally to the left hemisphere may be 
beneficial since majority of participants exhibited a greater symptom severity on the right 
side of the body, which is predominantly controlled by the left hemisphere. However, 
stride velocity and the FAP score did not exhibit any significant differences when 
comparing unilateral applications of CS to the electrode in the hemisphere predominantly 
controlling the more or less affected side (Figure 15 & 17). Notably, stimulation 
amplitudes were tailored towards symptom asymmetry; thus, for the majority, a higher 
amplitude stimulated the hemisphere controlling the more affected side. This may suggest 
that the fine-tuning ability of CS does not address asymmetric symptom severity when 
already accounted for by stimulation amplitude. 
 Furthermore, the findings may be explained by the predominant role of the left 
hemisphere in bilateral coordination and control of complex movement sequences, which 
has been exhibited in studies assessing unilateral and bilateral movements (Barber et al., 
2011; Goto et al., 2009; Haaland, Elsinger, Mayer, Durgerian, & Rao, 2004; Scholz et al., 
2000). The BG have been reported to exhibit a stronger left-sided lateralization compared 
to the motor cortex; as depicted by, a greater activation of the BG in the left hemisphere 
during unilateral and bilateral movements using functional magnetic resonance imaging 
(Scholz et al., 2000). Lateralization of the BG may be attributed to the asymmetry of the 
nigrostriatal network; for instance, post-mortem analysis found that the left GP exhibits 
higher dopamine concentrations than the right GP among right handed individuals (Glick 
et al., 1982). The striatum also exhibits lateralization as it was found that the magnitude 
of right handedness was correlated to the degree of left-sided dominance of the putamen, 
and the putamen to thalamus projection in the left hemisphere is predominantly related to 
movement speed regulation (Barber et al., 2011; de la Fuente-Fernández et al., 2000). 
Furthermore, the putamen is suggested to be more affected by dopamine depletion in PD 
compared to the caudate nucleus (Kish et al., 1988). Thus, lateralized benefit of 
implementing CS to the left hemisphere for stride velocity improvements may be 
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attributed to fine-tuning the stimulation field on the side that is associated with motor 
dominance and the influence of structures (putamen) more affected in PD (Barber et al., 
2011; de la Fuente-Fernández et al., 2000; Kish et al., 1988).  
Notably, all participants were right handed except for one, which supports the 
hemispheric dominance theory for the present findings over asymmetrical symptom 
severity. Thus, the unilateral benefits of CS found may allude to the importance of motor 
control lateralization for bilateral, sequential movements. This may suggest that the left 
STN may be more sensitive to the resultant stimulation area because circuitry of the left 
hemisphere is more implicated in coordinating bilateral sequential movement. 
Nonetheless, it warrants clinical consideration of hemispheric dominance in addition to 
symptom severity when implementing asymmetric therapy particularly for gait, which is 
a bilateral phenomenon. 
Furthermore, unilateral benefit of implementing CS to the left STN was only 
exhibited by stride velocity and FAP, despite calculation of the FAP score incorporating 
measures of step time, step length, gait velocity, and dynamic base of support (Gouelle, 
2014). This may suggest the predominant influence of stride velocity as a marker for 
healthy ambulation. Espy and colleagues reported that gait velocity may independently 
reduce locomotion when both step length and velocity are deviated from healthy values 
(Espy, Yang, Bhatt, & Pai, 2010). In addition, gait speed at a self-selected pace has been 
correlated with functional ability and confidence that may predict health decline, 
mortality, and need for hospitalization; therefore, serving as a valid and specific marker 
of ambulation health (Stacy & Lusardi, 2009).  
Similarly, the argument for implementing CS unilaterally to the left STN may be 
exhibited by the effects of the stimulation settings and models on step time. Significant 
reductions in step time were exhibited by unilateral applications of CS to the right STN 
compared to bilateral applications (Figure 12). In reference to a hypokinetic, 
Parkinsonian gait, reductions in step time may represent faster ambulation, which is more 
representative of a healthy gait (Morris et al., 1994). However, decreases in step time 
must be assessed in regard to clinical context; for instance, step time reductions are also 
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associated with shuffling of gait. The right CS stimulation model elicited reductions by 
nearly 50% at the highest investigated stimulation models; in contrast to, L-DOPA which, 
elicited modest increases in step time by a magnitude no larger than 10% with the median 
suggesting negligible changes (Figure 21 & 22). Therefore, step time changes elicited by 
the bilateral CS stimulation model were more similar to L-DOPA, which is an established 
therapy and all participants exhibited L-DOPA responsive symptoms (Kalia & Lang, 
2015). Hausdorff and colleagues also reported negligible changes between step time 
elicited by independent L-DOPA therapy and independent DBS therapy, which 
corresponds to the two therapeutic conditions of the present investigation (Hausdorff, 
Gruendlinger, Scollins, O’herron, & Tarsy, 2009). Therefore, step time changes induced 
by bilateral CS may be interpreted as improvements. Furthermore, L-DOPA elicited 
significant differences between both laterality stimulation models, which also induced 
reductions in step time (Figure 22). Perhaps, unilaterally implementing CS elicits an 
imbalance in the circuitry that disrupts the rhythmicity of ambulation that is exacerbated 
when applying CS to the hemisphere less dominant in motor control (Figure 21). 
3.4.4 Differential effect of L-DOPA compared to stimulation  
A differential effect between L-DOPA and stimulation was found for step length and 
time, which does not support the hypothesis. The outcome of STN-DBS has been 
correlated with the L-DOPA response as clinical practice relies on an adequate response 
to L-DOPA as an inclusion criterion for DBS (Fasano et al., 2015; Welter et al., 2002). 
Changes to gait velocity, step length, step time, and TDST have been reported to be 
uniformly affected by L-DOPA and STN-DBS (Cantiniaux et al., 2009; Faist et al., 2001; 
Krystkowiak et al., 2003; Stolze et al., 2001). The differential effect of L-DOPA and 
stimulation on the percent change in step length was exhibited among laterality 
stimulation models (Figure 19). L-DOPA exhibited significant increases from baseline, 
which has been reported in the literature; however, at the lowest investigated stimulation 
amplitude (around 20% of the TW) L-DOPA elicited a significantly greater increase 
compared to unilateral applications of CS to the electrode in the hemisphere controlling 
the more symptomatically severe side (Figure 19; Table 8). All stimulation models 
elicited a smaller increase in the percent change in step length; however, the significant 
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difference elicited by unilateral CS influencing the more severe side may arise from the 
larger variation of this stimulation model (Figure 19). Nonetheless, it is possible that at 
lower stimulation amplitudes current fractionation may under stimulate the active contact 
receiving a smaller proportion of current, which suggests its inferiority to improve step 
length as compared to conventional stimulation, bilaterally applied CS stimulation, and 
unilateral applications of CS to the hemisphere influencing the less severe side.  
In addition, there was a differential effect on the percent change in step time 
between L-DOPA and conventional stimulation, the unilateral right hemispheric and both 
laterality stimulation models but not bilateral applications of CS (Figure 20-22). L-DOPA 
elicited modest increases from baseline no larger than 10% in the present study, which is 
similar to reports of Hausdorff and colleagues who reported negligible changes of step 
time when comparing therapeutic conditions of L-DOPA and STN-DBS (Hausdorff et 
al., 2009). The findings suggest the ability of bilaterally implemented CS to influence 
step time similarly to L-DOPA, which is an established therapy (Kalia & Lang, 2015). 
3.4.5 Limitations 
The predominant limitation of this study is the inaccurate representation of clinical 
implementation of CS. All participants were recruited pre-surgically and programmed 
with CS despite some exhibiting adequate symptom alleviation with conventional single-
contact stimulation. Therefore, the sample did not entirely consist of those experiencing 
inadequate gait improvement following conventional programming standards. In 
addition, CS was implemented without personalization whereas in actual clinical practice, 
CS would be applied following inadequate symptom alleviation with conventional 
programming and current fractionations would be tailored to contact localizations. With a 
larger sample, the technique could be implemented only in those requiring fine-tuning, 
which more precisely reflects clinical practices. 
Hence, a second major limitation is related to the size and demographics of the 
sample. Statistical analyses with the small sample size may be sensitive to inherent 
variations in disease phenotype; furthermore, an unbalanced representation of right 
handedness and disease asymmetry of the right-side warrants further investigation of 
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unilateral applications of CS. For instance, a left CS stimulation setting elicited 
significantly greater increases of stride velocity compared to a setting using single-
contact stimulation; however, median comparisons portray opposite trends from 
presenting findings such that right CS and single-contact stimulation are most beneficial 
for stride velocity improvement (Figure 14). In addition, the BG are involved with 
timing, amplitude, and movement features; therefore, the benefit from left-sided 
implemented CS should presumably be elicited among step length and time as well. 
Particularly for step length, asymmetrical benefits of CS are reasonable since step length 
asymmetries are also common in healthy adults (Lizarraga et al., 2017). 
Minor limitations include modelling conventional stimulation with CC devices, 
the washout period, and the current fractionations implemented. The single-contact 
unipolar stimulation in the present investigation may not truly reflect conventional 
stimulation, which is implemented with VC systems. Single-contact stimulation 
programmed with CC systems may not truly reflect conventions since VC IPGs deliver 
charge inconsistently as a result of impedance fluctuations. A true comparison should 
involve recruitment of patients implanted with VC devices or to include patients whose 
gait has been evaluated with VC IPGs but receive subsequent implantation of IPGs 
capable of CS. However, the former fails to provide for repeated measures and the latter 
may be biased because subsequent implantation would occur at a substantially later time 
point in the disease. In addition, a 25-minute washout period was implemented based on 
recommendation of the supervising specialist; however, the literature has reported that 
the period required for adequate washout of STN-DBS varies across participants and is 
inversely related with disease duration (Cooper, McIntyre, Fernandez, & Vitek, 2013). 
Therefore, assessments may be confounded by residual effects of previous settings. 
Furthermore, unequal fractionations of 70%/30% modelled CS but the 30%/70% 
counterpart was not implemented, which biased the more ventrally located contact with a 
greater proportion of current. Arguably, greater stimulation of more ventrally located 
contacts decreases the likelihood of stimulating fibre tracts such as the Zi associated with 
gait worsening (Fleury et al., 2016). In future studies, personalized fractionations tailored 
to contact localizations should be implemented with sessions spread out by a greater 
amount of time to ensure an adequate wash-out period for all patients. 
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3.4.6 Conclusion 
Results of the present study suggest implementing CS bilaterally for step time and length 
improvement and unilaterally to the left STN for improvement of stride velocity and the 
FAP score. No differential effect between stimulation types were found for TDST; in 
addition, non-CS stimulation did not elicit any significant improvements reflecting the 
variable outcome associated with single-contact stimulation. Failure to find a differential 
effect between CS and conventional stimulation for TDST may allude to separate sub-
cortical networks predominantly regulating amplitude, rhythm/timing, and velocity of 
movement versus balance. Furthermore, L-DOPA appears to elicit a similar outcome for 
all gait parameters compared to all types of stimulation except for step time, which 
exhibited a variable outcome from unilaterally implementing CS and single-contact, 
conventional stimulation. In addition, unilaterally implementing CS at low amplitudes 
improved step length to a poorer degree than L-DOPA; however, this inadequacy of CS 
was only found for step length at the lowest investigated amplitude.  
Lack of significant differences between implementing CS unilaterally to the more 
versus less affected side suggests that the benefit of asymmetrically implementing CS 
reflects the dominance of the left hemisphere in facilitating motor control exhibited by 
the BG and motor cortex (Barber et al., 2011; Scholz et al., 2000). Therefore, present 
findings suggest hemispheric dominance to explain the benefit of unilateral applications 
of CS; however, disease asymmetry should not be completely dis-regarded for explaining 
the unilateral benefit since the present sample is imbalanced with greater right-sided 
severity. Overall, the findings of this study suggest the potential advantage of utilizing 
CS over conventional stimulation to effectively improve gait while accounting for 
hemispheric laterality, particularly at higher stimulation amplitudes. 
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Chapter 4  
4 General Discussion & Conclusions 
Bilaterally implementing current steering (CS) exhibited greater practical and clinical 
efficacy through eliciting improvement of overall ambulation with lower total electrical 
energy delivered (TEED) values. Thus, CS elicited better ambulation performance with 
lower TEED values as CS was able to significantly reduce the TEED (Figure 6a & 7b). 
Assessments of individual gait parameters and inclusion of unilateral applications 
portrayed a particular benefit of implementing CS bilaterally for step time and length 
improvement and unilaterally to the left subthalamic nucleus (STN) for stride velocity 
and functional ambulation performance (FAP) score improvement (Figure 11, 12, 14, 
16). As predicted, conventional single-contact stimulation did not elicit significant 
improvements over unilateral and bilateral CS, and a non-differential effect between CS 
and conventional stimulation was found for total double support time (TDST) (Figure 
18).  Notably, CS improved step length, stride velocity, TDST, and overall ambulation 
(FAP) to a similar degree as Levodopa (L-DOPA); however, only bilateral applications 
of CS elicited a comparable effect on step time, which may suggest that unilateral 
applications induce asymmetric modulation that is unfavourable for rhythm regulation 
(Figure 20-22). Significant improvements elicited by bilateral and unilateral CS tended to 
manifest at higher stimulation amplitudes when single-contact stimulation is more 
susceptible to radial current spread, which may influence surrounding neural structures 
and undermine the clinical outcome (Kuncel & Grill, 2004).  
The unilateral benefit of implementing CS to the left STN may demonstrate 
dominance of the left hemisphere in motor control, which is exhibited by the basal 
ganglia (BG) and motor cortex (Barber et al., 2011; Scholz et al., 2000). Lack of superior 
benefit portrayed by conventional stimulation on the individual gait parameters exhibits 
the variable responsiveness and disadvantage of this practice. In addition, the non-
differential effect of various stimulation types on TDST suggests separate neural control 
of spatio-temporal gait parameters and balance for which, the former may be more related 
to the STN-internal globus pallidus (GPi)-cuneiform nucleus projection and the latter 
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may be more related to cholinergic modulation in the brainstem involving the STN-
substantia nigra pars reticulata-pedunculopontine nucleus projection (Collomb-Clerc & 
Welter, 2015; Takakusaki, 2017). The non-differential effect of CS on balance measures 
as opposed to the greater improvement of amplitude, timing, and velocity gait deficits in 
L-DOPA responsive patients may reflect the greater representation of the GPi in the BG 
motor circuit and a similar therapeutic influence of the cortical-BG-thalamus-cortical 
loop to L-DOPA (Hamani, Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004).  
 Present findings portray the practical benefit of implementing CS to reduce TEED 
values, which reduces power consumption, tissue damage and side effect risk, impulse 
generator (IPG) battery drainage rate, and need for IPG replacement. In addition, benefits 
of applying CS unilaterally to the left STN suggests that the circuitry of the left 
hemisphere may be more dominant in coordinating bilateral sequential movement; thus, 
benefiting more from the fine-tuning effect. Nonetheless, it warrants clinical 
consideration of hemispheric dominance in addition to symptom severity when applying 
therapy asymmetrically. Overall, the results suggest the practical and clinical efficacy of 
CS over conventional stimulation, particularly at high stimulation amplitudes. CS allows 
for fine-tuning of the stimulation field to address the complex integration of neural 
networks facilitating gait, neuroanatomical variations, contact localization deviations, and 
potential deficits induced by a bias of upper limb symptom improvement during deep 
brain stimulation implementation procedures. However, present findings are limited by a 
small sample size and an imbalanced representation of right handedness and greater 
motor symptom severity of the right side of the body; therefore, further investigation 
particularly for unilateral CS applications should be conducted. 
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Appendix B: Letter of Information and Consent 
Letter of Information and Consent 
Study Title: The use of whole-body kinematic technology for optimizing current steering 
deep brain stimulation in Parkinson’s disease patients  
Principal investigator: Dr. Mandar Jog, London Health Science Movement Disorders 
Clinic, UWO  
Protocol Version: 8.0 
Protocol Date: 1/June/2018 
Participant Number: BSC - __ __ 
In this Consent document, “you” always refers to the study participant. Participants 
of this study must be able to give informed consent and cannot have a substitute decision 
maker (SDM) (i.e. someone who makes the decision of participation on behalf of a 
participant).  
This consent form explains the research study you are invited to join. Please ask 
the study doctor or the study staff to explain any words or facts that you do not 
understand. You should keep a signed copy of this consent form. You may wish to 
discuss this study with your family and friends before making your decision. If you 
decide to take part in the research study, you must sign this form before you have 
anything done for this research study. 
Introduction  
We are inviting you to voluntarily participate in a research project designed to 
assess the use of a new method in the practice of a surgical procedure known as deep 
brain stimulation (DBS). This procedure allows electrical signals to be sent to brain areas 
related to control of body movement – one area being the subthalamic nucleus (STN). 
The device being implanted in the STN is part of the routine DBS therapy; therefore, the 
surgery and clinical management of your DBS device will not be changed. However, 
during the research visits of this study, we will be exploring a new method of delivering 
current to the appropriate brain region.    
 
During DBS, electrodes are placed deep in the brain and are connected to a 
programmable stimulator device. Similar to a heart pacemaker, the stimulator uses 
electric pulses to help regulate the amount of stimulation delivered to the electrodes. The 
doctor controls the stimulator settings with a wireless device and stimulation settings can 
be adjusted as a patient's condition changes over time. The surgical procedure to implant 
the electrodes will have been clearly explained to you by your surgeon and neurologist, 
and you will have already signed a separate consent form for this operation as part of the 
treatment of your Parkinson’s disease (PD). 
 
Currently, the delivery of current is directed toward the same brain region for all 
patients. A new DBS technique has broadened our ability to control and thus, investigate 
different programming settings of the stimulator device. Through stimulating different 
regions in the brain, this investigation can help us to determine the best location to deliver 
current, for each patient. The ability to change where and how much current is being 
delivered is called current-steering. This study seeks to investigate current-steering with 
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the use of your DBS device to determine the effectiveness of this new programming 
technique.  
Background  
DBS of the STN is a therapy for individuals who are no longer responding to 
Levodopa (the current drug used to treat PD) as well as they were at the start of their 
treatment. The purpose of the method of DBS is to stimulate target brain structures while 
minimizing the stimulation of surrounding regions. The success of DBS therapy is reliant 
on 3 main aspects: 1) proper patient selection, 2) accurate placement of the electrode lead 
within the brain, 3) effective selection of stimulator settings of the DBS device. The 
precise location of the electrode lead and the stimulator settings contribute equally to the 
therapeutic effect for the patient. However, if the electrode is misplaced within the brain 
tissue, corrective surgery possesses an added risk for the patient.  
 
  The DBS device being used for this study will allow the current to enter the 
patient’s brain through multiple contact points. The device used in this study is not new; 
however, current steering or the ability to control the amount of current delivered at each 
contact point is a new technique. The technique of current steering will be investigated in 
this study. The current steering feature of DBS devices has not been extensively 
researched. Current steering allows for a more personalized treatment of PD. The ability 
to direct the current to the optimal location for each patient is a very promising approach 
to improve the therapeutic success of DBS.    
 
In this study, we attempt to use our lab expertise to investigate the current steering 
technique. The STN is composed of many different types of brain cells that respond 
differently to electrical stimulation. It is hypothesized that PD symptom relief is highly 
dependent on the location of DBS electrical stimulation. Therefore, it is predicted that 
current steering can change the area of brain tissue being stimulated, and a notable 
change in PD motor and perceptual features will result as different types of STN brain 
cells can be targeted. The objectives of the study are: 
1. Investigate whether using current steering settings during DBS to direct the 
current to an optimal location within the brain tissue has any direct effect on 
PD motor and perceptual symptoms. 
2. Determine if there are common settings of the programmable DBS device that 
are best for treating symptom improvement among all patients. 
We are looking to investigate current steering in 16 persons that have undergone 
STN-DBS recruited from the Movement Disorders Clinic at London Health Sciences 
Centre (LHSC). This study will require you to come to the research lab 4 days a week for 
a month post-operation.  
Study Funding  
The study is funded in part by Boston Scientific who manufacture the DBS device 
being used in the current study. Other funding is coming from a research grant from 
Movement Disorders Center at London Health Sciences Centre (LHSC).   
Inclusion and Exclusion criteria  
If you decide to join, you will be asked to sign this consent form and you must 
agree to follow the instructions given by the research staff during the study. You may not 
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participate in this study if you participated in another clinical research project less than 4 
weeks ago. Based on your screening information, the study doctor will determine if you 
are eligible to join this study. 
Inclusion criteria: 
1. Diagnosed Idiopathic Parkinson Disease with excellent response to levodopa 
medication 
2. A score of between II-IV on the Hoehn-Yahr scale 
3. Severe motor fluctuations with disabling off periods and dyskinesia during on 
phases 
4. Assessed for eligibility for the DBS procedure  
5. Able to give informed consent  
6. Able to visit the clinic for assessment  
7. No dementia or psychiatric abnormalities.  
Exclusion criteria: 
1. Any previous brain surgery or a cardiac pacemaker   
2. If your medication routine is unstable and/or you take levodopa containing 
medications less than 3 times a day.  
3. Any diagnosis of dementia, severe cognitive disturbances or severe 
psychiatric symptoms (in particular hallucinations and depression) as assessed 
by DSM criteria 
4. Any hip or joint replacements (unless well treated as assessed by the study 
team) 
5. Lack of compliance at follow-up. 
6. Additional exclusion criteria for perceptual test: Severe visual impairment 
determined from visual testing (i.e., convergence insufficiency) 
Study Tools    
The study will make use of several technological devices to objectively measure 
all motor symptoms associated with Parkinson’s disease. The whole-body mobility is 
assessed using a motion capture suit which houses several motion sensors that track all 
body movements. You will be dressed in a lightweight, stretchable, and breathable suit 
over your regular clothing. You will also wear a head sensor attached to a lightweight 
cap, as well as fingerless gloves and shoe attachments with hand and foot sensors. The 
total weight of the suit is 1.5 kg. Walking will be assessed using a pressure sensor carpet 
walkway. You will be required to walk across the carpet so that the system can capture 
your walking patterns in various ways. Your speech will also be recorded using a head 
mounted microphone and a digital recording device. To assess the perceptual capabilities 
of the PD subjects, a computational virtual reality environment and haptics-enabled 
robots (such as the KINARM Exoskeleton and End-Point robots) may be used.    
You will also complete standard clinical scales at each visit that are used to 
monitor motor and non-motor features of Parkinson’s disease (Table 1.) 
Table 2. Clinical scales used at every visit. 
Clinical Scale Description 
The Unified Parkinson's 
Disease Rating Scale 
A widely used clinical scale used to measure the 
impairment and disability associated with Parkinson 
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(UPDRS) Disease 
The Montreal Cognitive 
Assessment (MoCA) 
A brief 30-question test which assesses different types 
of cognitive abilities such as short-term memory and 
concentration. 
Freezing of Gait 
Questionnaire (FOG-Q) 
A 6 item questionnaire used to monitor freezing of gait 
in Parkinson’s disease 
Activities-specific Balance 
Confidence (ABC) Scale 
A 16 item scale that measures one’s confidence in 
maintaining their balance when completing specific 
activities  
Beck’s Depression Inventory A 21 item questionnaire used to measure affect related 
to depression  
All visits will be recorded with a video camera for data analysis purposes only. 
The recorded videos will be coded and not linked to your personal information. You may 
opt-out from these recordings by selecting an option on page 10 of this letter.     
 
Study Procedure and Design 
This is a trial seeking to optimize a patients’ DBS device programming using 
objective and quantitative data that will be obtained from kinematic technology such as 
the motion capture suit and the carpet walkway.  
Participants will then undergo DBS implantation into the STN on both sides of the 
brain with the Boston Scientific DBS device. Patients will be given at least 4 weeks to 
recover from the operation; for instance, from week 0 to week 4. At least 6 weeks post-
operation, each participant will undergo a 4-week titration regime to determine the effect 
that current steering has on their primary motor symptoms. Classic hallmark PD symptoms 
will be assessed using the kinematic technology. 
Visit 1: 1 week before surgery 
Study participants will be seen one week prior to the DBS surgery to assess their response to the 
levodopa medication. You will arrive at the research laboratory after being OFF levodopa 
medications for 12 hours. Full body mobility assessments will be conducted in your OFF 
state using the motion capture suit, carpet walkway and the speech recorder. Following 
these assessments, you will be asked to take 135% of your usual levodopa medication. 
For example, if the patient usually takes 100mg of levodopa for the treatment of their PD, 
135% of that would be 135mg. During the wait time for the medication to take into 
effect, clinical rating scales for movement difficulties and other difficulties (depression, 
memory etc.) will be completed (outlined in Table 1.). Once the levodopa medication has 
taken effect a full body mobility assessment will be conducted in your ON state using the 
motion capture suit, carpet walkway and the speech recorder.  
Visit 2: at least 4 weeks post-surgery 
At least 4 weeks post-operation a Movement Disorder Neurologist will turn on the 
patients’ device. 
**Note: The next visit sessions will occur over 1 consecutive 
month, with 4 visits each week** 
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Visit 3-6: at least 6 weeks post-surgery 
 During these visits 16 current steering paradigms will be explored, 4 each day. These 
setting paradigms will be randomized for each participant so the same settings are not 
presented in the same order for each person. Your device will also be set to 20% more of the 
therapeutic amplitude (current) you will be at clinically. After each current steering setting is 
implemented, a 30-minute wait period will be allowed for the setting to take effect. Full body 
assessments will be performed for each setting change as well as the UPDRS. At the end of 
each day, following the 4 setting changes, your DBS device will be returned to the original 
setting you came in with. At the end of the week you will be turned to a setting that was 
found to be most beneficial. You will then be asked to return the following week.   
Visit 7-10: at least 7 weeks post-surgery 
This visit will be the exact same as visits 3-6 except the amplitude (current) of the 
device will be increased by 40% of the baseline setting. 
Visit 12-15: at least 8 weeks post-surgery 
This visit will be the exact same as visits 3-6 except the amplitude (current) of the 
device will be increased by 60%. 
Visit 16-19: at least 9 weeks post-surgery 
This visit will be the exact same as visits 3-6 except the amplitude (current) of the 
device will be increased by 80%. 
Visit 20 (optional): at least 12th week post-surgery 
 During this visit, the subject’s various perceptual capabilities will be measured. The 
subject will be asked to perform two-forced alternative choice perceptual tasks while sitting 
down. These tasks will be displayed on a computer monitor and the patient will be asked to 
provide verbal responses to questions asked during the tasks. The perceptual tasks will 
involve tasks to test for temporal perception, displacement perception and velocity perception 
(an example is when two objects are shown on a monitor and the participant is asked to tell 
which object is moving faster or further). Alternatively, the subjects may carry out 
proprioceptive perceptive tests (such as temporal, displacement and velocity perception) 
using a haptics-enabled device (such as the KINARM Exoskeleton and End-Point robots). 
An example of a task involves the subject comparing two speeds of passive movement 
(powered by the haptics device), and verbally answering which of the compared speeds they 
perceive to be faster. 
Study Tasks 
Patients will perform various tasks during the programming sessions including: 
1. Relaxed position (20 Seconds): The participants are asked to rest their arms in 
neutral position while: back hunched forward, both forearms on legs, and hands 
hanging loose between legs. The participants hold this position for 20 seconds. 
2. Supported Posture (20 seconds): The participants are asked to rest their arms in 
neutral position on the arm rests of a chair. The participants hold this position for 
20 seconds. 
3. Pronated Posture (20 seconds): While sitting, participants fully extend their arms 
forward with hands in pronation at shoulder height level. The participants hold this 
position for 20 seconds. 
4. Supinated Posture (20 seconds): While sitting, participants fully extend their 
arms forward with hands in supination at shoulder height level. The participants 
hold this position for 20 seconds. 
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5. Pronation-supination (20 seconds): Same position as   posture, participants are 
asked to turn hands one at a time and as fast as possible so that their palms face up 
and down alternatively. The participants keep this motion for 20 seconds. 
6. Normal walking (90 seconds): consists of rising from a chair and walking around 
a 25 meter track 5 times at a preferred normal pace.  
7. Fast walking (90 seconds): consists of rising from a chair and walking around a 25 
meter track 5 times at a fast as possible pace. 
8. Backwards walking (90 seconds): consists of rising from a chair, turning around 
and walking down the 7 meter long gait carpet. Once off the carpet the patient 
turns around and walks backwards across the carpet back into the starting chair. 
9. 180 Degrees Turn (60 seconds): while standing, the participant is asked to turn 
left/right 180 degrees on the spot to face the back. After a few seconds, they are 
asked to return to the original position. This task is performed for 8 turns. 
10. Speech recording (120 seconds): a microphone will be taped to the patients’ 
cheekbone and speech tasks will be carried out. 
11. UPDRS (5 minutes): this clinical rating scale will be carried out to assess motor 
symptom severity after each setting change. 
12. Visual Temporal Perception (about 30 minutes): Patients will perform a 2-
Alternative-Forced-Choice task composed of approximately 160 trials. In each 
trial, comparisons between the time of shapes flashing on the screen (i.e., the first 
shape appears, disappears for varying amount of time [this time changes between 
trials and shapes compared in trials] then reappears again briefly before 
disappearing permanently. This is followed by another shape flashing on the 
screen. The subject will be asked which time duration between the shape 
disappearing and reappearing was faster (or if they were the same) between the 
two compared shapes in each trial.  
13. Visual Displacement Perception (about 30 minutes): Patients will Perform a 2 
Alternative Forced Choice task composed of approximately 160 trials. In each 
trial a shape at a certain point displayed on a computer monitor will displace to 
twice, the subject must answer which displacement was greater, or if their 
displaced was of the same magnitude. 
14. Visual Velocity Perception (about 40 minutes): Patients will perform a 2-
Alternative-Forced-Choice task composed of approximately 200 trials. In each 
trial two shapes will be moving in opposite directions on a computer monitor for 
10 seconds, the subject must answer which velocity was greater, or that the 
velocities are the same speed. 
15. Proprioceptive Temporal Perception (about 30 minutes): Patients will 
perform a 2-Alternative-Forced-Choice task composed of approximately 160 
trials. In each trial, subjects should compare the difference in time between the 
release of force applied from the haptics device (i.e., in each trial, the device will apply 
force, remove force for a set time, apply force again, remove force a second time, reapply 
force, end of trial). The subject will be asked which time duration between the 
removal of the force applied to the patient and the force being reapplied was 
longer (or if they were the same) between the two compared pauses in force for 
each trial.  
16. Proprioceptive Displacement Perception (about 30 minutes): Patients will 
perform a 2-Alternative-Forced-Choice task composed of approximately 160 
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trials. In each trial the subject’s limb will begin at a starting point and be passively 
displaced twice from this starting point. The subject should compare the 
proprioceptive displacements and verbally answer which displacement they felt 
was greater, or that the displacements were the same. 
17. Proprioceptive Velocity Perception (about 40 minutes): Patients will perform a 
2-Alternative-Forced-Choice task composed of approximately 200 trials. In each 
trial the haptic device will passively move the patient’s limb at a certain velocity 
for around 7 seconds, and then move their limb again for around 7 seconds. The 
subject will then compare the speeds of the limb movements, and verbally 
respond which speed they perceived to be greater, or that they perceived the speed 
to be the same. 
18. Visual Shape Perception (about 30 minutes): Patients will perform a 2-
Alternative-Forced-Choice task composed of approximately 150 trials. Each trial 
will consist of sequential (visual) presentation of two rectangles. The subject will 
compare the length of the two rectangles, and indicate which rectangle they 
perceive to be bigger in length by selecting one of the two options, shown in the 
monitor at the end of each trial, using the haptic device. 
19. Proprioceptive Shape Perception (about 30 minutes): Patients will perform a 
2-Alternative-Forces-Choice task composed of approximately 150 trials. Each 
trial will consist of a sequential (haptic) presentation of two rectangles. The 
subject will be able to haptically explore the length of the rectangle by moving the 
haptic device along its edge. The subject will then compare the length of the two 
rectangles, and indicate which rectangle they perceive to be bigger in length by 
selecting one of the two options, shown in the monitor at the end of each trial, 
using the haptic device. 
20. Combined Visual-Proprioceptive Shape Perception (about 30 minutes): 
Patients will perform a 2-Alternative-Forced-Choice task composed of 
approximately 150 trials. Each trial will consist of a sequential (visual and haptic 
both) presentation of two rectangles. In these trials, subjects will simultaneously 
look at and haptically explore the length of the rectangle. In one of the two 
presentations, the visually and haptically specified length of the rectangle will be 
the same, whereas in the other presentation the visually and haptically specified 
length of the rectangle may differ. The subject will compare the length of the 
rectangles, and indicate which rectangle they perceive to be bigger in length by 
selecting one of the two options, shown in the monitor at the end of each trial, 
using the haptic device. 
 
Each task will be performed twice with the exception of tasks 6, 7, 9-11. The total amount 
of time for the motor testing sessions is approximately 20 minutes with appropriate rest 
periods. Perceptual tests will be done when the DBS system is turned off, and again when 
it is turned on during one day of experimenting. 
 
Possible Risks and Harms 
This study has some risks that we know about. There is also a possibility of risks that we 
do not know about and have not been seen in study participants to date. Please call the 
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study doctor if you have any side effects even if you do not think it has anything to do 
with this study. Risks are grouped according to two categories; a brief overview is 
provided for standard of care risks which your doctor will have discussed with you in 
greater detail. The second group is risks related to participation in this research study: 
Study Related Risks 
 
Withholding of medication: You may have transient worsening of parkinsonian 
symptoms following overnight withdrawal of antiparkinsonian medications. However, 
this should be no different from the procedure performed as part of the routine clinical 
assessment before and after surgery. You may get tired during the procedure. You will be 
OFF medications about 12 times total throughout the study.  
Risks of Current Steering: You may experience worsening of motor symptoms during 
the setting changes at the research visits. Some common side effects patients report 
during settings changes are: 
1. Worsening of motor features associated with Parkinson’s disease 
2. Tingling and numbness in limbs 
3. Dizziness and lightheadedness 
4. Upset stomach 
5. Blurred vision 
6. Slurred speech 
While these symptoms do not usually occur it is important to monitor for them. 
The study team understands the common side effects and will monitor them throughout 
the study. Should you be experiencing any of these symptoms, or others, please let the 
study team know.  
Risks associated with study tools: The full body suit is a light weight and fully portable 
technology for collecting information about your mobility. There is a minimal risk 
associated with wearing such a suit as the system only uses simple sensors that are 
attached to the suit. Some study participants may experience discomfort such as itching 
and sweating in their body while wearing the suit. Some study participants may 
experience minor emotional distress with completing the scales and questionnaires. 
Scales will be administered by an experienced researcher trained in administering items 
in a sensitive manner. You will be allowed rest periods as necessary during the scales and 
questionnaires to facilitate comfort.   
Possible Benefits 
You may not directly benefit from the study, but the information obtained may 
lead to new knowledge on movement disorders and may lead to new treatment for 
movement disorders. 
Compensation 
 You will not be compensated for participating in this research study, however you 
will be reimbursed for parking expenses and potential travel costs.   
Confidentiality 
Personal Health Information 
If you agree to join this study, the study doctor and his/her study team will look at 
your personal health information and collect only the information they need for the study. 
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Personal health information is any information that could be used to identify you and 
includes your: 
1. Name 
2. Address 
3. Partial Date of birth  
4. New or existing medical records that includes types, dates and results of medical 
tests or procedures   
5. Telephone Number 
Research Information in Clinical Records  
If you participate in this study, information about you from this research project 
may be stored in your hospital file and in the LHSC computer system. The study team 
can tell you what information about you will be stored electronically and if you have any 
concerns about this, or have any questions, please contact the laboratory  
The following people may come to the hospital to look at the study records and at 
your personal health information to check that the information collected for the study is 
correct and to make sure the study is following proper laws and guidelines: 
1. Representatives of Lawson Health Research Institute (LHRI) including the LHRI 
Research Ethics Board  
2. Representatives of the University of Western Ontario Health Sciences Research 
Ethics Board.  
3. The study sponsor or its representatives’/partner companies (Canadian Institutes 
of Health Research and Boston Scientific) 
4. Representatives of Health Canada or other regulatory bodies (groups of people 
who oversee research studies) outside of Canada, such as the United States Food 
and Drug Administration.   
The information that is collected for the study will be kept in a locked and secure 
area by the study doctor for 25 years. Only the study team or the people or groups listed 
below will be allowed to look at your records. Your participation in this study also may 
be recorded in your medical record at this hospital.   
Following completion of the study, identifiable videos and photographs will be 
stored using a code number only and will never leave University Hospital. The videos 
and photographs will remain stored in a secure location and will not be viewed by anyone 
outside the study team without your permission. If these videos are used for scientific 
presentations or education purposes, you will not be identified as all personal identifiers 
(such as your face) will be blurred or blackened out. All videos and photographs will be 
destroyed after the study is complete. 
Your signed consent, which will have your name on it, will not be stored with the 
data collected from the study and will not be connected to the data collected.  The master 
list with your contact information on it will also be stored separately from the data 
collected to avoid linking your personal information to your data recordings. Consent 
forms and the master list will be stored in a secure location in the Movement Disorders 
Laboratory of Dr. Jog at University Hospital. 
Voluntary participation  
Participation in this study is voluntary. You may refuse to participate, refuse to 
answer any questions or withdraw from the study at any time with no effect on your 
141 
 
future care. You will be able to withdraw from the study at any point in time. However, 
to protect the integrity of the study the data collected up to the point of your withdrawal 
will remain a part of the study. You will not have the option of withdrawing your data 
once it has been collected even if you choose to withdraw from the study. No new 
information will be collected without your permission.   
Alternatives to study participation  
The alternative to study participation is to continue on your current course of 
medication and disease management under the direction of Dr. Mandar Jog.   
Withdrawal from the study by the investigator  
The investigator may decide to take you off the study if he feels your continued 
participation would impair your wellbeing or if the measuring devices are causing 
discomfort. The investigator may also decide to terminate your participation if 
compliance at follow-up is deemed insufficient. 
Rights as a Participant 
If you are harmed as a direct result of taking part in this study, all necessary 
medical treatment will be made available to you at no cost. By signing this form you do 
not give up any of your legal rights against the investigators, sponsor or involved 
institutions for compensation, nor does this form relieve the investigators, sponsor or 
involved institutions of their legal and professional responsibilities. 
Persons to Contact with Questions  
For more information about this research study, or if you believe that you may 
have a research related injury or experienced any side effects as a result of participating 
in this study you may call Dr. Mandar Jog. If you have questions about the conduct of the 
study or your rights as a research participant, you may call Dr. David Hill, Scientific 
Director, Lawson Health Research Institute.  
Publication 
If the results of the study are published, your name will not be used. If you would 
like to receive a copy of any potential study results, please contact Dr. Mandar Jog. 
You do not waive any legal rights by signing the consent form. You will receive a copy 
of the letter of information for your records. 
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Patient Consent Form 
Study Title: The use of whole-body kinematic technology for optimizing current steering 
deep brain stimulation in Parkinson’s disease patients  
Principal Investigator: Dr. Mandar Jog, MD 
Medical Personnel:  
Dr. Mandar Jog, MD – Neurologist  
Ms. Heather Russell – Clinic Nurse  
 
I have read the Letter of Information, have had the nature of the study explained to me 
and I agree to participate. All questions have been answered to my satisfaction.  
 
 I give permission for my visits to be recorded on camera for data analysis 
purposes only 
 I do not give permission for my visits to be recorded on camera 
 
__________________________________     _______________________     __________ 
    Signature of Study Participant                          Printed Name                           Date  
__________________________________     _______________________     __________ 
    Signature of Study Investigator                          Printed Name                          Date  
__________________________________     _______________________     __________ 
    Signature of Person Obtaining Consent             Printed Name                          Date  
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Appendix C: UPDRS III 
18 . Speech 
0: Normal: No speech problems. 
1: Slight: Loss of modulation, diction or volume, but still all 
words easy to understand. 
2: Mild: Loss of modulation, diction, or volume, with a few words unclear, but the 
overall 
sentences easy to follow. 
3: Moderate: Speech is difficult to understand to the point that some, but not 
most, sentences are poorly understood. 
4: Severe: Most speech is difficult to understand or unintelligible. 
 
19. Facial Expression 
0: Normal: Normal facial expression.  
1: Slight: Minimal masked facies manifested only by 
decreased frequency of blinking.  
2: Mild: In addition to decreased eye-blink frequency, 
Masked facies present in the lower face as well, namely 
fewer movements around the mouth, such as less spontaneous smiling, but lips 
not parted.  
3: Moderate: Masked facies with lips parted some of the time when the mouth is 
at rest. 4: Severe: Masked facies with lips parted most of the time when the 
mouth is at rest. 
 
20. Tremor at Rest 
Extremity ratings 
0: Normal: No tremor. 
1: Slight.: ≤ 1 cm in maximal amplitude. 
2: Mild: > 1 cm but < 3 cm in maximal amplitude. 
3: Moderate: 3 - 10 cm in maximal amplitude. 
4: Severe: > 10 cm in maximal amplitude. 
Lip/Jaw ratings 
2: Mild: > 1 cm but ≤ 2 cm in maximal amplitude. 
3: Moderate: > 2 cm but ≤ 3 cm in maximal amplitude. 
4: Severe: > 3 cm in maximal amplitude 
 
21. Action or Postural Tremor of hands 
0: Normal: No tremor. 
1: Slight: Tremor is present but less than 1 cm in amplitude. 
2: Mild: Tremor is at least 1 but less than 3 cm in amplitude. 
3: Moderate: Tremor is at least 3 but less than 10 cm in amplitude. 
4: Severe: Tremor is at least 10 cm in amplitude. 
 
 
 
 
Speech 
 
Facial 
Expression 
 
Face/lip RUE LUE RLE LLE 
     
RUE LUE 
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22. Rigidity (passive movement of major joints) 
0: Normal: No rigidity. 
1: Slight: Rigidity only detected with 
activation maneuver. 
2: Mild: Rigidity detected without the activation maneuver, but full range of motion 
is easily achieved. 
3: Moderate: Rigidity detected without the activation maneuver; full range of 
motion is achieved with effort. 
4: Severe: Rigidity detected without the activation maneuver and full range of 
motion not 
achieved. 
 
23. Finger taps (patient taps thumb with index finger) 
0: Normal: No problems. 
1: Slight: Any of the following: a) the regular rhythm is broken 
with one or two interruptions or hesitations of the tapping 
movement; b) slight slowing; c) the amplitude decrements near the end of the 10 
taps. 
2: Mild: Any of the following: a) 3 to 5 interruptions during tapping; b) mild 
slowing; c) the amplitude decrements midway in the 10-tap sequence. 
3: Moderate: Any of the following: a) more than 5 interruptions during tapping or 
at least one longer arrest (freeze) in ongoing movement; b) moderate slowing; c) 
the amplitude 
decrements starting after the 1st tap. 
4: Severe: Cannot or can only barely perform the task because of slowing, 
interruptions or decrements 
 
24. Hand movements (patient opens and closes hands) 
0: Normal: No problem. 
1: Slight: Any of the following: a) the regular rhythm is broken 
with one or two interruptions or hesitations of the movement; 
b) slight slowing; c) the amplitude decrements near the end of the task. 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild 
slowing; c) the amplitude decrements midway in the task. 
3: Moderate: Any of the following: a) more than 5 interruptions during the 
movement or at least one longer arrest (freeze) in ongoing movement; b) 
moderate slowing; c) the 
amplitude decrements starting after the 1st open-and-close sequence. 
4: Severe: Cannot or can only barely perform the task because of slowing, 
interruptions or decrements. 
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25. Rapid alternative movements of hands (pronation-supination movements 
of hands) 
0: Normal: No problems. 
1: Slight: Any of the following: a) the regular rhythm is broken 
with one or two interruptions or hesitations of the movement; 
b) slight slowing; c) the amplitude decrements near the end of the sequence. 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild 
slowing; c) the amplitude decrements midway in the sequence. 
3: Moderate: Any of the following: a) more than 5 interruptions during the 
movement or at least one longer arrest (freeze) in ongoing movement; b) 
moderate slowing c) the 
amplitude decrements starting after the 1st supination-pronation sequence. 
4: Severe: Cannot or can only barely perform the task because of slowing, 
interruptions or decrements. 
 
26. Leg agility (patient taps heel on the ground in rapid succession picking up 
entire leg) 
0: Normal: No problems. 
1: Slight: Any of the following: a) the regular rhythm is broken 
with one or two interruptions or hesitations of the movement; 
b) slight slowing; c) amplitude decrements near the end of the task. 
2: Mild: Any of the following: a) 3 to 5 interruptions during the movements; b) mild 
slowness; c) amplitude decrements midway in the task. 
3: Moderate: Any of the following: a) more than 5 interruptions during the 
movement or at least one longer arrest (freeze) in ongoing movement; b) 
moderate slowing in speed; c) amplitude decrements after the first tap. 
4: Severe: Cannot or can only barely perform the task because of slowing, 
interruptions or decrements 
 
27. Arising from chair (patient attempts to arise from chair with arms folded 
across chest) 
0: Normal: No problems. Able to arise quickly without 
hesitation. 
1: Slight: Arising is slower than normal; or may need more 
than one attempt; or may need to move forward in the chair 
to arise. No need to use the arms of the chair. 
2: Mild: Pushes self up from arms of chair without difficulty. 
3: Moderate: Needs to push off, but tends to fall back; or may have to try more 
than one time using arms of chair, but can get up without help. 
4: Severe: Unable to arise without help. 
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28. Posture  
0: Normal: No problems. 
1: Slight: Not quite erect, but posture could be normal for 
older person. 
2: Mild: Definite flexion, scoliosis or leaning to one side, but 
patient can correct posture to normal posture when asked to do so. 
3: Moderate: Stooped posture, scoliosis or leaning to one side that cannot be 
corrected 
volitionally to a normal posture by the patient. 
4: Severe: Flexion, scoliosis or leaning with extreme abnormality of posture. 
 
29. Gait  
0: Normal: No problems. 
1: Slight: Independent walking with minor gait impairment. 
2: Mild: Independent walking but with substantial gait 
impairment. 
3: Moderate: Requires an assistance device for safe walking (walking stick, 
walker) but not a person. 
4: Severe: Cannot walk at all or only with another person’s assistance. 
 
30. Postural Stability (Response to sudden, strong posterior displacement  
produced by pull on shoulders while patient is standing with feet shoulder width 
apart) 
0: Normal: No problems: Recovers with one or two steps. 
1: Slight: 3-5 steps, but subject recovers unaided. 
2: Mild: More than 5 steps, but subject recovers unaided. 
3: Moderate: Stands safely, but with absence of postural response; falls if not 
caught by 
examiner. 
4: Severe: Very unstable, tends to lose balance spontaneously or with just a 
gentle pull on the shoulders. 
 
31. Body bradykinesia and hypokinesia (combining slowness, hesitancy, 
decreased arm swing, small amplitude and poverty of movements in general)  
0: Normal: No problems. 
1: Slight: Slight global slowness and poverty of spontaneous 
movements. 
2: Mild: Mild global slowness and poverty of spontaneous 
movements. 
3: Moderate: Moderate global slowness and poverty of spontaneous movements. 
4: Severe: Severe global slowness and poverty of spontaneous movements. 
Total UPDRS score: __ __ 
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Appendix D: The Activities-specific Balance Confidence (ABC) Scale 
For each of the following, please indicate your level of confidence in doing the 
activity without losing your balance or becoming unsteady from choosing one of 
the percentage points on the scale from 0% to 100%. If you do not currently do 
the activity in question, try and imagine how confident you would be if you had to 
do the activity. If you normally use a walking aid to do the activity or hold onto 
someone, rate your confidence as it you were using these supports. If you have 
any questions about answering any of these items, please ask the administrator. 
For each of the following activities, please indicate your level of self-
confidence by choosing a corresponding number from the following rating 
scale: 
0%  10  20  30  40  50  60  70  80  90  100% 
no confidence              completely confident 
“How confident are you that you will not lose your balance or 
become unsteady when you…” 
1. …walk around the house? ____% 
2. …walk up or down stairs? ____% 
3. …bend over and pick up a slipper from the front of a closet floor 
____% 
4. …reach for a small can off a shelf at eye level? ____% 
5. …stand on your tiptoes and reach for something above your head? 
____% 
6. …stand on a chair and reach for something? ____% 
7. …sweep the floor? ____% 
8. …walk outside the house to a car parked in the driveway? ____% 
9. …get into or out of a car? ____% 
10. …walk across a parking lot to the mall? ____% 
11. …walk up or down a ramp? ____% 
12. …walk in a crowded mall where people rapidly walk past you? 
____% 
13. …are bumped into by people as you walk through the 
mall?____% 
14. … step onto or off an escalator while you are holding onto a 
railing?____% 
15. … step onto or off an escalator while holding onto parcels such 
that you cannot hold onto the railing? ____% 
16. …walk outside on icy/wet sidewalks? ____%  
Total: ________ 
*Powell, LE & Myers AM. The Activities-specific Balance Confidence (ABC) Scale. J Gerontol Med Sci 1995; 50(1): M28-34 
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Appendix E: Beck’s Depression Inventory 
Instructions: This questionnaire consists of 21 groups of statements. Please read each 
group of statements carefully, and then pick out the one statement in each group that 
best describes the way you have been feeling the past two weeks. Place the 
corresponding number on the score line. If several statements in the group seem to apply 
equally well, pick the highest of the numbers. Be sure to not choose more than one 
statement per group. This depression inventory can be self-scored. The scoring scale is at 
the end of the questionnaire.  
1. 0 I do not feel sad. 
1 I feel sad. 
2 I am sad all the time and I can't snap out of it. 
3 I am so sad and unhappy that I can't stand it. 
Score: 
______ 
   
2. 0 I am not particularly discouraged about the future.  
1 I feel discouraged about the future.  
2 I feel I have nothing to look forward to.  
3 I feel the future is hopeless and that things cannot 
improve. 
Score: 
______ 
   
3. 0 I do not feel like a failure.  
1 I feel I have failed more than the average person.  
2 As I look back on my life, all I can see is a lot of 
failures.  
3 I feel I am a complete failure as a person.  
Score: 
______ 
   
4. 0 I get as much satisfaction out of things as I used to.  
1 I don't enjoy things the way I used to.  
2 I don't get real satisfaction out of anything anymore. 
3 I am dissatisfied or bored with everything.  
Score: 
______ 
   
5. 0 I don't feel particularly guilty. 
1 I feel guilty a good part of the time.  
2 I feel quite guilty most of the time.  
3 I feel guilty all of the time. 
Score: 
_____ 
   
6. 0 I don't feel I am being punished.  
1 I feel I may be punished.  
2 I expect to be punished.  
3 I feel I am being punished.  
Score: 
______ 
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7. 0 I don't feel disappointed in myself.  
1 I am disappointed in myself.  
2 I am disgusted with myself.  
3 I hate myself.  
Score: 
______ 
   
8. 0 I don't feel I am any worse than anybody else.  
1 I am critical of myself for my weaknesses or mistakes.  
2 I blame myself all the time for my faults.  
3 I blame myself for everything bad that happens.  
Score: 
______ 
   
9. 0 I don't have any thoughts of killing myself.  
1 I have thoughts of killing myself, but I would not carry 
them out.  
2 I would like to kill myself.   
3 I would kill myself if I had the chance.  
Score: 
______ 
   
10. 0 I don't cry any more than usual.  
1 I cry more now than I used to.  
2 I cry all the time now.  
3 I used to be able to cry, but now I can't cry even 
though I want to.  
Score: 
______ 
   
11. 0 I am no more irritated by things than I ever was.  
1 I am slightly more irritated now than usual.  
2 I am quite annoyed or irritated a good deal of the 
time. 
3 I feel irritated all the time.  
Score: 
______ 
   
12. 0 I have not lost interest in other people.  
1 I am less interested in other people than I used to be.  
2 I have lost most of my interest in other people.  
3 I have lost all of my interest in other people.  
Score: 
______ 
   
13. 0 I make decisions about as well as I ever could.  
1 I put off making decisions more than I used to.  
2 I have greater difficulty in making decisions more than 
I used to. 
3 I can't make decisions at all anymore.  
Score: 
______ 
14. 0 I don't feel that I look any worse than I used to.  
1 I am worried that I am looking old or unattractive.  
2 I feel there are permanent changes in my appearance 
that make me look unattractive.  
3 I believe that I look ugly.  
Score: 
______ 
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15. 0 I can work about as well as before.  
1 It takes an extra effort to get started at doing 
something.  
2 I have to push myself very hard to do anything.  
3 I can't do any work at all.  
Score: 
______ 
   
16. 0 I can sleep as well as usual.  
1 I don't sleep as well as I used to.  
2 I wake up 1-2 hours earlier than usual and find it hard 
to get back to sleep.  
3 I wake up several hours earlier than I used to and 
cannot get back to sleep.  
Score: 
______ 
   
17. 0 I don't get more tired than usual.  
1 I get tired more easily than I used to.  
2 I get tired from doing almost anything.  
3 I am too tired to do anything.  
Score: 
______ 
   
18. 0     My appetite is no worse than usual.  
      1         My appetite is not as good as it used to be.  
2     My appetite is much worse now.  
3      I have no appetite at all anymore.  
Score: 
______ 
 
19. 0 I haven't lost much weight, if any, lately.  
1 I have lost more than five pounds.  
2 I have lost more than ten pounds.  
3 I have lost more than fifteen pounds.  
Score: 
______ 
20. 0 I am no more worried about my health than usual.  
1 I am worried about physical problems like aches, 
pains, upset stomach, or constipation.  
2 I am very worried about physical problems and it's 
hard to think of much else.  
3 I am so worried about my physical problems that I 
cannot think of anything else.   
Score: 
______ 
   
21. 0 I do not feel like a failure.  
1 I have not noticed any recent change in my interest in 
sex.  
2 I am less interested in sex than I used to be.  
3 I have almost no interest in sex.  
4 I have lost interest in sex completely.  
Score: 
______ 
Total Score: ________ 
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Interpreting The Beck Depression Inventory 
Now that you have completed the questionnaire, add up the score for each of the 
twenty-one questions by counting the number to the right of each question you 
marked. The highest possible total for the whole test would be sixty-three. This 
would mean you circled number three on all twenty-one questions. Since the 
lowest possible score for each question is zero, the lowest possible score for the 
test would be zero. This would mean you circles zero on each question. You can 
evaluate your depression according to the Table below.  
Classification Total Score Level of Depression 
Low 1-10 These ups and downs are considered 
normal   
11-16 Mild mood disturbance   
Moderate 17-20 Borderline clinical depression   
21-30 Moderate depression   
Significant 31-40 Severe depression 
over 40 Extreme depression 
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Appendix F: Montreal Cognitive Assessment Scale (MOCA) 
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Appendix G: Contact Localizations for each Participant 
BSC-01 
 
 
BSC-02 
 
 
BSC-03 
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BSC-06 
 
BSC-07 
 
 
 
 
Note: Contact localizations for BSC-05 and BSC-08 are not available. 
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